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Abstract   
 
The work presented in this thesis has demonstrated the purification of a range of viruses from 
both clarified lysate and cell culture using 3D-printed chromatography columns. Previous 
research and development of 3D-printed columns suggested they would benefit the recovery 
of virus and virus-like particles used for biopharmaceutical applications such as vaccines and 
gene therapies. The columns' ability to passage solids while effectively bind and elute a target 
biological allowed the combination of multiple steps (clarification, filtration, and capture 
chromatography) in the downstream processing of viruses. This reduction in processing steps 
and production time should minimize costs for virus production, especially for expensive 
gene therapies.   
 
A triply periodic minimal surface known as the Schoen gyroid formed the cellulose hydrogel-
based columns' channel structure. These monolithic-style columns had 300 µm hydraulic 
diameter channels allowing the passage of solids. Anion exchange (Q or DEAE) or multimodal 
(hydroxyapatite) ligands were attached to the structure's walls and pores to bind and elute a 
range of viruses.  Both DEAE (229 µeq/mL & 85 mg/mL) and Q (346 µeq/mL & 138 mg/mL) 
functionalities have comparable ligand densities and BSA static binding capacities compared 
to bead-based media. Recovery of oncolytic adenovirus (69 ± 6%) and lentivirus (57%) from 
DEAE columns is high compared with traditional media. Purification of M13 bacteriophage 
directly from cell culture under comparable conditions to an expanded bed chromatography 
process showed a high recovery (87.7% ± 5% for 1.49×1011 pfu/mL). Additionally, it was 
completed three times faster without the difficulties associated with a fluidized bed.  
 
This work also acknowledged and examined how this technology could scale from the lab to 
pilot-size columns capable of processing larger volumes of feedstock. Development of a 
‘segmentation method’ alongside commercially available printer advancement led to a single 
part size increase of 1500%. Fabrication of pilot-sized column (30 cm long by 5 cm diameter, 
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EDTA Ethylenediaminetetraacetic Acid 
ELISA Enzyme-Linked Immunosorbent Assay 
FDA Food and Drug Administration 
FDM Fused Deposition Modelling 
FE-SEM Field Emission Scanning Electron Microscope 
FPLC Fast Protein Liquid Chromatography 
FT-IR Fourier Transform - Infrared Spectroscopy 
GMAC Glycidyl Trimethylammonium Chloride 
HA Hydroxyapatite 
HCP Host Cell Proteins 
HEK293 Human Embryonic Kidney Cells 
HELA Henrietta Lack Cells 
xxi 
 
HETP Theoretical Plate Height 
HIC Hydrophobic Interactions Chromatography 
HIS Histidine 
HIV Human Immunodeficiency 
HSPG Heparan Sulfate Proteoglycan 
IDA Iminodiacetic Acid 
IMAC Immobilized Metal Affinity Chromatography 
IPA Isopropyl Alcohol 
LDS Lithium Dodecyl Sulfate 
NHS N-Hydroxysuccinimide 
NTA Nanoparticle Tracking Analysis 
OCP Octacalcium Phosphate 
PEG Polyethylene Glycol 
pfu plaque forming units 
Q Quaternary amine 
qPCR quantitative Polymerase Chain Reaction 
RNA Ribonucleic acid 
RPI Rensselaer Polytechnic Institute 
SBF Simulated Body Fluid 
SCID Severe Combined Immunodeficiency 
SDS-PAGE Sodium Dodecyl Sulfate–Polyacrylamide Gel Electrophoresis 
SEC Size Exclusion Chromatography 
STL Standard Triangle Language 
TEM Transmission Electron Microscope 
TLC Thin Layer Chromatography 
TPMS Triply Periodic Minimal Surface 
TU Transducing Units 
VG Viral Genomes 
VLP Virus-Like Particles 








HETP Theoretical plate height  
a Right side of a peak 
b Left side of a peak 
hmin Reduced plate height 
Dp Particle diameter 
Vr Retention volume 
Wh Peak width at half peak height 
l Unit cell length 
s Surface area of a unit cell 
ε  Porosity  
d Hydraulic diameter 
a Specific surface area 
C0 Feed concentration 
Vb,10% Break through volume at 10% of feed concentration 
V0 Void volume 
CV Column Volume 
DBC10% Dynamic binding capacity at 10% 






Current advances in biopharmaceutical medicine have explored the use of viruses as delivery 
mechanisms to insert modifications genes to a patient’s cells as a cure to genetic diseases 
(Figure 1-1) [1]. This technology, termed gene therapy, has grown steadily in the past 5 years 
with the approval of two therapies (Luxturna and Glybera) for sale [2, 3]. The pipeline for US 
Food and Drug Administration (FDA) approval sees hundreds of these therapies currently 
undergoing various stages of clinical trials [4]. Gene therapies are a lifeline for patients whose 
condition was previously a potential death sentence. As with the advancement in the use of 
these modified viruses, efforts are being made to optimize the production (upstream) and 
purification (downstream) processes to produce them.  
 
Figure 1-1:  Diagram showing a method for administering virus based gene therapies [5].   
 
Upstream processing involves culturing the virus inside a host cell used as a biological factory 
for replication. Host cells and culturing methods are specific to each type of virus and even 
differ between serotypes of the same virus. Downstream processing involves separating the 
newly replicated viral particles away from contaminants such as host cells, proteins, DNA, 
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and endotoxins. There are multiple steps in a purification strategy, including cell lysis, 
clarification, capture chromatography, intermediate purification, polishing, and formulation 
(Figure 1-2). Current purification strategies use previously optimized technologies for 
proteins and adapted for use with viruses. Of these, the most common, packed bed 
chromatography columns used in the capture, intermediate, and polishing steps have low 
recoveries and capacities for virus and virus-like particles [6]. Technologies such as monoliths 
and membranes have emerged specifically designed to purify viruses [7-9]. Although 




Figure 1-2:  Overview of the steps for the industrial purification of adeno-associated virus [11]. 
 
Expanded bed adsorption (EBA) chromatography can purify target biologicals such as 
proteins or viruses directly from cell culture or lysate. A bed of chromatography beads is 
fluidized by an upwards flow of buffer, expanding the bed to between two and three times its 
original height. This fluidization allows for the passage of solids through the bed while 
allowing the chromatography beads to contact the feedstream and bind the target biological 
[12]. EBA was a revolution in bioprocessing; however, the industry did not widely adopt it 
3 
 
because of issues related to the fluidized bed, such as channeling, fouling, need for specialized 
equipment, and bed collapse [13, 14].  
 
 Additive manufacturing, or the more commonly termed 3D printing, involves the layer-by-
layer production of a 3D object.  Computer-Aided-Design (CAD) software combined with 3D 
printing can produce complicated items not possible with other manufacturing techniques. 
Many industries now use 3D printing with a wide range of materials such as plastics, metals, 
and waxes. 3D printing in chromatography is an emerging field with the ability to design 
ordered flow channels within a given structure.  Large ordered channels within a cylindrical 
agarose-based hydrogel can passage solids such as cells, while functional groups on the walls 
and internal pores can bind and elute protein. Proteins have been separated from a simulated 
cell broth directly similar to an expanded bed process using 3D-printed chromatography 
columns (Figure 1-3) [15]. This technology could purify viruses directly from crude cell lysate 
more effectively than traditional media [16].  
 
Figure 1-3:  Comparison between how expanded bed chromatography and 3D-printed columns passage solids. 





The previous research using 3D-printed chromatography media has shown its potential as an 
alternative to expanded bed chromatography. This thesis describes work carried out to 
investigate optimizing 3D-printed chromatography columns to be a platform for the 
purification of viruses. A unique cellulose hydrogel is investigated as a potential 
chromatography stationary phase. Various chemical and mineral functionalities of the 
cellulose hydrogel are used to bind and elute a range of viruses. Purification directly from cell 
culture is compared between 3D-printed columns and an expanded bed adsorption process. 
The scalability of this technology has also been investigated using the currently available 
commercial 3D printers. Scalability and practicality of production are important if this 
technology is to be adopted by the industry at any level. 
 
1.2 Objectives  
This work aims to evaluate the purification of virus or virus-like particles directly from cell 
culture or lysate using 3D-printed chromatography columns. More specifically, the objectives 
are as follows: 
- To evaluate a novel cellulose hydrogel to be the stationary phase of the 3D-printed 
chromatography columns.  
 
-  Expand on and optimize the current range of functional ligands useable with the 3D-printed 
chromatography columns.  
 
- To determine the column’s performance purifying a range of viruses from both clarified and 
unclarified feed streams. Including evaluating the resulting purity of separated viruses. 
 
- To understand and optimize factors that affect the column’s performance to maximize 
recovery and minimize processing time. 
 
- To compare the 3D-printed column purification process against an established expanded 
bed chromatography purification.  
 
-   Evaluate scale-up of this technology, including determining current 3D printing constraints.   
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1.3 Organization of thesis 
Chapter 2 details literature around the downstream processing of gene therapies, focusing on 
the current state of the art and new and emerging technologies such as monoliths and 
membranes. The recovery at each step in the downstream processing of viruses is examined. 
Chromatography performance indicators are explained and used in experimental chapters to 
compare different chromatography media. Various 3D printing methods are examined, with 
a focus put on those currently used in chromatography. The literature on 3D printing in 
chromatography is limited; however, more researchers are investigating its potential as the 
field grows. 
 
Chapter 3 outlines all of the materials and equipment used throughout this project. It also 
contains the standard methods used for most of the work except those used in Chapter 6. The 
final experimental chapter contains its methods section to be standalone detailing upscaling 
methods and results. The chapter contains details of construction, functionalization, 
stationary phase analysis, and viral purification testing of 3D-printed columns.   
 
The following three chapters detail the results and discussion of these experiments in a logical 
order. The first chapter investigates the cellulose stationary phase proposed for these columns 
and its appropriateness for viral purification. The second chapter details using these 
optimized columns to purify a range of viruses from clarified and unclarified feed streams. 
Finally, the last experimental chapter explains a potential upscaling method of 3D-printed 
chromatography columns with current technology. Recommendations based on the results of 
this research are made in the conclusive chapter of this thesis.  
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2 Literature review 
The following is a review of downstream purification looking at viral vectors used in gene 
therapies. Attention is also focused on alternatives to current strategies, specifically 3D-
printed chromatography columns.  These columns are the primary focus of this work as an 
alternative to current technology for viral purification.  
2.1 Gene therapies 
Cystic fibrosis, Huntington’s disease and, Duchene muscular dystrophy are genetic diseases, 
which up until the discovery of gene therapies have been incurable and, in some cases, death 
sentences. Previously, doctors could only minimize the symptoms and treat the side effects of 
these diseases. However, gene therapies have provided a possible pathway to develop cures 
by using viruses as vehicles to deliver corrected or modified genes directly to a patient’s cells. 
Recombinant viruses or virus-like particles can have specific genes inserted into their genetic 
code. Upon infection with these modified viruses, the inserted gene is transferred into the host 
cell’s genome. It is possible to control what type of cells will be infected depending on the 
virus’s morphology. For example, Duchene muscular dystrophy results from a mutation in a 
gene that encodes the muscle protein dystrophin. Sufferers slowly lose muscle function due 
to not being able to produce this protein, with treatments aimed at mitigating this loss with 
steroids. It was proposed that a corrected version of the gene could be inserted into a patient’s 
DNA via a modified adeno-associate virus (AAV) [17]. The corrected gene could, in theory, 
allow that patient to produce dystrophin, effectively curing the disease. Multiple 
pharmaceutical companies are working on AAV-based therapies for  Duchene muscular 
dystrophy, most of which are in phase 1 or 2 clinical trials [18, 19]. Extensive testing is required 
for these therapies as genetic code modification can have unforeseen results causing cancerous 
cells or extensive immune responses by the host cells.  Most notably, a gene therapy used to 
treat X-linked severe combined immunodeficiency (SCID) resulted in four patients from a 
clinical trial developing T cell leukemia 31 to 68 months after treatment [20].  
 
Gene therapy has rapidly grown in the past 20 years, expanding to encompasses a range of 
potential viral vectors and targeted diseases [21]. Challenges in this field are a limited 
understanding of genetics, virus life cycles, human biological pathways, and the production 
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and commercialization of these treatments. The development of therapies through clinical 
trials and commercialization means the production of these viruses and resulting therapies is 
crucial to their success. Minimizing cost and production time is also essential to make these 
therapies more readily available to those who need them. The following is a review of the 
downstream processing of such therapies and viruses. 
 
2.1.1 Range of viruses for gene therapy 
There is a large range of viruses currently being used for gene therapy research and 
undergoing clinical trials. Of these, the three most used are adenovirus, AAV, and retrovirus 
[22]. They make up nearly 50% of all clinical gene therapy trials [1]. Each of these viruses 
undergoes its purification strategy specific to the vector, serotype, and upstream processing. 
Figures 2-1 to 2-3 have been taken from the review paper “Gene therapy clinical trials 
worldwide to 2017: An update” by Edelstein et al. [4]. Figure 2-1 shows the increase in the 
number of new gene therapies in clinical trials since 1989. The number of therapies in clinical 




Figure 2-1: Number of new gene therapy clinical trials approved worldwide 1989-2017 [4]. 
 
Figure 2-2 shows which diseases are the main focus of the current clinical trials. Cancer 
treatments are the main research area for gene therapy research (65% of clinical trials) as they 
target the largest number of patients. Many genetic diseases are rare, affecting only a small 





Figure 2-2: Break down of gene therapies to treat different diseases worldwide 1989-2017 [4]. 
 
The viral vector required for a specific gene therapy is chosen depending on where the gene 
needs to be inserted, its size, the target cell type, and other biological conditions. Figure 2-3 
shows how the current clinical trials are broken down based on the viral vector used. 
Adenovirus, retrovirus, and AAV are the most commonly used and studied in this field. There 
is the potential for other viral vectors to emerge and become predominant in this field; 
however, based on current clinical trials, the three previously mentioned viruses will focus on 
this work. Viruses that infect bacterial cells are also of interest for proof of concept 
experiments. They have similar morphologies while being inexpensive and lower safety risks 





Figure 2-3:  Break down of viruses used in current gene therapy clinical trials worldwide 1989-2017 [4]. 
 
2.1.2 Adenovirus 
The adenovirus has a nonenveloped capsid, made up of hexon and penton proteins with an 
overall 70 to 100 nm diameter [23]. Figure 2-4 shows the overall structure, which has a protein 
fiber extending from each hexon base topped with a distal knob that interacts with the cell 
receptor CAR (Coxsackievirus and Adenovirus Receptor) [24]. The capsid has an overall 















Figure 2-4:  Depiction of the structure of an adenovirus [28]. 
 
 The adenovirus’s genetic material is not incorporated into its host’s genome during infection, 
and it is left free inside the host’s nucleus [29]. Therefore, as cells divide and replicate, new 
cells will not contain the virus’s DNA. Therapies using adenoviral vectors are short-term and 
may require follow-up treatments. The replicated virus is contained inside the host cell till cell 
death is triggered [30]. Therefore, cell lysis is required to release the virus into the solution 
before downstream processing. The adenovirus is the cause of the common cold and is easily 
identified by the body’s immune response system [31]. This immunogenic response can limit 
the virus's effectiveness for use as a  gene therapy [32]. Deletions in the adenovirus plasmid 
can allow for a recombinant gene size of up to 7.5 kb [23]. Deletions are in the E1 region, which 
renders the virus unable to replicate without help from a packaging cell line or helper virus, 
and E3, which codes for immunogenic evasion not associated with virus replication [33]. 
Replication of recombinant adenovirus is performed in transformed HEK293 (human 
embryonic kidney cells with E1 plasmid) to replicate and packaging adenovirus [34]. The 
focus of adenovirus gene therapies is for cancer treatments to destroy tumor cells. The focus 
of adenovirus gene therapies is for cancer treatments to destroy tumor cells. However, other 
researched diseases are Duchene muscular dystrophy, cystic fibrosis, and glaucoma [35-39]. 
Several of which are in various stages of clinical trials [40]. Oncolytic therapies target cancer 
cells, causing lysis and inflammation, which in turn activates the host’s immune response to 
target these cells [41]. Other anti-cancer therapies use the gene P-53, the gene that regulates 
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cell apoptosis, to reduce the size of cancerous tumors [37, 42]. Adenovirus is also used for 
vaccines, where the virus stimulates an immunogenic response by replicating a surface 
protein from a targeted virus, most recently for COVID-19 [43]. 
 
2.1.3 Adeno-associated virus 
The AAV also has a nonenveloped capsid relatively smaller than the adenovirus, 20 to 30 nm 
in diameter [44]. It comprises three capsid proteins VP1, VP2, and VP3 expressed in the ratio 
of 1:1:10, respectively [45]. These surface proteins can differ between serotypes resulting in 
variations in the type of cells they can infect [46]. They also affect the various purification 
methods because of changes in binding affinity, hydrophobicity, and isoelectric point [47-50]. 
It is helper virus dependent, requiring coinfection with either adenovirus or herpes simplex 
virus to replicate [51]. Although very prevalent in the human population, the virus has not 
been associated with any specific disease and has a minimal immunogenic response [52].  
AAV has a single strand of DNA, approximately 4.7 kb long, coding for structural and 
packaging proteins. Removal of these genes allows for an insertion up to 4.5 kb with the 
deleted genes provided in trans either by a packing cell line (HEK293) or by helper adenovirus  
[51]. AAV infects dividing and non-dividing cells and integrates into the host’s genome site 
specifically [53]. This results in long-term genome alteration, with the gene being inserted into 
chromosome 19 nearly 100% of the time. AAV is produced in the cytoplasm and can either 
follow a lytic or lysogenic reproductive pathway [54, 55]. Glybera by Amsterdam Molecular 
Therapeutics was an AAV serotype 1 therapy approved by the European Union to treat 
lipoprotein lipase deficiency, although heavily criticized [3]. Only one person has ever 
received the drug because of how rare the disease is and the expensive one million dollar price 
[56]. Its approval from the European Union was not reapplied for in 2017 and is currently no 
longer on the market. The first-ever FDA approved in vivo gene therapy was Luxturna by 
Spark Therapeutics, a recombinant AAV serotype 2 used to treat Leber’s congenital amaurosis 
retinal disease [57]. It too costs nearly one million dollars; however, it has had more success 
with multiple patients receiving the drug with varying degrees of success in restoring vision 
[57]. There are currently 204 clinical trials of various AAV taking place in 2017 compared with 




2.1.4 Retrovirus  
The retrovirus is an enveloped virus larger than both the adenovirus and AAV up to 200 nm 
in diameter. It contains a genome of 130 to 280 kb of which transgenes greater than 10 kb can 
be included [58]. The retrovirus does not contain DNA. Its genetic material is RNA, which 
must be transcribed into DNA before insertion into the host genome. The integrase enzyme 
can insert the genetic material into any arbitrary position in the host’s genome, which in some 
cases can lead to oncogenesis [20]. Site-specific integration requires targeted retrovirus 
transduction by localizing the virus's delivery and addition of insulators to prevent 
unintended positional effects causing oncogene activation [59].  Most enveloped viruses do 
not require cell lysis before purification. The virus is secreted by the host cell into the culture 
medium through a process called budding. Lentivirus is a genus of retrovirus commonly 
known to cause human immunodeficiency (HIV), which can cause Auto Immune Deficiency 
(AIDS). Targets for lentivirus gene therapies are mostly cancer treatments and extended to 
ocular gene delivery, cystic fibrosis, and other genetic diseases [60-62]. Production of 
lentivirus can be difficult compared with nonenveloped viruses because of rapid inactivity of 
the virus at room temperature. Lentivirus has a narrow survivability range of pH, salt 
concentration, and titer, which cause rapid inactivity if exceeded [63, 64]. Lab-based culturing 
techniques produce low titers of these viruses, which hinders the scale-up of potential retro 
and lentivirus therapies [65, 66].  
 
2.1.5 Bacteriophage 
Viruses that infect bacterial cells are known as bacteriophages (prokaryotic viruses). These 
phages act similarly to mammalian viruses infecting a host cell and hijacking its bio-molecular 
machinery to replicate itself [67]. Two different replication methods can occur during 
bacteriophage infection, the lytic cycle or the lysogenic cycle [68]. The first involves the 
injection of the bacteriophage's plasmid into the cell's cytoplasm. The plasmid's genes are 
expressed, replicating the virus's DNA and protein coat followed by assembly and lysis of the 
cell. The second involves the incorporation of the phage's plasmid into the host cell's genetic 
material. When the host cell replicates, it copies the bacteriophage's DNA and incorporates it 
into the newly divided cells. Typically, at a later stage, after multiple divisions, the 
bacteriophages plasmid will be removed from the host's DNA and revert to the lytic cycle. 
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Like eukaryote viruses, bacteriophages come in various strains and serotypes that depend on 
different bacterial hosts to replicate. There are 13 different bacteriophage families, with 96% 
having tails while the other 4% are filamentous or icosahedral [69]. Typical examples of these 
variations in shape are M13 (Filamentous), T4 (head-tail), and cystovirus (icosahedral) [70-72]. 
Bacteriophages have been used as an alternative to antibiotics as they only infect and kill only 
bacterial cells, specifically for antibiotic-resistant infections [73]. Another more common use 
for them is phage display to study protein-protein, protein-peptide, and protein-DNA 
interactions. Common purification methods used for bacteriophages are polyethylene glycol 
(PEG) precipitation of aqueous two-phase systems (ATPS) [74, 75]. Purification of various 
phages using chromatography has given mixed results  [76, 77].  
2.2 Current viral downstream processing 
 
2.2.1 Lab-scale methods 
Current lab-scale viral purification methods commonly use density gradients, either with 
CsCl or iodixanol, for high purity separation. CsCl is toxic, and trace amounts remain in the 
solution after purification. Therefore, it is avoided by researchers preparing doses for clinical 
trials. This method is also time-consuming and produces low overall yields [78]. A benefit of 
this type of separation is removing empty capsids (protein coats not containing genetic 
material) from infectious viruses resulting in high full to empty capsid ratios [79].  
 
2.2.2 Clinical/manufacturing scale methods 
Figure 2-5 outlines the major manufacturing steps for clinical trial grade viral vectors. 
However, the order of some of these steps can vary depending on the vector.  Before 
chromatography, there are multiple steps to remove solids, such as cell debris, organelles, and 
DNA. Smaller contaminants such as host proteins, endotoxins, and digested DNA can then 
be removed using packed bed chromatography. Final polishing and formulation removes any 





Figure 2-5:  Outline of the major steps in downstream processing of virus and virus-like particles.  
 
2.2.2.1 Cell incubation and virus replication 
Developed cell lines contain plasmids for viral replication and packaging, such as HEK293 
[80]. The cells contain plasmids for deleted E1 genes that are associated with the replication 
of adenovirus and AAV. These cells have been used for many viral host cells (lentivirus – 
HEK293 E or T) but mostly adenovirus and AAV [66]. Other cell lines, such as Henrietta Lack 
(HELA) cells, have previously been used but have been phased out because of HEK293 
producer cell lines [81]. Retrovirus has been produced by trans-infection with a helper virus 
into HELA cells, but a packaging cell line (PSI-2) is now used for helper virus-free production 
[82]. Cells can be grown in a variety of ways depending on the quantity required. Cell 
factories, shaker flasks, and roller bottles are all used for small-scale, while perfusion and 
bioreactors are more common for larger scale. Transfection of the cells occurs when the 
required cell density is reached, typically after 48 to 72 hours of seeding growth. Cell harvest 
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occurs 72 and 96 hours after incubation. These growth conditions, media used, and protocols 
are different for each individual, cell line, virus, serotype, gene insert, and end application [46, 
77, 83-85]. 
 
2.2.2.2 Virus harvest 
Techniques used for cell collection and concentration vary based on host cells' growth 
conditions and the replicated virus. Cells grown on supports are detached before cell death 
by the addition of trypsin [86]. Suspended cell cultures are centrifugated or filtrated to form a 
cell pellet or paste, and the culture medium discarded. The discarded culture medium can 
contain up to 47% of the total viral production After collection, cells are lysed to mediate the 
release of the replicated virus into the solution. There are many different techniques for cell 
lysis characterized into mechanical or chemical lysis. A 3 cycle freeze-thaw method is used for 
lab-scale but does not scale up effectively [87]. Mechanical lysis uses shear forces or 
mechanical disruption to break open cell walls, for example, homogenization, bead mill, or 
tangential flow filtration [88, 89]. Multiple passes through a homogenizer or a fine bead mill 
can reduce the size of cell debris from lysis [90]. Typically, a lysis buffer such as triton X-100 
is used in conjunction with an increase in agitation speed for manufacturing scale lysis [91]. 
The addition of other ionic detergents followed by incubation is also an effective lysis method, 
but removing additives downstream can be an issue. However, as of 2021, triton X-100 will 
no longer be used in clinical-grade gene therapies [92]. New surfactants are being developed 
and tested for improving gene therapy recovery rates, such as polysorbate 20 used for lysis 
and recovery of oncolytic viruses [93]. 
 
2.2.2.3 Clarification  
The lysate from the cells contains large amounts of unwanted cell debris, organelles, lipids, 
and DNA that need to be removed before most chromatography forms can occur to prevent 
column blocking, low capacity, and fouling [94]. The initial step is to remove these larger 
particles (solids) by short centrifugation or lysate filtration. Centrifugation at high speed or 
extended periods can lead to losses in the titer of infectivity because of aggregation of the 
virus or sedimentation [95]. Filtration can remove cell debris, typically using membranes or 
depth filters with cut-off sizes (0.2 to 0.3 µm) large enough to allow the virus to pass through 
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[96]. Recovery rates from these sorts of filters can be upwards of 90% [85, 97]. Normal flow 
filtration using depth filters can also remove DNA and host cell proteins by adsorption in the 
membrane [98]. However, these devices' capacity is low and entirely dependent on cell culture 
conditions and lysate composition [99]. Filtration devices can be single-use to simplify 
cleaning and validation controls required by goods and manufacturing practices [97, 100]. 
Benzonase is used to digest leftover DNA after removing cell debris to reduce solution 
viscosity [101]. This digestion is also required to meet FDA regulations for host DNA levels 
below 10 ng/mL, no bigger than 200 bp [102]. Benzonase is an expensive nuclease enzyme that 
adds a considerable cost to gene therapy production. Recently, Oxford Biomedica has released 
a new product SecNunc™, in which nucleases are produced either within the host cell or in a 
helper cell-cultured alongside [103]. Then during lysis, the enzyme is released from the cells 
directly into the lysate.  
 
2.2.2.4 Concentration 
After primary and secondary clarification (if required), a concentration step is used to reduce 
volume before chromatography-based purification. Typically, ultrafiltration is employed to 
concentrate lysate. This reduction of volume reduces processing time and overall cost [104].  
 
2.2.2.5 Capture and Purification 
Fast protein liquid chromatography (FPLC) is currently the preferred method for the 
purification of viral particles. FPLC uses cylindrical columns (known as packed beds) filled 
with small beads (40-120 µm diameter) functionalized to adsorb target biologicals. The 
random nature of the packing leaves small gaps between beads allowing liquid flow. The 
clarified lysate is passed through said column allowing components of the lysate to be bound. 
After a washing step to flush through contaminates and weakly bound particles, the virus is 
eluted from the column by introducing counter ion or competitive species that preferentially 
bind to adsorption sites. Binding and elution from the column can exploit different aspects of 
the virus's physical characteristics [105]. Characteristics are typically isoelectric point, 
hydrophobicity, particle size, or cell receptor binding sites. Commonly, between two and four 
steps are required, the first one to two steps being the capture and intermediate purification 
followed by purification and polishing steps. Packed bed chromatography has been the classic 
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method for purifying proteins, monoclonal antibodies, DNA, and viruses. New technologies 
such as membranes and monoliths are also explored later in this review. 
2.2.2.6 Ion exchange 
Ion exchange is an effective purification method because of its high bind capacity and 
resolution [106]. Ion exchangers can be used as the capture step or the purification step, or in 
some cases, both [107]. It relies on the electrostatic charge of the capsid or envelope of the 
virus. The stationary phase's functional ligands will either have a positive or negative charge 
to bind the opposite charge. Anion exchange purification of adenovirus, AAV, and lentivirus 
is possible because of their negative charge at pH 7 because of an overall acidic isoelectric 
point [108, 109]. Purification using cation exchange requires biologicals with a basic isoelectric 
point. Cation exchange purification of AAV requires specific pH conditions that limit its use 
[110]. Cation and anion exchange work for binding viruses because of the large size of the 
virus's capsid or envelope containing both positive and negative patches of their surfaces, 
even though the overall charge may be negative. 
 
The binding of viral vectors occurs at higher conductivities than that of proteins and 
endotoxins, allowing them to be separated effectively. DNA is highly negatively charged and 
will elute off at a greater salt concentration after the virus has been eluted, providing 
separation [95]. Anion exchange can also separate infectious viruses from empty capsids. 
Empty capsids are unwanted by-products of viral therapies as they will stimulate an immune 
response without infecting the host cell with the gene of interest. Full and empty capsid have 
slight differences in isoelectric point, allowing for elution at different conductivities from an 
anion exchange column [48, 111, 112].  
 
 Recently, membrane and monolithic supports for anion exchangers have shown larger 
capacities for binding [113]. Lentivirus vectors have been purified by anion exchange 
chromatography while maintaining high gene expression levels and recovery from the 
column of 68% [114]. Anion exchange methods have also been described for pseudotyped 
HIV-1 based lentivirus vectors for purification and concentration up to 1010 transforming units 
per mL (TU/mL) [115]. Adenovirus was purified using a range of anion exchange resins with 
a recovery of 75% for dynamic binding capacities of 1.2×1010 plaque forming units per mL 
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(pfu/mL) [26]. Anion exchange has been used extensively for AAV purification over a range 
of serotypes; The purification of clinical-grade AAV serotype 8 achieved a recovery of 41% 
and a 90% purity [116]. The purification of AAV serotypes 1, 2, and 5 by anion exchange has 
produced 99% pure stocks with titters of 1×1012 to 1×1013 vector genomes/ml (VG/mL) [117]. 
Work on AAV serotypes 2, 8, and 9 for human gene therapies have provided similar results 
[118]. Purification of M13 bacteriophage with anion exchange managed a  recovery of 74% 
[76]. A cation exchange packed bed column was used to purify AAV serotype 2 gene therapy 
encoding cystic fibrosis transmembrane chloride regulator [119]. 
 
2.2.2.7 Size exclusion chromatography (SEC) 
SEC for purification of viruses and virus-like particles does not involve adsorption to the 
column; instead, it relies on the proteins and smaller molecules being slowed in pores while 
the comparatively larger virus is eluted in the flow-through or just thereafter [79]. This effect 
is caused by these resin beads' pore size, which is large enough for proteins to diffuse into but 
exclude the larger viral particles. As size-exclusion relies on smaller particles' diffusion into 
pores, it is very slow compared with other chromatography methods. The resolution also 
deteriorates if sample volume exceeds 4-5% of the bed volume [95]. However, it is still a useful 
technique used across all viral purifications, often as a polishing or purification step [120]. 
Taking advantage of convective transport instead of diffusion can enchant SEC. Monoliths 
and membranes for size exclusion typically can operate at a flow rate 10 to 20 times faster 
while offering better resolution than packed beds [44]. Viral particles leave the column in the 
equilibrium buffer allowing reformulation of the solution. SEC is an attractive polishing step 
for viral purification. 
 
GE has designed Capto Core 700 to polish adenovirus serotype 5 to meet new regulatory 
requirements for DNA and host cell protein (HCP) levels [121]. Purification of adenovirus 
serotype 5 by SEC in a two-column open-loop system gave a recovery rate of 86% [122, 123]. 
DNA and HCP clearance was found to be 90% and 89%, respectively. DNA and HCP clearance 
was to be 90% and 89%, respectively. Running two SEC columns in the loop type series system 
increases recovery up from 45% and increases load capacity and reduces purification time. 
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SEC is predominantly a polishing step used for lentivirus and AAV of various serotypes [64, 
66, 117, 118, 124-126]. 
 
2.2.2.8 Affinity 
Affinity chromatography involves binding viral particles to highly selective ligands attached 
to a solid phase support media. Porous media dominate this field, typically optimized for 
proteins, resulting in pore sizes between 60 to 100 nm.  Viral particles are too big to diffuse 
into these pores at standard flow rates. This limits interactions of the virus with the support 
media's surface, reducing the binding capacity of columns However, highly selective binding 
can still be effective at viral separation using heparin affinity for some AVV serotypes and 
lentivirus [51, 127]. Heparan sulfate proteoglycan (HSPG) is a cellular receptor that binds 
AAV used for affinity chromatography. It is not used widely at clinical or commercial scale 
because of column leaking and the toxicity of HSPG [128]. Newly developed AVB affinity 
resin and POROS AAV CaptureSelect for AAV purification make use of single-domain 
antibody fragment to bind and elute a range of AAV serotypes. These resins have shown a 
great affinity for AAV particles with recoveries between 70 - 90% [129-131]. However, as an 
affinity resin, ligand leaking is still an issue with the need for detection kits to measure how 
much of the camelid antibody fragment has leached into the eluent [132, 133].  
 
2.2.2.9 Immobilized Metal Affinity Chromatography (IMAC) 
IMAC is a variation on affinity chromatography taking advantage of specific interactions 
between proteins and metal ions. Metal ions are bound to a support media in a complex with 
a chelating ligand. Subsequently, bound viral vectors can be then eluted with a change in pH 
or the addition of competitors such as Ethylenediaminetetraacetic Acid (EDTA) or imidazole 
[95]. The most common is the purification of histidine-tagged (HIS-tagged) proteins by Nickel 
(II) affinity [134, 135]. Purification of adenovirus is possible using the interaction between the 
virus and 𝑍𝑛2+or 𝐶𝑢2+ ions. IMAC has successfully purified AAV by the addition of a HIS-
tag into the viral capsid. This modified AAV serotype 8 achieved a recovery of 90% in one 
step [136]. Herpes simplex virus type 1 has also been purified by IMAC chromatography using 
an immobilized cobalt column with a recovery of 90% [137]. This technique also suffers from 
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leaching similar to affinity chromatography. Metal ions can become detached from the 
support material and be found in the purified solution.   
 
2.2.2.10 Hydrophobic interactions (HIC) 
This method of purification employs a hydrophobic stationary phase and an aqueous mobile 
phase. Binding relies on hydrophobic interactions between the viral vector and the stationary 
phase. Higher conductivities allow the virus to bind to the stationary phase; usually, 
ammonium salts are used with butyl or phenyl ligands for the stationary phase. Deformation 
of proteins can be common in HIC, but proteins tend to refold when eluted as such viral 
particles may suffer the same fate but be unable to configure themselves back to their original 
structure[79, 95].  HIC purifications are ignored for purifying infectious particles but are still 
used for some quantitative analysis. 
 
2.2.2.11 Multimodal chromatography 
Multimodal chromatography uses two or more discrete mechanisms to bind and elute specific 
target proteins or viruses. These types of media provide a unique and selective binding at the 
cost of complexity. The most commonly used for viral purification is hydroxyapatite (HA), a 
mineral of calcium and phosphate. The phosphate group acts as a strong cation exchanger, 
while the calcium group provides metal coordination binding sites [138, 139]. Elution with a 
phosphate salt gradient causes the conductivity increase to elute the cation exchanger 
component while the phosphate ion competes for the calcium affinity sites [140]. Sodium 
chloride elution gradients are also possible where the increased conductivity elutes the cation 
exchange part of the media, but the chloride ions do not elute off the calcium affinity 
component. This variation in elution buffers allows a completely different set of selectivities. 
Enveloped viruses show strong binding to HA’s calcium component through exposed 
phosphate groups. This suggests phosphate gradients may be better suited for enveloped 
viruses such as retrovirus and lentivirus, while sodium chloride gradients may work better 
on non-enveloped such as adenovirus and AAV [79].  Many AAV and adenovirus 
purifications have been commercialized and patented using an HA step in the process [141-
145]. Most notably, purification of  AAV serotype 2 using HA in conjunction with an anion 
exchange step to yield a  90% purity [146]. A two-step purification of poliovirus used both 
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ceramic HA and fluorapatite, removing 99% of host cell proteins and double-stranded DNA  
[147]. HA has not been as prolific for the purification of lentivirus.  Elution conditions required 
by hydroxyapatite purifications can cause viral inactivation because of the narrow range of 
pH and salt concentration the virus can survive in. 
 
Other forms of multimodal functionalities combine ion exchange and SEC by covering ion 
exchange beads in a layer of inert porous material. This outer layer excludes larger molecules 
from reaching the ion exchange binding sites. Multimodal anion-SEC for the polishing step of 
viral purification has shown promise with the range of Capto™Core resins. Notably, 
purification using this type of multimodal resin includes yellow fever virus for inactivated 
vaccine manufacturing and the separation of enveloped virus-like particles from extracellular 
vesicles [148, 149]. Combinations of hydrophobic interactions and anion exchange are also 
available but have not been used for virus purification  [150].  
 
2.2.2.12 Polishing 
After intermediate purification, smaller trace contaminants remain, which need to be removed 
by a final purification step. Polishing requires high-resolution chromatography, typically 
anion exchange or SEC (gel filtration). Contaminants could be traces of DNA, endotoxins, 
helper virus, or empty viral capsids [151]. SEC or gel filtration is the most common polishing 
step next to anion exchange [107, 152]. The final steps after polishing of the viral particles are 










2.2.3 Lysate particle size distribution 
Crude cell lysate is a soup-like mixture containing proteins, lipids, organelles, DNA, and 
various biological components. Table 2-1 outlines the size distribution of some potential 
contaminants and varying viruses found in cell lysates. 
 
Table 2-1: Size of particles in potential cell lysate [44, 153-156] 
Particle Diameter nm 
AAV 20-26 
Minute virus of mouse 25 
Rhinovirus 30 
Hepatitis B 42 
Adenovirus 59-67 
Epstein-Bar virus 80-100 
HIV 100-120 
Herpes simplex virus 110-200 
Murine leukemia virus 120-150 




Cell debris (bacteria) 200-500 
Cell debris (mammalian) <5000~ 
Cell debris (CHO) <7000~ 
Cell debris (mammalian, homogenized, 5 passes)  1000~ 
HELA median HCP size  3-8 
 
As previously mentioned, cell lysate needs to be clarified to remove larger solid particles 
before loading onto chromatography columns to prevent fouling.  Cell lysate can contain 
many particles with varying sizes depending on the cell lysis techniques employed.  Multiple 
passes through a homogenizer can minimize cell debris to around 1000 nm [90]. However, 
more passes through the homogenizer could increase the risk of losing infectious viruses by 
24 
 
shear forces. It is important to know what contaminants are present and their size distribution 
for SEC purification. 
 
In current manufacturing, clarification (the removal of solids such as cell debris and large 
molecular weight molecules) occurs using centrifugation or filtration [95]. The large weight 
and size difference provides a simple method for debris removal but can result in losses in 
infectious particles. There has not been adequate research detailing cell lysates' particle size 
distribution or the effects cell lysis conditions have on cell debris size. Digestion of DNA by 
Benzonase can reduce the size of DNA can be reduced down to below 10 base pairs and reduce 
solution viscosity [101]. Digestion is an essential step in any chromatography-based 
purification of viruses, as the reduction in viscosity is needed to allow flow through the 
column to avoid high back pressures. 
 
2.2.4 Column loading potential 
Chromatography media was originally designed for protein purification with pore sizes 
between 50 to 100 nm. The same beads are used for viral purification and have significantly 
lower binding capacities than those observed for proteins [157]. This lower capacity is because 
of the virus not being able to penetrate the beads' pores, limiting the virus to the 
chromatography beads' surface. Pore sizes over 4× larger than the viral vector still exhibited 
monolayer binding on the surface. This monolayer is because of the strong binding of the 
virus at the pores' entrance, resulting in pore blockage or steric hindrance [158]. Therefore, the 
pore size may need to be an order of magnitude larger for the viral particles to penetrate the 
pores and increase potential binding capacity. 
 
The dynamic binding capacity (DBC) of adenovirus serotype 5 on an anion exchange resin 
was 1.2 × 1010 𝑉𝑃/𝑚𝐿 from clarified cell lysate [26]. This DBC is the benchmark for viral 
binding capacity for current anion exchange chromatography media. This purification used 
clarified lysate, where cell debris and host DNA are considerably less than crude lysate. 
Therefore, the binding capacity may be much lower for crude lysate because of biomass 
contending for binding positions on the chromatography media. However, purification of 
adenovirus serotype 5 by expanded bed chromatography from crude lysate gave a DBC of 
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1.1 × 1010 𝑉𝑃/𝑚𝐿. This capacity is only slightly less than what was found for purification from 
clarified lysate [159].  
 
The volume of lysate loaded depends on the concentration of viral particles, which may vary 
depending on upstream processing and virus production. Many papers only start taking note 
of viral concentration after initial filtration and clarification; however infectious particles may 
be lost during these steps [95]. Purification of adenovirus by continuous two-column quasi-
continuous SEC allowed for the increase of loading volumes from the recommended 1 to 5% 
of column volume to 20.7% [152]. It also increased virus recovery and reduced processing time 
significantly. Optimization of ligand density for anion exchanger hydrogel membranes 
showed a medium-density (2.2µmol/cm²) provided the best recovery rate for adenovirus [8]. 
 
2.2.5 Chromatography performance  
 
Various identifiers can be examined to determine a chromatography column’s performance 
and used for comparisons. The main three examined in this work are asymmetry, theoretical 
plate height (HETP), and binding capacity (dynamic and static). Both asymmetry (As) and 
HETP can be determined from residence time distribution data from a pulse test (tracer 
experiment). An example peak can be seen in Figure 2-6, taken from a GE Healthcare 
pamphlet on column efficiency [160]. As is a measure of how symmetrical an elution peak 
from a column is. It is defined by the ratio of the length of one side of the peak (b) (at 10% of 
the peak height) to the other side (a). Typical values for As in packed bed columns are between 




Figure 2-6:  Example of a tracer elution peak from a packed bed chromatography column [160]. 
 
HETP is a measure of column resolution, identified by how narrow and tall a peak elution is 
in addition to the column’s bed height. HETP can be calculated from the following equation 
2-2, where L is the length of the column: 
 








,    (2-1) 
 
The lower the value of HETP the better resolution you should expect from the column. The 
reduced plate height (hmin) can then be calculated from the HETP by dividing it by the beads’ 
particle diameter (Dp). 
 
ℎ𝑚𝑖𝑛 = 𝐻𝐸𝑇𝑃/𝐷𝑝,     (2-2) 
 
The reduced plate height can be used to compare between columns of varying bed height and 
particle size. For traditional packed beds, for optimal column performance, hmin value is 
suggested to be below 3. 
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Multiple pulse tests are carried out over a range of flow rates to compared theoretical plate 
height values to determine the best operating flow rate. A plot of HETP by flow rate is a Van 
Deemter plot, as shown below in Figure 2-7. The Van Deemter plot curve shows the best 
operating flow rate, which occurs at the minima. The Equation shown in Figure 2-7 describes 
the coefficients (A, B, and C) that give rise to the graph's tick shape. A is a constant value that 
describes random eddy diffusion within the system regardless of fluid velocity (u). B describes 
the longitudinal molecular diffusion through the column, which is minimized at higher flow 
rates. C represents the mass transfer limitations of the system, which rise with an increase in 
flow rate. Additionally, determining the slope to the right of the minima provides information 
regarding maximum operating flow rates. The more gradual the slope, the larger the 
operating range of flow rates possible near peak system performance. Higher flow rates are 
more desirable to minimize processing times for chromatography steps. 
 
 




A reduction in particle diameter can minimize the HETP for a packed bed chromatography 
system [162]. However, this will increase the pressure drop across the column. Optimization 
of flow rates, particle size, and pressure drop are required to maximize column production 






























2.3 Alternative purification techniques 
 
2.3.1 EBA chromatography 
EBA chromatography can separate proteins from crude lysate material without the need for a 
prior clarification or filtration step. It can be a combination of clarification, concentration, and 
an initial purification capture step. Unlike packed bed chromatography, the crude lysate is 
pumped to flow up through a fluidized bed of porous beads where the target protein or virus 
can interact and bind with the chromatography media while all the unwanted contaminants 
pass through (cell debris, cell culture medium, and cell DNA) [163-165].  After a long wash 
step, the protein is eluted off the column by changing pH or conductivity. The benefit of 
expanded bed chromatography over a packed bed is its ability to passage solids because of 
the fluidized bed. EBA allows for purification directly from crude cell lysates or culture fluids. 
EBA can suffer from a variety of issues resulting from the column’s load material and bed 
fluidization. Figure 2-8 shows a comparison between a packed bed and an expanded bed 
system. 
 




Crude lysate contains significant amounts of biomass, non-targeted proteins, lipids, and other 
unwanted particles. These unwanted particles can deposit themselves onto the 
chromatography media, reducing available binding sites and disrupting column flow [167]. 
Excessive biomass significantly affects anion exchange media as cell membranes, DNA, and 
proteins from host cells are typically negatively charged. Biomass fouling is less common in 
cation and affinity adsorbents than anion exchange resins because of their specific binding 
requirements or negative charge [168]. In attempts to reduce bio adhesion during loading of 
EBA columns, higher conductivities resulting in reducing unwanted particles' zeta potential 
have proven effective [169]. However, this is only effective to a point, as conductivity plays a 
crucial part in binding targeted proteins, so an upper limit to this effect is quickly reached. 
Reducing cell debris size has been correlated with reducing zeta potential, resulting in less bio 
adhesion of unwanted particles [90]. However, breaking down the cell into smaller pieces 
requires higher shear forces resulting in protein degradation and activity loss. Therefore, 
potential viral capsid damage could also occur when trying to reduce cell debris size. The 
expanded bed flow rate is also limited and must remain constant once set to maintain the bed 
expansion to around two to three times its packed size. 
 
Specifically, for EBA chromatography, coating the resin beads with a high molecular weight 
polymer has been found to stop biomass deposition on the resins' surface. A highly negatively 
charged polymer like PAA (Poly(acrylic acid)) has been used to reduce the binding of cells to 
anion exchanger resin's surface during purification [170]. If the coating is too dense, the 
polymer can affect the resin's binding capacity, blocking the entrance of the pores for proteins 
to diffuse into. A cross-linked coating of agarose reduced bio deposition for E. coli cells and 
cell debris during purification [171]. Agarose provided a more stable coating than PAA, which 
suffered from leaking into the solution at higher conductivities. 
 
A one-step anion exchange EBA purification of adenovirus gave a recovery of 32% infectious 
viral particles and a concentration factor of 5 using a quaternary amine (Q) resin [159]. 
Additionally, the VP: IU (viral particles to infectious units ratio) was 13:1, within the FDA’s 
30:1 range [172]. The crude cell lysate was loaded onto the expanded bed without the need for 
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centrifugation or filtration, allowing for the binding of viral particles present in the culture 
medium because of early cell lysis [173].  
 
Anion exchange EBA purification of M13 bacteriophage gave a recovery of 82% [174]. This 
bacteriophage is a good candidate for expanded bed purification as the particles are secreted 
out of the cell without requiring lysis. Without the need for cell lysis, there is significantly less 
DNA and other negatively charged contaminants in the solution to compete with the M13 
particles for binding. 
 
2.3.2 Monoliths  
Monoliths are a single piece stationary phase (column) used as an alternative to packed bed 
chromatography. They contain a random interconnected porous structure that acts as flow 
channels through the column. Monoliths are one interconnected piece capable of higher fluid 
flow rates and back pressures than conventional packed beds [175]. The main difference 
between packed beds and monoliths is how solutes are transported to and from the surface. 
Where packed beds rely on diffusion, monoliths use convection imposed by the mobile 
phase's pressure [44]. Convective transport occurs faster than diffusion, which tends to limit 
larger molecules such as viruses, as it is relative to the velocity of the mobile phase not the 
size of the particle. Because of the monolith's porous nature, a larger number of binding sites 
are available, resulting in monoliths having higher capacities than packed beds. Monoliths 
exhibit clogging/fouling of pores, especially when high host cell DNA is present in lysate, but 
it has been suggested increasing pore size up to 6 nm could solve this issue [176]. Monoliths 
can be functionalized with ligands for ion exchange (cation and anion), affinity, IMAC, or 
hydrophobic interactions. 
 
Monoliths are an emerging technology for protein and virus purification. researchers used a 
monolith composed of chitosan and poly(vinyl) alcohol (50:50) was used to recover 
adenovirus serotype 5  by anion exchange [7]. Development of a streptavidin derivatized 
macro-porous monolith enabled a single-step capture of chemically biotinylated Moloney 
Murine Leukaemia virus by affinity chromatography  [177]. Although only 8% of recoveries 
were achieved, it was a proof of concept for monolithic purification from crude load material. 
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More effective capture of proteins from crude lysate has been performed with a super macro-
porous monolith with pore sizes ranging from 10 to 100 µm [178]. However, monolith fouling 
is an issue with caking forming on the column's top or at the inlet. Lipid fouling from clarified 
supernatant reduces binding capacity and increase back pressure [179]. In an attempt to 
prevent fouling, another epoxy monolith was used to first remove lipids from the supernatant, 
essentially adding in a clarification step [180]. 
 
Purification using a CIM® QA monolith was employed for influenza A virus for vaccines 
yielding 98% recovery and 52% reduction of host cell DNA and HCP, respectively [181]. 
Icosahedral bacteriophage PRD1 was purified using Q and dimethylamine (DEAE) anion 
exchange monoliths with yields of infectious particles up to 80%. Purified particles were 
eluted in high concentrations of approximately 5 mg/ml [182]. A range of monoliths made 
from biomaterials has also been tested and characterized for the purification of adenovirus. 
Variations of chitosan, dextran, agarose, and polyvinyl alcohol created various porous 
structures from freeze-drying. The resulting structures functionalized with Q anion exchange 
ligands gave recoveries between 33 to 70% [183]. 
 
2.3.3 Membranes 
Membranes are microporous sheets typically made of polymers wrapped into spherical rolls 
to maximize surface area per volume.  They allow for higher flow rates as most of the mass 
transfer occurs by convection like monoliths; however, unlike monoliths, membranes do not 
suffer from high-pressure drops. As with advances in monoliths, membranes are also seeing 
increasing use for viral purification. Porous membranes functionalized with ligands for 
affinity and ion-exchange chromatography have purified adenovirus, AAV, and influenza 
virus [184, 185]. Like monoliths, membranes use convection rather than diffusion to facilitate 
the transport of solutes to and from the pore surface. Therefore, membranes use higher flow 
rates and have better dynamic binding capacities than conventional packed bed 
chromatography; however, membrane capacity is roughly 1/3 compared with monoliths [44]. 
Rotavirus-like particles have also been purified from a clarified lysate using an anion 
exchange membrane [186]. Although recovery was low in this case, it still provides a starting 
point for optimization and proof of concept. Work on ligand grafting and optimization of 
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grafted ligand densities has provided a 5-fold increase in the dynamic capacity for adenovirus 
purification. This optimized membrane with a ligand density of 2.4 μmol/cm2 gave a recovery 
of 60% [8].  
 
Alternative membrane configurations are also being trailed, such as lateral flow (LFMC) 
instead of radial flow using different flow distributors. LMFC was used to purify adenovirus 
on a small scale with recoveries of 90% and HCP and DNA below 10% of load amounts [9]. 
Metal affinity Sartobind iminodiacetic acid (IDA) membranes have purified adenovirus with 
comparable recoveries to packed bed chromatography [187]. Additional to the benefits of 
higher flow rates and reduced production time, membranes can be single-use. This style of 
product is attractive to the pharmaceutical industry as an alternative to vigorous Clean In 
Place (CIP) methods to ensure equipment is sanitized and cleaned to FDA standards [92].  
 
2.3.4 Miscellaneous purification strategies 
ATPS formed by the mixing of two different liquid polymers has been used to purify 
adenovirus. Purification from crude lysate separated the adenovirus from contaminants 
capturing it in the top phase. The two-phase solution PEG 300- phosphate  (20%, w/w PEG 
300, 20% K2HPO4–KH2PO4 ratio 18:7, pH 7.5) gave a recovery of 82% from crude lysate [188]. 
AAV serotype 8 has also been purified by ATPS [189].  
 
Chromatography methods currently run a positive capture mode where the virus is bound to 
the stationary phase and eluted after contaminants have passed through. Alternatively, 
purification is possible by negative mode chromatography where contaminates are bound to 
the column, and the virus is in the flow-through/non-bound phase. While being relatively 
new,  resins and stationary phases specifically designed to run in this mode are being 







2.4 3D printing technology 
 
2.4.1 General 3D printing 
Additive manufacturing or more commonly termed 3D printing, has been around since the 
1970s but has only recently become common technology [191]. Advancement in affordability 
and availability has increased its popularity and showcased its potential uses from bespoke 
plastic components for cars, airplanes, and computers, to patient-specific medical implants 
and dentistry [192-194]. Four forms of 3D printing are material extrusion, vat polymerization, 
material jetting, and powder bed fusion. Schematic style drawings of each printing technology 
as shown in Figure 2-9 [195]. Material extrusion or Fused Deposition Modelling (FDM) is the 
most common. A heated nozzle liquefies a feed filament of plastic that is pushed through an 
extrusion tip. This nozzle can then move along the X and Y axis, laying down the filament, 
which quickly cools and re-solidifies. The printing stage can then be moved down a set 
amount from the nozzle for another layer to be deposited building up the structure. Material 
extrusion has created microfluidic on-chip systems for automated colorimetric enzyme-linked 
immunosorbent assay (ELISA) to detect malaria [196]. 
 
Vat polymerization works because of the chemistry of resins that cure with UV light. A stage 
is dipped to be touching the top of a resin vat. A UV light of a particular pattern and 
wavelength is then shown onto the stage to cure the resin. The stage is drawn down so that 
the cured resin pattern is just touching the surface of the vat and a new pattern is shone 
through. This process is repeated building up the structure out of the resin vat. The structure 
is then washed in Isopropyl Alcohol (IPA) to remove the excess resin before a secondary UV 
curing process to complete the curing process and strengthen it. 
 
Material jet printing uses existing inkjet printing technology applied to waxes and plastics to 
build up structures layer by layer [197]. A fine nozzle head sprays down small droplets of 
liquefied wax or plastic as it moves along the X and Y-axis. The printing stage is then lowered, 
similar to material extrusion, so that the printer can add another layer. The difference between 
material jet printing and material extrusion is layers are built out of combinations of small 
droplets instead of a continuously extruded filament. Jet printing offers a higher level of 
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precision because of the droplets' size compared with the extruded filament. Material Jet 
printing of wax has allowed for the fabrication of microfluidic channels not possible with 
other printing methods. The high precision offered by material jet printing can create channels 
with features as small as 100 µm [198, 199]. Wax printing has also helped fabricate tissue 
scaffolds with bio-compatible waxes and create a hydrogel scaffold using a negative 
templating method [200].  
 
Powder bed fusion printing is specific to metal printing [201]. Small spherical beads of metal 
are spread evenly over a stage where a laser or electron beam can tracer over a pattern, 
sintering the beads together. The stage is then lowered, and more powder is spread across the 
stage. This process is then repeated, building up a structure. The 3D-printed part is porous 




Figure 2-9:  Schematic displaying each additive manufacturing technique. FDM (a); Material jet printing (b); Vat 





2.4.2 3D printing for chromatography 
3D printing in chromatography began in 2014 where the first structures were printed out of 
UV cured acrylonitrile-butadiene-styrene powder layers [202]. Comparisons between the 3D-
printed structures and simulated models for ordered packed beds showed a close resemblance 
in performance. Further modeling showed improved performance over randomly packed 
beds of beads, with lower theoretical plate numbers for ordered structures [203, 204]. 
Advancement in printing technology allowed for 3D-printed wax templates via material jet 
printing [205]. Templates in the shape of triply periodic minima surfaces (TPMS) such as the 
Schoen gyroid were printed on a Solidscape 3Z Pro out of paraffin-based wax. A solution of 
either dissolved cellulose or agarose could be injected into the template's void spaces and 
solidified. The wax template was then melted away in boiling water, leaving behind the 
hydrogel-based 3D-printed column [15]. Functionalization of these columns with both anion 
and cation exchange ligands allowed the binding and elution of proteins.  Direct printing of 
TPMS structures using thermal laser gelation of dissolved cellulose solution similar to vat 
polymerization printing provided mixed results [206]. Although possible, the resolution and 
troubleshooting issues of this technology prevented further development. Columns produced 
by 3D printing are single piece like monoliths; however, they differ by having defined ordered 
flow channels rather than randomly connected pores. They allow for any number of 
conceivable flow structures or packing geometries; additionally, flow distributors and 
collectors can be printed as a part of the column [202].  Control over packing can optimize 
reduced plate heights and other flow characteristics such as tortuosity that can affect 
performance [204].  
 
 
Simon & Dimartino developed a 3D-printed stationary phase for chromatography [207]. They 
used UV-cured polymers functionalized with quaternary amine groups to produce a 
monolithic structure with ordered TPMS channels. They have also shown comparable Bovine 
Serum Albumin (BSA) protein binding capacities to commercially available packed bed resins 
and purification of protein directly from a simulated cell broth. The 3D-printed stationary 
phase was unaffected by the solids (cells) in solution [208]. Their process is currently limited 
by the printable structures' resolution and size because of the mechanical properties of the 
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solid phase and light scattering during printing. A different 3D-printed stationary phase for 
analytical planar chromatography was developed by Macdonald et al. [209]. The Thin Liquid 
Chromatography (TLC) plate separated small amounts of different dye molecules and 
proteins. There are no reported 3D-printed chromatography stationary phase columns used 
to purify viruses or virus-like particles reported in the literature at the time of this research. 
 
Previous research suggests a 3D-printed monolithic columns of a triply periodic minimal 
surface (TPMS) such as a Schoen gyroid could purify virus or virus-like particles in a similar 
way to EBA chromatography [16]. Where the flow channels are large enough to passage solids 
allowing for purification directly from cell lysates and culture fluids. The governing equation 
for a Schoen Gyroid is shown in equation 2-3, where 𝑙 is the length of a single unit cell of the 




















) = 𝑡,   (2-3) 
 
Therefore, by printing a solid phase at all points where t is negative, a uniform periodic 
repeating network of channels is created. For reference, Figure 2-10 shows how the gyroid 
surface intersects a given volume. The Schoen Gyroid has been printed out of metal by 
additive manufacturing showing the complex shape can be constructed using this new 
manufacturing technique [211]. The Schoen gyroid is one of many different TPMS structures 





Figure 2-10:  Matlab plot of the surface of a Schoen gyroid. 
 
As previously mentioned, research by Conan Fee has suggested the possibility of using 3D-
printed TPMS columns of cellulose hydrogel to facilitate the capture and purification of virus 
and virus-like particles from crude cell lysates [16]. The column’s channels should allow cell 
debris and other larger contaminants to pass through easily while viral particles can penetrate 
the micro-pores. Anne Gordon confirmed this in her thesis “Development, Functionalization, 
and Characterization of Triply Periodic Minimum Surface Hydrogels for Solid-Tolerant 
Chromatography” [15]. Her work showed that 3D-printed columns were solid tolerant while 
binding and eluting proteins separating them from a broth of yeast cells. Both anion and cation 




2.4.3 3D modelling 
 All printers require a 3D model of the desired structure in a specific file format, typically 
standard triangle language (STL). Each model has points in space that are connected to form 
triangles. The more triangles there are per a given area, the high the resolution of the structure.  
Figure 2-11 shows two Schoen gyroid columns that have been created with varying 
resolutions. Like other modeling software, Slicer software has limitations when working with 
large files. There is a compromise in terms of resolution and file size, especially for TPMS 
column structures. File sizes can quickly grow to multiple gigabytes because of the small size 
of the complex channels and the overall column's potentially large size. The model is 
translated into G code by the slicer software, which gives the printer direct instructions about 
printing the structure. Slicer software divides up the structure's Z-axis into traceable layers of 
a set thickness (layer height). This G code contains directional commands for each layer that 
the printer can follow.    
 
Figure 2-11:  Comparison between two identical Schoen gyroid columns with different resolutions; Right side, 30 





2.4.4 Stationary phase material  
As mentioned in section 2.4., 3D-printed columns are made by filling wax templates with a 
dissolved solution of agarose or cellulose. These two materials thermally set into gels with the 
agarose solidifying once cooled and the cellulose gelling with a temperature increase above 
20 °C [213]. Agarose dissolves in hot water where cellulose requires a specific solvent. 
Cellulose polymer is made up of subunits, as shown in Figure 2-12. 
 
Figure 2-12:  Chemical structure of a cellulose subunit [214]. 
 
Cellulose can be dissolved in a range of ionic liquids and is soluble in a urea/NaOH mixture 
at low temperatures (-12°C)  [215-219]. The cellulose chains are broken apart by the NaOH 
and form complexes with the urea. These complexes break down upon heating, and hydrogen 
bonding is allowed between cellulose chains to form a gel structure [220].  Post gelation, the 
hydrogel is regenerated in water to remove the NaOH and urea trapped within the gel [221]. 
Anne Gordon's previous work with this technology investigated agarose columns 
predominantly; however, the main focus will be on cellulose for this work. This is because of 
the ability to increase the cellulose hydrogel's pore size above 1 µm into a range larger enough 
to theoretically allow viral diffusion [222]. Pore size alteration is possible by adding chemical 
cross-linking agents such as epichlorohydrin (ECH), which also increases the mechanical 







2.4.5 Chemical functionalization 
Both agarose and cellulose are common stationary phases for packed bed resins. Both 
polymers have free OH groups along their chains, which can be modified with various 
functional groups. Current functionalization tested on 3D-printed agarose and cellulose are 
DEAE and carboxymethyl [15]. As previously mentioned in Section 2.2.6, other potential 
functionalities include quaternary amine (Q), IMAC, and hydroxyapatite, which can be 
attached to a cellulose-based hydrogel [134, 135, 224-226].  A quaternary amine ligand attaches 
to cellulose via a reaction between the epoxide ring of the chemical glycidyl 
trimethylammonium chloride (GMAC) and the polymer chain's hydroxyl groups under 
alkaline conditions. While DEAE has two amine arms, a Q functionality has three. DEAE is a 
weak anion exchanger, and Q is a strong anion exchange ligand. A weak anion exchanger has 
a narrow range of pH where it maintains its positive charge, unlike a strong exchanger that 
maintains its charge across the entire pH range.    
 
An IMAC ligand is attached to a cellulose stationary phase in a two-part reaction with ECH 
and iminodiacetic acid (IDA) under alkaline conditions. First, the epoxide ring of ECH reacts 
with the hydroxyl groups of the polymer chain. IDA then reacts with either the epoxide ring 
or the chloride group forming an amide bond [134]. The two acid arms of the IDA can then 
bind metal ions, specifically Ni2+, for His-tag affinity. Nitrilotriacetic acid can also be used as 
a metal affinity ligand—first, tosylation of the celluloses hydroxyl groups followed by 
persilylation of nitrilotriacetic acid. The activated cellulose and nitrilotriacetic acid react 
together to form nitrilotriacetic -cellulose via an amination reaction [135]. The nitrilotriacetic-
cellulose has three acidic arms that can co-ordinate metal ion immobilization. The difference 
in coordination can be seen in Figure 2-13. While both of these ligands immobilize metal ions, 
they provide different selectivities and binding capacities. Typically, IDA has a higher ion 
loading capacity and, therefore, protein binding capacity. Nitrilotriacetic-cellulose has a 
higher selectivity for His-Tagged proteins and stronger metal ion coordination, so it is less 






Figure 2-13:  Depiction of IDA metal ion coordination compared with nitrilotriacetic acid [227].  
 
HA has not previously been incorporated into a cellulose hydrogel; however, HA coatings of 
bacterial cellulose have been used in the medical field for bone implants [228-231]. In all cases, 
HA is mineralized onto the cellulose's surface using calcium and phosphate salt solutions, in 
some cases aided by citric acid. There are no reports that this mineral binds and elutes protein 
but does have favorable bio interactions. Mineralized Ha (Ca10(PO4)(OH)2) is nearly always 
calcium deficient, meaning it contains fewer calcium atoms than should be stoichiometrically 
present (Ca to P ratio of less than 1.66). This ratio suggests the HA produced by mineralization 
is not pure and maybe a combination of other calcium phosphate minerals [232].  
 
Other potential functionalities include specifically designed peptides or proteins attached to 
the stationary phase by click chemistry [233, 234]. Specifically, N-hydroxysuccinimide (NHS) 
ester reactions can be performed on cellulose to bind these designer molecules [235]. The 
hydroxyl groups of the cellulose can be oxidized into a carboxylic acid. Figure 2-14 then shows 
the potential reaction pathways for attaching a biological molecule with a stable amide bond. 
This reaction scheme is one of many click-type chemistries that can enable an affinity molecule 




Figure 2-14:  Reaction pathway for NHS-ester coupling of a potential peptide chain to a cellulose stationary 




2.5 Direction of current work 
This chapter has described the promise of gene therapies in addition to the state-of-the-art 
downstream processing for them. Although there are new technologies such as membranes 
and monoliths, there isn’t a specifically designed purification platform for viruses and viral 
particles. As such, difficulties in purification as self-evident, with low recoveries, a high 
number of processing steps, and variation in the process even between different serotypes of 
the same virus. 3D-printed chromatography columns have been identified as a potential 
platform technology for a capture step combining clarification, filtration, and initial 
chromatography purification. The combination of multiple steps should increase the overall 
recovery while minimizing processing time and therefore cost. 
 
Previous work with 3D-printed columns has shown functionalization of cellulose and agarose 
stationary phases with cation and anion exchangers is possible. The columns could also 
passage solids efficiently while binding and eluting proteins. Additional ligands were also 
discussed concerning how they may be incorporated into a cellulose stationary phase. 
Specifically, a quaternary amine, hydroxyapatite, and IMAC are all possible 
functionalization’s that have previously been used to purify viruses successfully. Cellulose 
hydrogel could be an alternative to agarose because of its larger pore size specifically 
advantages to viral purification. As the templating method is already established primary 
focus can be on optimizing ligands, stationary phase, and eventual scale-up. 
 
Because of the number of different viruses being used for gene therapies and other 
applications (vaccines and phage therapy), testing will encompass as many of these as 
possible to show its versatility as a platform technology. Purification from clarified lysate and 
directly from cell culture will benefit traditional media by combining multiple processing 
steps. Column performance will be important and determined by multiple factors, including 
recovery, purity, processing time, dynamic and static binding capacity. Techniques for 
determining these indicators are common research practice but are outlined in Chapter 3 




3 General materials and methods  
 
The following list of chemicals shown in Table 3-1 and equipment shown in Table 3-2 
summarize those used in the experimental work of this project. Many of these appear in 
multiple experimental steps. Appropriate figures and diagrams are listed for custom rigs and 
manufactured processing equipment within the method. Additional diagrams for these can 
be found and explained in more depth in Chapter 6. The experimental method is described in 
the same chronology as the subsequent chapters as accurately as possible. The methodology 
is referred to at the start of each experimental section with additional detail for experiments' 
variations. Chapter 6 is self-contained with its own methods section used for up-scaling of the 
3D printing technology. 
 
Table 3-1: Chemicals and materials used in experimentation. 





A549 cells Microbiology ECACC 
Acetone Technical Thermo Fisher Scientific 
Adenovirus serotype 5 clarified lysate iBET 
Agar Microbiology Sigma-Aldrich 
AgeI-HF Analytical Thermo Fisher Scientific 
Anhydrous citric acid ACS Thermo Fisher Scientific 
Anhydrous di-sodium 
orthophosphate 
ACS Thermo Fisher Scientific 
Anhydrous sodium sulphate ACS Thermo Fisher Scientific 
Anhydrous di-potassium 
orthophosphate 
ACS Thermo Fisher Scientific 
Associate-adeno virus serotype 
5 (CMV promoter, no insert) 
Microbiology Creative Biogene 
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Chemical Grade Source 
Associate-adeno virus serotype 
9 
Crude lysate US Southwestern medical 
Bacto™ Tryptone Microbiology Fort Richards Laboratories 
Benzonase Microbiology Merck 
Bovine serum albumin 99% Thermo Fisher Scientific 
Cellulose powder, Type 20 Highly purified fibres Sigma-Aldrich 
CFM4HEK293 medium Microbiology 
GE Healthcare Life 
Sciences 
Coomassie Brilliant Blue stain Analytical Thermo Fisher Scientific 
Cytochrome C 99% Thermo Fisher Scientific 
Dithiothreitol (DTT), reducing 
agent 
500 mM, 10x 
concentrated 
Thermo Fisher Scientific 
Dnase I, from bovine pancreas Analytical Thermo Fisher Scientific 
Dulbecco’s modified Eagle’s 
medium 
Microbiology Thermo Fisher Scientific 
EDTA Analytical Sigma-Aldrich 
Epichlorohydrin Analytical Sigma-Aldrich 
Escherichia coli (15669) Microbiology ATCC 
Escherichia coli bacteriophage 
M13 (15669¬B1) 
Microbiology ATCC 
Ethanol Analytical BDH Lab Supplies 
Fetal bovine serum Microbiology 
GE Healthcare Life 
Sciences 
Food colouring Food Local market 




Ham's F12 medium, Kaighn's 
modification 
Microbiology 
GE Healthcare Life 
Sciences 
HEK 293 T cells Microbiology ATCC 
47 
 
Chemical Grade Source 
High Pure Viral Nucleic Acid 
Kit 
- Roche 
HIS-Tagged protein crude 
UC School of Biological 
Sciences 
Hydrochloric acid Analytical Bio Lab 
Hydroxyapatite 20 µm powder Analytical Acros Organics 
Imidazole Analytical Thermo Fisher Scientific 
Iminodiacetic acid ACS Sigma-Aldrich 
INNOTEST HIV Antigen mAb Microbiology Fujirebio Diagnostics 
Isopropanol Analytical BDH Lab Supplies 
Lentivirus clarified lysate iBET 
LightCycler® 480 Probes 
Master 
Microbiology Roche 
Lithium dodecyl sulfate (LDS) 
buffer 




Methanol Analytical BDH Lab Supplies 
Novex Sharp Pre-stained 
Protein Standard 
Analytical Thermo Fisher Scientific 
Polysorbate 20 Analytical Sigma-Aldrich 
Proteinase K from Tritirachium 
album 
Analytical Thermo Fisher Scientific 
Saccharomyces Food Local market 
Sodium bicarbonate ACS Merck 
Sodium chloride ACS Sigma-Aldrich 
Sodium dihydrogen 
orthophosphate 
ACS Thermo Fisher Scientific 
Sodium dodceyl sulfate buffer 20x concentrated Thermo Fisher Scientific 
Sodium hydroxide 97% Thermo Fisher Scientific 
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Chemical Grade Source 
Sodium Pyruvate Analytical Thermo Fisher Scientific 
SYBR Master mix Analytical Thermo Fisher Scientific 
Tyrosinase 99% Sigma-Aldrich 
UltraPure Tris buffer Analytical Invitrogen 
UltraPure water Analytical Thermo Fisher Scientific 
Urea ACS Sigma-Aldrich 





Table 3-2: List of equipment and machinery used for experimentation. 
Equipment Supplier 
311DS environmental shaking incubator Labnet 
ÄKTA PURE Chromatography Hardware GE Healthcare 
ÄKTA Start Chromatography Hardware GE Healthcare 
ÄKTA10 Explorer Chromatography Hardware GE Healthcare 
Autoclave full automatic 60 Priorclave 
Bruker Vertex 70 spectrometer with OPUS operating 
software 
Bruker Optics 
Custom cellulose infusion rig University of Canterbury 
Custom support wax removal rig version 1 University of Canterbury 
Custom support wax removal rig version 2 University of Canterbury 
Formlabs 2 resin printer Formlabs 
Frac-P90 GE Healthcare 




Hei-Tec hot plate and magnetic stirrer Heidolph 
Hitachi H-7650 120 kV electron microscope Hitachi High-Technologies 
iBlot dry blotting system Invitrogen 
Infinite 200 PRO NanoQuant microplate multimode 
reader Tecan 
Inverted TCS SP5 confocal microscope Leica 
JSN 7000F field emission high resolution scanning 
electron microscope 
JEOL 
LightCycler® 480 instrument Roche 
Mitsubishi refrigerator Mr-385E Local Electronics Store 
MJP ProJet 2500W 3D Systems 
NanoDrop 2000 ThermoFisher 
NanoSight NS300™ Malvern Instruments 
pH-meter CP105 Elmetron 
Purifier Biological safety cabinet Labconco 
Rotorgene qPCR machine Qiagen 
Samsung Timesaver 1000 W Microwave Local Electronics Store 
Silverson L4RT Stirrer 
Advanced Packaging Systems 
Ltd 
Smartlab 3kW powder XRD Rigaku 
Solidscape Pro 3Z Solidscape 




TX3202L Top load balance Shimadzu 
Ultrospec 2100 Pro UV/Vis Spectrophotometer Amersham Biosciences 
Variable speed Console drive 100 rpm MasterFlex 
 
 
3.1 Column fabrication 
3.1.1 Cellulose hydrogel synthesis 
7 wt% sodium hydroxide and 12 wt% urea were mixed into deionized (DI) water and left to 
cool inside a fridge down to 4°C. Once cooled, 5 or 6 wt% cellulose powder was slowly added 
while the solution was mixed at 8000 rpm in a Silverson overhead mixer. After the cellulose 
was evenly dispersed, it was placed in a glycol bath (1:1 glycol to water) inside a freeze at -
12°C. After one to two hours, the solution was removed and examined to ensure no cellulose 
particles could be seen in the solution then stored at 4 °C until use.  
 
Formulation of the cellulose hydrogel was adjusted by the addition of a chemical (ECH) and 
physical (additional undissolved cellulose powder) cross-linker. Various amounts of each 
cross-linker were added depending on the experiment or formulation required for each 
chromatography column or test cube. After the addition of cross-linking agents, the solution 
was mixed at 8000 rpm in Silverson overhead mixer for one minute. Mixing occurred with the 
solution below 5 °C to reduce the chance of premature gelation. The solution was then heated 
to 50 °C in a water bath for two hours to gel the cellulose and activate the chemical cross-
linker if present.  The subsequent experimental methods will indicate the composition of the 
resulting cellulose hydrogel. Post gelation, all cellulose hydrogels were regenerated in tap 
water over five days [220].  
 
3.1.2 3D models 
Cylindrical column models of Schoen gyroids of varying channel diameters (150 to 500 µm) 
were modeled in a Matlab TPMS generation program and saved as STL files. This code was 
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developed by Dr. Daniel Clarke and can be found in the supplementary material. The 




















) = 𝑡,  (3-1) 
 
 
At t = 0, the surface intersects a volume evenly, whereby filling in one side of the surface 50% 
of the volume is filled in. l is the length of the unit cell. The unit cell length is related to the 







,     (3-2) 
 
where ε is the porosity and s is the specific surface area of the unit cell. In the case of TPMS 
channels, a hydraulic diameter is used as the cross-sectional width of these channels is not 
circular. The hydraulic diameter was chosen and then the unit cell was scaled to match. The 
surface area was estimated by summing the area of triangular elements of a mesh that 
approximates the level surface. The Matlab program evaluates the level surface function for 
the Schoen gyroid over the spatial domain. Next, this scalar field was intersected with the 
level surface for the cylindrical exterior. The build material is assigned to where the scalar 
field is negative, the void space is where the scalar field is positive. The mesh describing the 
column was generated by applying the marching cube algorithm to the scalar field [237]. The 
marching cube algorithm is applied only to a cylinder either of a given length or one-unit cell 
in length. The face and vertex data are patterned along the vertical axis to produce a cylinder 
of the requisite length. The STL files are then sent to a wax 3D printer via the 3D Sprint 

















3.1.3 Wax templates 
 
Two different 3D printers were used for the fabrication of TPMS wax templates, a SolidScape 
3Z Pro printer (old) and a 3D systems MJP 2500W ProJet (new). The new printer produced the 
majority of the templates used however, some were printed on the old printer before the start 
of this project. Additionally, a set of columns were purchased from Regal Casting LTD 
(Auckland, New Zealand) which were printed on a 3D systems MJP 2500W ProJet. Both 
printers produced templates out of a build and support wax, however, each printer used a 
different set of waxes that required different post-processing methods. 
 
3.1.3.1 SolidScape 3Z: 
 
Column templates were placed into a beaker of 70% VSO on a hot plate with a temperature 
control probe. The VSO was heated to 50 °C to dissolve the support wax (bright red) from the 
column. VSO was replaced every two to three hours until all support wax was removed noted 
by no color change in the VSO. The template was dried at 50 °C in an oven for 48 hours.  
 
3.1.3.2 3D systems MJP 2500W ProJet: 
 
Column templates were placed into a beaker of IPA on a hot plate with a temperature control 
probe. The IPA was heated to 35 °C to dissolve the support wax from the column. IPA was 
replaced every four hours, a minimum of five times, before the template was placed in a 500 
mL bottle of fresh IPA for one week to ensure complete removal of support wax. Unlike the 
SolidScape support wax, the 3D systems support wax is white and dissolves to be colorless. 
At the time of experimentation, there was no way to accurately determine complete support 
wax removal. Therefore, multiple columns were processed at the same time which could be 
used sacrificially to ensure complete support wax removal. This was done by breaking open 
one of the templates to examine the internal channels for remaining support wax. If support 
wax remained further IPA soaking was completed followed by checking of another template 
sacrificially. This ensured all of the support wax was removed from that batch of templates. 




3.1.4 Templates to hydrogel columns 
Wax templates (post support wax removal) were placed inside a 3D resin printed hollow 
plastic cylinder with syringe attachable caps (Figure 3-2) at each end secured with Parafilm. 
This method was developed by Anne Gordon as described in her doctoral thesis [15]. A 
disposable syringe (10 to 20 mL depending on the template size) was filled with cellulose 
solution just after the addition and mixing of crosslinking agents. The syringe was attached to 
one end of the plastic mold via an end cap and slowly pressed to inject the solution into the 
cavities of the wax mold. 8 to 16 mL of the cellulose solution was injected in over two minutes. 
After injection the other end of the mold was capped with Parafilm™ and placed inside a 
water bath at 50 °C for two hours. The mold was then transferred to a fridge to cool to 4 °C 
for one hour before the caps and syringe were removed from the mold. The cellulose-infused 
template was gently pushed out of the plastic cylinder and place into a beaker of water. A 
drop of liquid hand soap was then added to the water before the beaker was placed onto a 
hot plate to boil. The water was replaced every three hours and allowed to boil again. This 
process is repeated two to eight times to ensure all wax was removed from the column. The 
column was visually inspected to determine if wax remained inside the translucent cellulose 
structure. The column was then placed in a container of tap water to regenerate. Water was 








3.2 Cellulose functionalization  
3.2.1 DEAE  
The protocol for functionalizing cellulose with the DEAE ligand 2-chloro-N,N-
diethylethylamine hydrochloride follows previous work by Gordon et al. [238]. Cellulose 
hydrogel (columns or pieces) was placed in glass beakers of 4 M NaOH and 3 M DEAE at a 
ratio of 1 g cellulose: 27 ml DEAE: 20 ml NaOH and stirred at 30 or 80 °C for six hours. 
Following the reaction, functionalized cellulose was washed with 1 M NaOH and three 
washes with DI water. DEAE cellulose was stored in DI water until use. Figure 3-3 shows the 
chemical structure of the 2-chloro-N, N-diethylethylamine hydrochloride used for the DEAE 
functionalization. The exposed hydroxyl groups of the cellulose are substituted with the 
diethylethylamine ligand under the caustic conditions [239].  
 
Figure 3-3: Chemical structure of 2-chloro-N,N-diethylethylamine hydrochloride [240]. 
 
 
3.2.2 Quaternary amine (Q) 
The protocol for functionalizing cellulose with a Q ligand was based on works by He et al. 
who functionalized aerogels made from cellulose nanofibers [225]. Cellulose hydrogels 
(columns or pieces) were placed inside a conical flask with 1 M NaOH and 90% 
glycidyltrimethylammonium chloride (GMAC) at a ratio of 1 g cellulose: 50 g NaOH: 30 g 
GMAC and stirred at 80°C for six hours. Following the reaction, cellulose was washed with 1 
M NaOH and three times with DI water. Q cellulose was stored in DI water until use. Figure 
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3-4 shows the chemical structure of GMAC, showing the epoxide ring, which reacts with the 
exposed hydroxyl groups of the cellulose forming an ester bond in caustic conditions.  
 
Figure 3-4: Chemical structure of GMAC [241]. 
 
3.2.3 Hydroxyapatite  
 
Three different methods for HA functionalization were tested as follows: 
 
3.2.3.1 Alternating solutions: 
This functionalization was based on hydroxyapatite growth on bacterial cellulose for medical 
implants by Saska et al. [228]. Cellulose hydrogel (columns or pieces) was soaked in a solution 
of 11 g/L of CaCl2 for 24 hours. The hydrogel was then briefly rinsed with DI water before 
being placed in a solution of 8.6 g/L Na2HPO4 for 24 hours. This cycle of alternating between 
calcium and phosphate solutions was repeated for 7 to 14 days. Post functionalization HA-
cellulose was washed and stored in DI water until use.  
 
3.2.3.2 Solid incorporation: 
Before cellulose gelation fixed amounts of 20 µm hydroxyapatite powder (3 to 11 g) were 
added to 100 grams of 5% dissolved cellulose solution. The powder was mixed into the 
solution using the Silverson overhead mixer at 8000 rpm for three minutes. The solution was 
transferred into a square 30 x 30 x 20 mm fully sealed Tupperware™ container and placed in 
a drying oven at 50 °C for two hours. Post gelation hydrogels were removed from the 
container and regenerated in a 500 mL beaker of DI water. The water was replaced every 24 




3.2.3.3 Simulated Body Fluid (SBF) soaking: 
The mineralization of hydroxyapatite onto bacterial cellulose by SBF soaking was based on 
works by Zimmermann et al. [229], and Rhee et al. [242]. An SBF solution containing citric acid 
was produced by adding the following reagents in order to 900 mL of DI water stirred on a 
hot plate at 37°C. 
 
1. 6.5456 g NaCl 
2. 2.2682 g NaHCO3 
3. 0.373 g KCl 
4. 0.1419 g Na2HPO4 
5. 0.3049 g MgCl2 .6H2O 
6. 0.3675 g CaCl2 .2H2O 
7. 0.071 g Na2SO4 
8. 6.057 g Tris [(CH2OH)3CNH2] 
9. 30 mL of 1 M HCl 
10. 0.192 g Citric acid 
 
While maintain mixing, the pH was adjusted to 7.4 by additions of either 1 M NaOH or HCl 
and the volume made up to 1000 mL. Pieces of cellulose hydrogel (5 mm side length cubes) in 
a 500 mL plastic container of SBF fluid were placed in a shaker incubator at 37°C for 48 hours. 
The SBF fluid was then replaced and this cycle was repeated for 7 to 14 days until a white 
precipitate was seen to form inside the hydrogel.  
 
3.2.4 Crystal growth control 
In between soaking cellulose hydrogel in alternating solutions of CaCl2 and Na2HPO4 (as 
described in 3.2.3.1) the hydrogel is washed with DI water. By lengthening the time of the 
wash step calcium and phosphate ions can be removed limiting the growth of the 
hydroxyapatite to the pores and not upon the surface. Wash times of 10 to 60 seconds were 





3.3 Microscopy and mineral analysis  
 
3.3.1 Freeze drying 
Various sized samples (columns and cubes) of cellulose hydrogel (functionalized and non-
functionalized) were placed inside 50 mL centrifuge tubes with a needle-sized hole in the cap. 
These were then dipped into liquid nitrogen for a minimum of five minutes to snap freeze the 
hydrogel. Subsequently, the samples were freeze-dried using a Labconco freezone 2.5 freeze 
drier at -45 °C under vacuum. Samples were dried over 48 hours to ensure maximum removal 
of water. 
 
3.3.2 Energy-Dispersive X-ray Spectroscopy (EDS) & Field Emission Scanning Electron 
Microscopy (FE-SEM) analysis  
Various samples of cellulose hydrogel were freeze-dried as previously mentioned in Section 
3.3.1. The samples were manually fractured or sliced open to reveal the inner structure of the 
column for SEM analysis. The samples were gold-coated for 60 s in three cycles at 25 mA at 
varying angles using an Emitech K975X coater. Samples were attached to a copper stage 
mount by carbon tape. FE-SEM was performed with a JEOL 7000F FE-SEM using a probe 
current of 7 mA under an acceleration voltage of 7.5kV.  
 
EDS was performed with the same microscope with a probe current of 11 mA under an 
acceleration voltage of 15 kV. Complete surfaces of freeze-dried 5 mm cellulose gels cubes 
functionalized with HA were examined. Each EDS sample was examined in a minimum of 
five different locations with triplicate cubes of each HA variation tested. Overlapping maps 
were examined to see if the calcium and phosphate signals were coming from similar locations 
(crystal structures).  
 
3.3.3 Fourier transform infrared spectroscopy (FTIR) 
Samples were freeze-dried before analysis as described for SEM and EDS (Section 3.3.1). Small 
pieces of each sample were fractured and pressed under the pin arm. FTIR spectra were 
obtained using a Bruker Vertex 70 spectrometer and OPUS operating software. The 
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wavenumber range scanned was 4000 to 400 cm-1; 10 scans of 4 cm-1 resolutions were signal 
averaged. Triplicates of each HA functionality were tested.   
 
3.3.4 X-ray powder diffraction (XRD) 
5 mm cubes of hydroxyapatite functionalized cellulose hydrogel and control without 
functionalization were freeze-dried as described in Section 3.3.1. Powder samples of each cube 
were made by lightly rubbing them with grit 60 sandpaper. Samples were processed in a 
Rigaku Smartlab 3kW using copper Kα radiation at 2θ 5-70° at a rate of 5°/minute. Results 
were checked for the presence of potential carborundum contamination from the sandpaper. 
Peaks were analyzed from a library of standards for various calcium phosphate minerals.  
 
3.4 Viral diffusion 
Confocal laser scanning microscopy (CLSM) was used to examine the depth fluorescently 
tagged AAV particles had diffused into cellulose hydrogels. Rhodamine Red™-X was used to 
fluorescently label the viral particles following their reactive ammine probe guide [243]. The 
virus was buffer exchanged into a sodium bicarbonate solution, pH 8.3 via centrifugation with 
a 30 Kda Vivaspin falcon tube. 50 ng of the fluorescent dye dissolved in dimethylformamide 
(DMF) at 2.5 mg/mL was then added per 1 × 1011 virus particles (VP) and incubated at room 
temperature in the dark for one hour. Post reaction, the tagged AAV particles were separated 
from unreacted dye molecules and buffer exchanged via centrifugation with another 30 Kda 
Vivaspin falcon tube into 10 nm pH 7 phosphate buffer. Viral adsorption and UV-Vis were 
measured by Nanodrop at 280 nm and 560 to 580 nm. 100 µL of fluorescently tagged virus 
(1 × 1011𝑉𝑃/𝑚𝐿) was pipetted into wells of a 96 well plate.  The various cellulose hydrogels 
were cut into cubes with roughly 5 mm sides before being placed into the wells filled with 
virus. After one or 24 hours the solution was pipetted out of wells and collected. ~100-micron 
cross-sections of each hydrogel were cut with a razor blade to be examined under a Plan 
Apochromat 63x/1.4NA oil immersion objective at 560 nm. Images were examined using 
ImageJ software to determine the depth of penetration. 10 measurements per image were 
taken from the edge of the gel to the point of the band where the intensity starts to diminish. 
Three images for each cellulose composition or functionality were examined. Results were 
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averaged and the standard deviation was determined through Microsoft Excel’s statistical 
function.  
 
3.5 Adsorption studies 
3.5.1 Binding mechanics: 
5 mm cubes were cut out of cellulose hydrogel (various functionalities and hydrogel 
compositions) to be placed in 1.5 ml Eppendorf tubes with 1 ml of 10 mM phosphate buffer 
pH 7. Equilibration was left to take place overnight. Buffer was replaced with 1 M NaCl to 
add counter ions to the functional groups before being washed three times with 1 ml of 10 
mM phosphate buffer pH 7. 1 mL of 2.5 mg/ml of BSA was pipetted into the Eppendorf tubes 
and allowed to adsorb for two hours. After adsorption gels were washed three times with 
equilibrium buffer before elution with 1 mL of 1 M NaCl or 1 M NaCl with 400 mM Na2HPO4. 
BSA concentration in elution was measured by Nanodrop. All tests were carried out in 
triplicate. 
 
3.5.2 Static binding capacity (DEAE, Q and HA): 
1 cm long pieces of a 3D-printed column (varying channel hydraulic diameters, 1 cm column 
diameter, 6 wt% cellulose + 3 wt% added cellulose powder, and 15 wt% ECH) were cut to be 
placed in individual 50 ml centrifuge tubes with 40 mL of 10 mM phosphate buffer pH 7. 
Tubes were placed on a spinning wheel to equilibrate for two hours. Model proteins of BSA 
and cytochrome C were dissolved in 10 mM phosphate buffer pH 7 at varying concentrations 
(1 mg/mL to 30 mg/mL). 20 mL of each protein solution was placed with the equilibrated piece 
of a column. Protein concentration was measured periodically by Nanodrop over 24 hours to 
determine adsorption. All tests were carried out in triplicate. 
 
3.5.3 Protein binding selectivity and elution order: 
Schoen gyroid columns, 300-micron hydraulic channel diameter, 1 cm column diameter by 5 
cm in length (HA or DEAE functionalized) were loaded into individual SNAP column casings 
(S-10/125-PPSS-OV-FP20). The loaded casings were attached to an AKTA10 Explorer used for 
this set of chromatography experiments. For both columns, the following procedure was 




 Columns were equilibrated with 20 mL of running buffer (1 mL/min) before 200 µL of a model 
protein (varying protein at a concentration of 1 mg/mL) was loaded at 0.25 mL/min. The 
column was then washed with 20 mL of running buffer at 1 mL/min. Gradient elution was 
performed over 20 mL reaching a concentration of 100% elution buffer at 1 mL/min. UV signal 
was monitored at 280 and 260 nm for the elution peak. The retention time was measured to 
be from the start of the gradient to the maximum of the peak. All experiments were completed 
in triplicate.  
 
HA buffers: 
Running – 35 mM phosphate pH 7 
Elution - 35 mM phosphate 1 M NaCl pH 7 
 
DEAE buffers: 
Running: 10 mM phosphate buffer pH 7 
Elution: 10 mM phosphate 1 M NaCl pH 7 
 
3.6 Viral culturing and analysis 
3.6.1 M13 bacteriophage 
3.6.1.1 Culturing: 
Escherichia coli (E. Coli) strain ATCC 15669 was cultured according to the supplier’s 
instructions. A culture medium of 1 % tryptone pH 7 was prepared and autoclaved at 121°C 
for 30 minutes. The contents of the suppliers’ glass ampule were then re-suspended in 1 mL 
of culture medium and transferred to a 15 mL centrifuged tube containing 5 mL of culture 
medium. 1% tryptone agar plates were also streaked with the re-suspended E. coli culture and 
grown at 37°C for 24 hours. Liquid cultures of the E. coli were prepared using the same 
medium inoculated from single plate cultures inside a shaken incubator at 37°C for 24 hours. 
 
M13 bacteriophage ATCC 15669-B1 was also cultured according to the supplier’s instructions. 
A culture of host strain (E. coli strain ATCC 15669) was grown in 1% tryptone overnight to an 
OD 600 measurement between 0.8 to 1. 1 mL of cultured host strain was used to re-suspend 
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the contents of the glass ampule before being transferred to a 50 mL centrifuge tube with an 
additional 5 mL of the host culture. The inoculated culture was grown inside a shaker 
incubator at 37°C for 24 hours. 1 mL of this culture was then used to inoculate 150 mL of E. 
coli culture in 1% tryptone and kept in a shaking incubator at 37°C overnight. The crude cell 
culture samples were stored at 4°C for no longer than three days before use. 
 
3.6.1.2 Plaque forming assays: 
The titer of M13 phage samples was determined by plaque-forming assays with the units 
pfu/mL (plaque-forming units per milliliter). A culture of host strain E. coli was incubated 
overnight (1% tryptone) to an OD 600 measurement between 0.8 to 1. 1 mL of this culture was 
aspirated onto a 1% tryptone agar plate and tilted to completely cover the surface. The excess 
liquid was pipetted off the surface after one minute and the plate incubated for 15 minutes at 
37°C. Phage samples were serially diluted in a fresh culture medium from 1 ×10-1 to 1 ×10-12 to 
be spotted on incubated plates. 5 µL × 5 of each dilution was spotted onto the pre-prepared 
plates and incubated overnight. Visible plaques were counted at the appropriate dilution to 
determine the titer. Each sample was tested on three individual plates to ensure consistent 
results. 
 
3.6.1.3 Sodium Dodecyl Sulfate–Polyacrylamide Gel Electrophoresis (SDS-PAGE): 
The purity of eluted M13 and AAV particles was analyzed by SDS-PAGE under denaturing 
conditions [31]. The virus samples were incubated with lithium dodecyl sulfate (LDS) sample 
buffer and reducing agent and heated at 70 °C for 10 min. Novex™ Sharp Pre-Stained Protein 
Standard was used as a protein molecular weight marker. Electrophoresis was performed 
with a 15% resolving polyacrylamide gel on a mini-protein 3 apparatus at constant voltage 
(100 V). The gel was stained with Coomassie® Brilliant Blue R-250 and destained with an 
aqueous destaining solution containing 40% (v/v) methanol and 10% (v/v) acetic acid.  
 
3.6.2 Adenovirus and lentivirus 
Culturing and quantification (purity and titer) of adenovirus and lentivirus was completed at 
iBET by Mafalda Moleirinho and Sofia Moreira. The following method for culturing, purity 
analysis, and quantification of adenovirus and lentivirus is taken from our paper ‘3D-printed 
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ordered bed structures for chromatographic purification of enveloped and non-enveloped 
viral particles’ [244]. It has been included here for completeness of the upstream and 
downstream processing of these viral particles. 
 
3.6.2.1 Adenovirus culturing: 
A549 cells (86012804) were cultured in Ham’s F12 medium, Kaighn's modification 
(SH30526.01) supplemented with 10% fetal bovine serum (SH30071.01). Oncolytic 
adenoviruses were produced as described elsewhere [245]. Briefly, cells were cultured in an 
HYPERflask® (10020), in a humidified atmosphere of 5% CO2 in air at 37 °C. After the cells 
achieved 90% of confluence, they were harvested by trypsinization and centrifugated at 
200xg, to remove the serum-containing medium. The cell pellet was resuspended in 
CFM4HEK293 medium (SH30858.02) supplemented with 4 mM GlutaMAX (35050–038) and 
transferred to a ReadyToProcess WAVE™ 25 bioreactor. The bioreactor was inoculated at a 
cell concentration of 0.3 × 106 cells/mL to 0.6 × 106 cell/mL and after 72 h in culture, the cells 
were infected with a Multiplicity of Infection (MOI) of 10 infectious particles per cell. The 
harvest was performed 48 h post-infection (hpi) and the cell lysis was performed with 
Polysorbate 20 at a final concentration of 0.5% (v/v). For DNA digestion, 100 U/mL of 
Benzonase (1.01656.0001) was used. The digestion proceeded for 4 h at 37 °C in the bioreactor 
with agitation (16 rpm). Afterward, the virus culture was clarified using a ULTA Prime™ GF 
filter followed by a ULTA Prime™ CG filter (DGF-A-02-470, DMP-CG92-470). The 
clarification was performed at a constant flux of 600 LMH using a Tandem 1081 Pump and 
the pressure was monitored using a pressure transducer in-line (080-699PSX-5). 
 
3.6.2.2 Lentivirus culturing: 
HEK 293 T cells (ATCC® CRL-3216™) obtained from the American Type Culture Collection 
(ATCC) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (31053–028) 
supplemented with 10% (v/v) FBS (10270–106), 4 mM of GlutaMAX (35050–038) and 1 mM 
Sodium Pyruvate (11360–070), and maintained at 37 °C in an incubator with a humidified 
atmosphere of 5% CO2 in the air. Cell concentration and viability were assessed by the trypan 
blue exclusion method. Transient lentivirus (LV) was produced by transfecting at seeding 293 
T cells and using a four-plasmid system (pVSVg, pGag-Pol, pRev, and LV plasmid expressing 
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GFP, kindly provided by Dr. Didier Trono through Addgene plasmid repository) as described 
elsewhere [246]. Briefly, 1.5 × 105 cells/cm2 were transfected in a 225 cm2 tissue flask using 
linear 25 kDa polyethyleneimine, PEIpro®, (115–100, Polyplus transfection). The medium was 
exchanged 24 h after transfection and harvested 24 h upon the medium exchange. For DNA 
digestion, 50 U/mL of Benzonase (1.01656.0001) was used. The digestion proceeded for 30 min 
at room temperature. The supernatant collected was clarified with Sartopure® PP3 Sartoscale 
0.45 μm filter (5055306PS--FF—M). The clarification was performed at a constant pressure of 
0.5 bar using a Tandem 1081 Pump. 
 
3.6.2.3 Adenovirus quantification 
This method of quantitative polymerase chain reaction (qPCR) was also described in iBET’s 
paper ‘Clinical-Grade Oncolytic Adenovirus Purification Using Polysorbate 20 as an 
Alternative for Cell Lysis’ [245]. To quantify the adenovirus particles qPCR was used to 
identify the number of copies of genomic DNA. To ensure only the quantification of viral 
particles and the removal of the free viral genome, 20 µL of viral samples were incubated with 
10 U of DNAse for 30 minutes at 37°C. The reaction was then stopped by the addition of EDTA 
to bring the concentration up to 8 mM and then heated at 75°C for 10 minutes. The viruses’ 
genomes were then extracted using High Pure Viral Nucleic Acid Kit according to the 
manufacturer's instructions (11858874001). The viral genome copies were quantified by qPCR 
using the LightCycler® 480 Probes Master in the LightCycler® 480 instrument. 
 
Total particles were also quantified by Nanoparticle Tracking Analysis (NTA) using a 
NanoSight NS300™. Each sample was diluted before measurement in phosphate-buffer saline 
solution. Three videos of 30 seconds were taken for each sample and analyzed using the NTA 
2.3 software. The camera level was set to 16 and kept constant during all measurements. 
 
3.6.2.4 Lentivirus quantification 
This method of qPCR quantification is also described in ‘3D-printed ordered bed structures 
for chromatographic purification of enveloped and non-enveloped viral particles’ as 
performed by Mafalda G. Moleirinho and Anna S. Moreira [244]. The concentration of 
lentivirus physical particles (PP) was measured by the detection of p24 LV protein in 
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supernatants. The p24 protein detection was performed using the INNOTEST HIV Antigen 
mAb, following the manufacturer’s instructions. It was assumed that 1 ng p24 corresponds to 





) = [𝑝24 Protein] × 1,250,000    (3-3) 
 
The functional LV titers were determined by transducing 293 T cells with the produced LV 
supernatants. Green fluorescent protein (GFP) expression was analyzed by flow cytometry as 
described elsewhere [246]. The concentration of LV Transducing Units (TU. mL-1) was 
calculated using the following equation 3-4: 
 
𝑇𝑖𝑡𝑒𝑟 =
% 𝑜𝑓 𝐺𝐹𝑃 𝑃𝑜𝑠𝑡𝑖𝑣𝑒 𝑐𝑒𝑙𝑙𝑠÷100
𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑡𝑟𝑎𝑛𝑠𝑑𝑢𝑐𝑡𝑖𝑜𝑛
× 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 × 𝑛° 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑎𝑡 𝑡𝑟𝑎𝑛𝑠𝑑𝑢𝑐𝑡𝑖𝑜𝑛 𝑡𝑖𝑚𝑒  (3-4) 
 
3.6.2.5 Adenovirus purity 
 
To confirm the presence and shape of oncolytic adenovirus, transmission electron microscopy 
(TEM) was performed. A drop of sample was adsorbed onto a formvar-coated 150 mesh 
copper grids from Veco for two min. The grid was washed five times with sterile filtered water 
then soaked in 2% (w/v) of uranyl acetate for two min and dried in air at room temperature. 
The grids were analyzed using a Hitachi H-7650 120 kV electron microscope. 
 
To detect the presence of adenovirus proteins, SDS-PAGE followed by western blot analysis, 
was performed. Briefly, the virus samples were incubated with LDS sample buffer and 
reducing agent and heated at 70 °C for 10 min. NuPAGE Bis/Tris gels 4–12% were used for 
electrophoresis and SeeBlue Plus2 Pre-stained standard was used as a protein molecular 
weight marker. The SDS-PAGE gels were stained with InstantBlue™. Proteins were 
transferred onto a polyvinylidene difluoride membrane using iBlot dry blotting system and 
the membranes were blocked with 5% (w/v) of reconstituted milk powder in Tris-buffered 
saline with 0.1% (w/v) of Tween 20 (T-TBS buffer) for one hour. After blocking, membranes 
were incubated overnight with primary antibody anti-adenovirus type 5 (dilution 1:4000), 
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followed by secondary antibody incubation with goat anti-rabbit (dilution 1:5000) conjugated 
with peroxidase and developed using the ECL detection reagent protocol. 
 
Total dsDNA was assessed using the Quant-iT™ Picogreen™ ds-DNA Assay Kit, according 
to the manufacturer's instructions. The assay was performed in a black 96 well microplate and 
the fluorescence was measured using the Infinite 200 PRO NanoQuant microplate multimode 
reader. 
 
Total protein concentration was determined by BCA protein assay kit. The analysis was 
performed according to the manufacturer's instructions. The assay was performed in 
transparent 96 well plates and the absorbance was measured at 562 nm, using the Infinite 200 
PRO NanoQuant microplate multimode reader. 
 
3.6.3 AAV serotype 9  
AAV serotype 9 clarified lysate samples were kindly donated by Associate Professor Steven 
Grey from US South-western Medical Centre.  Samples were taken directly from their 
downstream processing post clarification.  
 
3.6.3.1 qPCR tittering: 
The protocol for quantification of AAV serotype 9 by qPCR was provided by Associate 
Professor Steven Gray from US South-western Medical Centre. The following procedure was 
used: 
 
3.6.3.2 DNA extraction from samples: 
10 µL of AAVs (upstream lysates, downstream purification) was added to 90uL of DNaseI 
mixture (Table 3-3) into a DNA/RNA free 1.5 mL Eppendorf and spun down at 1,000xg for 
two minutes. Eppendorf’s were then incubated for one hour at 37° C. Post incubation 6 µL of 
0.5 M EDTA was added and mixed by slow aspiration. 120 µL of Proteinase K solution (Table 
3-4) was then added and again mixed by aspiration. The Eppendorf’s were then spun down 
at 1000xg for two minutes and then incubated at 55°C for two hours followed by 10 minutes 
at 95°C to inactivated Proteinase K. Samples were then diluted 10x in Ultra-Pure water.  
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Table 3-3: DNase mix for qPCR.  
DNase mix (1mL) 
DNase I (10mg/ml) 10 ul (added before use) 
Tris HCl pH7.5 (1M) 10 ul 
CaCl2 (1M) 2 ul 




Table 3-4: Protease K mix for qPCR.  
Protease K (1mL) 
5M NaCl 200 ul 
10% sarcosyl 100 ul 
Proteinase K (10mg/ml) 10 ul (added before use) 
H2O 690 ul 
 
 
3.6.3.3 Plasmid linearization and standards: 
AAV plasmid was linearized by overnight digest with the enzyme AgeI-HF. 10 units of the 
enzyme were added for every 1 µg of plasmid DNA (checked by Nanodrop) with a total 
reaction volume of 50 µL. Post digest linearized plasmid was purified with a Qiagen kit 
(QIAquick PCR Purification Kit) into a Tris-EDTA buffer, pH 8. The plasmid was checked on 
a 1% agarose DNA gel stained with SYBR green, a band around 6,000 bp was indicative of the 
correctly linearized plasmid. The plasmid was then diluted with 10 mM Tris buffer, pH 8 into 
a working stock of 10 ng/µL. Serial dilutions of this working stock were used as standard 
points for a qPCR calibration graph. These points were as follows: 50 pg/µL, 5 pg/µL, 0.5 
pg/µL, 50 fg/µL, 5 fg/µL, and 0.5 fg/µL. 
 
3.6.3.4 qPCR reaction:  
Into each well of a qPCR plate 8 µL master mix (Table 3-5) was pipetted along with 2 µL of 
DNA (sample or standard). 2 µL of Ultra-Pure water and 10 mM Tris were added to separate 
wells along with 8 µL of master mix to be used as controls. The plate was sealed with adhesive 
68 
 
PCR strips and spun down at 1000xg for two minutes. Following centrifugation, tubes were 
cycled into a qPCR light cycler. 
 
 
Table 3-5: SYBR Green master mix for qPCR. 
SYBR Green master  mix 
2x SYBR mix 5 ul 
Forward Primer (20uM) 0.25 ul 
Reverse Primer (20uM) 0.25 ul 




The number amount of DNA plasmid was determined by a comparison of Ct values 
between the samples and the known standard dilutions. Sample calculations can be found in    
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Appendix A. The number of plasmid copies per femtograms (fg) of DNA was determined by 
equation 3-5: 
 





Where the size of the plasmid is 5.9 kbp. The titer of AAV of viral genomes per mL (VG/mL) 
could then be determined from the dilution factor shown in equation 3-6: 
 
Dilution factor = 
𝑠𝑡𝑎𝑟𝑡𝑖𝑛𝑔 𝑣𝑜𝑙𝑢𝑚𝑒 





before qPCR            3-6 
 
The final titer in VG/mL can be found from equation 3-7: 
 
Final titer in mL = 
𝐶𝑜𝑝𝑖𝑒𝑠 𝑜𝑓 𝑣𝑖𝑟𝑢𝑠 𝑔𝑒𝑛𝑜𝑚𝑒 
𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛  𝑓𝑎𝑐𝑡𝑜𝑟
















3.7 Chromatography and purification 
The purification of varying viruses all used 1 cm diameter, 300-micron hydraulic channel 
diameter, Schoen gyroid cellulose hydrogel columns. All of the columns were made from the 
same cellulose composition (6 wt% dissolved cellulose, 3 wt% added cellulose powder acting 
as a physical cross-linker, and 15 wt% ECH as a chemical cross-linker). The variations in the 
functionality and bed height for each purification are shown in Table 3-6. These columns were 
all loaded into SNAP casings. For up to 10 cm bed height an S-10/125-PPSS-OV-FP20 was used 
and for up to 25 cm be heights an S-10/250-PPSS-OV-FP20 was used. Columns were shrunk 
in 100% ethanol before being slid into the glass casing. The columns were then re-swelled by 
flowing tap water through the glass casing. Air bubbles were removed from the column by 
flushing with degassed DI water over 15 minutes using the AKTA pump system. 
 
 
Table 3-6: 3D-printed chromatography columns used for each virus purification (1 cm diameter, Schoen gyroid, 
300 µm hydraulic diameter channels). 
Virus Functionality Bed height cm 
M13 Q 5, 10, 15 
Adenovirus serotype 5 DEAE & HA 5 
Lentivirus DEAE 5 
AAV serotype 9 Ha & Q 20, 10 
 
 
3.7.1 Adenovirus and lentivirus purification 
5 cm bed height DEAE and HA cellulose column of the same geometry and size were used to 
purify adenovirus and lentivirus from clarified cell lysate. The DEAE functionalization was 
completed at 30°C. This set of experiments was completed before ligand density optimization. 
The HA functionality used was alternating calcium and then phosphate solutions over three 
weeks. Details of functionalization can be found in Section 3.2. Both viruses were cultured on-
site at iBET and details of this process can be found in our paper as well as in Section 3.6.2.1 
[244]. Columns were placed in individual SNAP glass casings and attached to an AKTA 100 
Explorer. For the column functionalized with DEAE, 20 mM Tris, pH 7 and, 20 mM Tris, 1 M 
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NaCl, pH 7 were used as equilibration and elution buffers, respectively for adenovirus. For 
the lentivirus, 50 mM Tris pH 7.5 and 50 mM Tris, 1 M NaCl, pH 7.5 were used as equilibration 
and elution buffers, respectively. For the hydroxyapatite column, 20 mM Tris pH 7 was used 
as equilibration buffer and 20 mM Tris, 1 M NaCl, 500 mM NaHPO4, pH 7 as elution buffer. 
A 1 mL injection loop was used to load clarified lysate samples onto both columns, except for 
experiments to determine dynamic binding capacity in which the sample pump of the AKTA 
100 was used. Elution was performed with a gradient over 5 column volumes (CV) for both 
columns. All eluted peaks and flow-through samples were collected and analyzed by qPCR 
and Nanosight particle tracking. The columns were cleaned with 20 mL of 2 M NaCl at 1 
mL/min and then sanitized with 20 mL of 0.5 M NaOH at 1 mL/min. The linear velocity for 
loading was 8 cm/h and 76 cm/h for elution, for both columns, unless otherwise stated. 
Triplicate replicates were completed for each purification.  
 
3.7.2 M13 purification  
 
The SNAP casing containing the 3D-printed Q chromatography column (either 5, 10, or 15 cm 
bed height) was attached to an ÄKTA start protein purification system. All chromatography 
was completed at room temperature. Details of functionalization can be found in Section 3.2. 
From previous experimentation, the 3D-printed columns maximize their recovery with the 
lowest load flow rate possible [247]. Unless otherwise stated flow rate of the ÄKTA start 
system was 0.5 mL/min (linear velocity of 76 cm/h). Each column was equilibrated with 5 CV 
of equilibration buffer (10 mM phosphate, pH 7.5). The crude cell culture was injected onto 
the column through either a 2 mL sample loop or for larger samples the ÄKTA systems sample 
pump. Following loading, the column was washed with 40 mL of equilibration buffer to 
remove unbound or weakly bound phage particles or unwanted contaminants. The adsorbed 
phage particles were eluted stepwise over 30 mL of elution buffer (10 mM phosphate with 1 
M NaCl pH 7.5). Eluted fractions were collected with a fraction collector included in the 





Initially, CIP for the column was with 1 M NaOH over 8 CV at 1 mL/min, followed by 8 CV 
of 1 M NaCl and a 20 mL flush of DI water at 4 mL/min. This was then changed to mitigate 
fouling post each purification trial. The new procedure was as follows: The column was 
stripped with 1 M NaOH at 1 mL/min for 60 minutes until the UV signal had stabilized below 
10 mAu. The column was then flushed with DI water (4 mL/min) until the conductivity was 
below 5 mS/cm. The column was then washed with an equilibration buffer over 10 CV (4 
mL/min). 
 
Purifications were also completed with similar operating conditions to an expanded bed 
purification completed by Ling et al. [20]. The same zero bed height of 15 cm was used with 
an adjusted load and elution flow rate of 0.8 mL/min (122 cm/h) to match the residence time 
of the expanded bed system. The same equilibration and elution buffer as the previous M13 
purification tests were used. The same volumes for equilibration and wash steps were also 
used except at a flow rate of 4 mL/min (611 cm/h). The load volume used was 3 mL or 0.25 CV 
based on previous experimentation for the highest recovery. The elution was collected with 
the fraction collector included in the system (Frac-P90) at fixed volumes during elution (3 mL). 
Triplicates of each purification were completed. 
 
3.7.3 AAV serotype 9 purification 
 
3.7.3.1 Hydroxyapatite purification strategy: 
 
The SNAP casing containing the 3D-printed HA chromatography column (4×5 cm plugs 
totaling a 20 cm bed height) was attached to an ÄKTA start protein purification system. The 
HA functionality used in this case was alternating solutions of calcium and then phosphate 
over two weeks. This was to maximize HA growth while still allowing for stationary phase 
penetration of the AAV particles. Details of functionalization can be found in Section 3.2. The 
column was equilibrated with 20 mL of equilibration buffer (16 mM imidazole, 25 mM NaCl 
and 5 mM phosphate, pH 6.5) at 611 cm/h. Clarified cell culture fluid was loaded directly onto 
the column as feed material at 76 cm/h using the sample pump. Alternatively, clarified cell 
lysate was diluted 10× in DI water before loading onto the column as feed material at 76 cm/h 
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using the sample pump. The column was then washed with 40 mL of equilibration buffer at 
611 cm/h. The AAV particles were then eluted at 76 cm/h over 30 mL with an elution buffer 
(16 mM imidazole, 500 mM NaCl and 500 mM phosphate pH 6.5). The elution’s were collected 
with a fraction collector included in the system (Frac-P90) at fixed volumes during elution (4 
mL). CIP for this column follows the same procedure as for the Q columns used for M13 
bacteriophage in Section 3.7.2.  All purifications were repeated in triplicate. 
 
3.7.3.2 Q purification strategy: 
The SNAP casing containing the 3D-printed Q chromatography column (10 cm bed height) 
was attached to an ÄKTA Start protein purification system. The column was equilibrated with 
20 mL of equilibration buffer (16 mM imidazole, 25 mM NaCl and 5 mM phosphate, pH 6.5) 
611 cm/h. The clarified cell lysate was diluted 10× in DI water before loading onto the column 
as feed material at 76 cm/h using the sample pump of the ÄKTA Start. Instead of operating in 
a bind and elute, the column was used to bind the negatively charged contaminants in the 
lysate instead of the AAV particles. As such, the flow-through was collected instead of the 
elution. This was done manually as the ÄKTA Starts software would not facilitate flow-
through collection. The flow-through was collected as soon as the UV signal spiked on the 
display screen, taken directly after the UV sensor on the ÄKTA. 50 mL of elution was collected 
to be analyzed by qPCR and SDS-PAGE. Contaminates were eluted at 152 cm/h over 30 mL 
with an elution buffer (1 M NaCl, 10 mM phosphate pH 6.5). The purity of flow-through 












3.7.4 Chromatography calculations 
 
3.7.4.1 Recovery: 
The recovery of viral particles was determined by the ratio of total viral particles loaded onto 
the column compared with the total number of viral particles found in the elution (or flow-
through in the case of AAV) (equation 3-8). The total number of viral particles was determined 
by the volume (V) multiplied by the titer (C). The number of viral particles was either 
determined in plaque-forming units (pfu), viral genomes (VG), or transducing units (TU). This 




 × 100 = 𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 %    (3-8) 
 
3.7.4.2 Dynamic binding capacity: 
To determine DBC samples of flow-through were collected and analyzed for viral content by 
qPCR. This determined a characteristic sigmoid-shaped curve from which the DBC could be 
calculated. The DBC10% was calculated according to equation (3-9), where 𝐶0 corresponds to 
the feed virus concentration, 𝑉𝑏,10% is the breakthrough volume at which the flow-through 




















3.7.4.3 Ligand density 
The charge density of both DEAE and Q functionalized columns was measured by the titration 
method adapted from Stone et al. [249]. 1 cm lengths of 1 cm diameter functionalized Schoen 
gyroid columns (varying channel diameter and ligand) as well as an un-functionalized control 
column were suspended in separate 50 mL centrifuge tubes with 1 M NaOH for 30 minutes. 
Column pieces were then washed in DI water until the effluent reached a pH of 7. Columns 
were then placed in separate 50 mL centrifuge tubes along with 20 mL of 0.5 M NaCl and 0.05 
M HCl. 10 mL of the 20 mL was removed after 12 hours to be titrated against 0.1 M NaOH 
until a neutral pH was reached. The ligand charge density was then determined (3-10) by the 
difference in total moles required to neutralize the solution between the functionalized 
(mfunctional) and the control (mcontrol) per mL of column (Vc) by a factor of 2. Sample calculations 








× 2   (3-10) 
 
This was also converted into µmol/cm2 to compare densities to membrane technology. TPMS 














4 Stationary phase analysis for viral purification 
chromatography 
 
As described in the literature review, the previous production of 3D-printed hydrogel 
columns by Anne Gordon showed their fidelity to the templates used and their ability 
to bind and elute proteins while passaging solids [15]. As this technology is very novel, 
limited literature on ligand chemistry for the chosen stationary phase material 
(cellulose hydrogel) was available. Chemical functionalization's which have been 
previously used on agarose, bacterial cellulose, and aerogels will be adapted for this 
research [134, 225, 226, 242, 250, 251]. The first step of this research was to investigate 
the stationary phase material's potential to effectively bind and elute virus or virus-
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like particles. As a different wax printer was used for most of this work, analyses of 
the printed columns' structural fidelity are briefly considered. 
 
It was hypothesized that this cellulose hydrogel could be chemically modified to bind 
and elute protein and therefore be used as the stationary phase to purify virus or viral 
particles. Building on Anne Gordon’s original work, the following chapter looks at 
extending the range of functionalities outside of ion exchange and optimizing ligand 
density and static protein binding capacity. Additionally, the stationary phase was 
investigated for its potential to allow diffusion of larger binding targets such as viruses 
inside of its pores. Literature showed that the pore size distribution should be 
theoretically large enough to allow diffusion but confirmation was need [222]. A 






4.1 Hydroxyapatite functionalization 
4.1.1 Hydroxyapatite Growth  
Two methods for incorporation of HA into the cellulose hydrogel matrix were tested, before 
gelation and post gelation. Incorporation before gelation was achieved by the addition of 
premade HA powder into the dissolved cellulose solution, while post gelation was achieved 
by seeding crystal growth in regenerated hydrogels. Two methods of seeding hydroxyapatite 
were tested, one involving alternating calcium and phosphate salt solutions and the second 
using SBF fluid with citric acid. Details of each functionalization method can be found in 
Section 3.2.3. Both methods of seeding HA crystals into cellulose hydrogels were successful, 
producing different crystal structures. FE-SEM was used to examine functionalized cellulose 
samples as described in 3.3.2. Triplicates of each functionalization were examined along the 
entire length of the hydrogel sample. Figure 4-1 shows SEM images of a cellulose hydrogel 
with and without HA formed from alternating saturated solutions of CaCl2 and Na2HPO4. The 
small spherical balls shown in Figure 4-1 panel B can be more clearly seen in Figure 4-2. After 
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one-week crystal structures were found in most of the pores in all cellulose hydrogels tested, 




Figure 4-1: SEM image of the microstructure of a 5% cellulose hydrogel (A); 5 wt% cellulose hydrogel 
functionalized with HA grown with alternating solutions of calcium chloride and disodium phosphate over two 
weeks (B).  
 
 
Figure 4-2: SEM of the HA crystal structure inside of a 5 wt% cellulose hydrogel. HA was grown with alternating 
solutions of calcium chloride and disodium phosphate over two weeks.  
 
Figure 4-3 shows an SEM image of hydroxyapatite formed from exposure to 1.5 x SBF with 1 
mM citric acid over one week. The structure of the crystal growth is significantly different 
from that shown in Figure 4-1 and Figure 4-2. The crystal structure from SBF is similar to a 
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coating of the gel instead of the sharp needle formations from alternating solutions. It has 
formed a layer over almost the entire external and internal walls of the gels pores with small 
patches of crystal squares starting to form.  
 
Figure 4-3. SEM image of HA crystal structure grown on 5 wt% cellulose hydrogels from exposure SBF with 1 
mM citric acid for one week. The red circle shows the beginning of square crystal formations. 
 
This difference in the crystal structure is due to how the initial hydroxyapatite crystals are 
seeded between the two methods. Alternating solutions of calcium chloride and di-sodium 
orthophosphate cause nucleation sites in small confined regions of the gel, specifically the 
pores. The positive Ca2+ ions loosely associate with the negatively charged free hydroxyl 
groups of the cellulose hydrogel. This has been shown previously with bacterial cellulose as 
well as other materials such as titanium, zirconium with hydroxyl groups, or natural polymers 
with free carboxylic acid groups [252, 253]. This was confirmed by Hutchens et al. who 
produced similar HA crystal structures as shown in his work [250]. Crystal growth is then 
stimulated from these nucleation sites outwards forming sharp needle structures. Over time 
smaller crystal structures meet, combining and forming the larger spherical needle ball shapes 
because of the curved shape of the cellulose pores. Crystal growth from the SBF solution 
occurs differently, facilitated by the citric acid initially binding to the exposed hydroxyl 
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groups of the cellulose [242]. The citrate then allows the binding of free Ca²+ ions creating a 
nucleation site for crystal growth. The citrate more favorably binds free Ca2+ ions than 
hydroxyl groups causing a larger covering of nucleation sites. This results in a complete 
saturation of HA crystals that grow like a coating versus a multitude of smaller structures. 
Interestingly, if the hydrogel is functionalized with alternating calcium chloride and di-
sodium orthophosphate solutions for longer than three weeks, a complete surface will form 
over the hydrogel that still maintains the sharp needle-like shapes. Figure 4-4 shows this 
formation on a 6 wt% cellulose hydrogel cross-linked with 15 wt% ECH. The smaller crystal 
structures grow and meet, combining to cover the cellulose. The sharp structure of these 
crystals is still maintained but has covered the cellulose during their growth. 
 
Figure 4-4: SEM image of HA crystal structure grown on a 6% cellulose hydrogel cross-linked with 15% ECH by 
alternating solutions over three weeks. 
 
If hydrogels that alternating calcium and phosphate solutions have initially seeded crystals 
are exposed to SBF solution, the previously formed crystals become smoothed and rounded.  
Figure 4-5 shows a 5 wt% cellulose hydrogel initially seeded with alternating calcium and 
phosphate solutions followed by SBF treatment. The SBF and citric acid coating effect cover 
the initial crystals seed by the alternating solutions with a layer of this different crystal 
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structure. These new crystals fill in any gaps in the needle-like structures made by the 
alternating solutions joining them together.  
 
 
Figure 4-5: SEM image of HA crystal functionalized on a 5 wt% cellulose hydrogel after one week of alternating 
calcium then phosphate solutions followed by one week of SBF fluid. 
 
The incorporation of HA powder before gelation resulted in a dense white hydrogel. Figure 
4-6 shows an SEM image of cellulose hydrogels' internal structure made with HA powder 
added before gelation. The pores of the resulting cellulose hydrogels become clumped with 
large HA crystals covered by cellulose. This alteration of the pore structure is detrimental for 
any chromatography media as the pores maximize the binding capacity by increasing surface 







Figure 4-6: SEM image of a sliced cross-section of cellulose gels with HA powder added to the solution before 
gelation. A; 10 wt% HA and B; 20 wt% HA 
  
HA also grew on native cellulose hydrogels and hydrogels that were physically cross-linked, 
chemically cross-linked or both. This benefits the functionality as control over chemical and 
physical cross-linking causes changes in the microstructure related to pore size and shape, as 
described previously in Section 2.4.4 [222]. Adjusting the pore size and limiting crystal growth 
inside the pores could allow the gel to act as a multimodal functional ligand combining size-
exclusion and HA. 
 
4.1.2 HA functionality 
Protein adsorption studies were carried out on HA functionalized cellulose hydrogels as 
described in Section 3.5.1. Table 4-1 shows the amounts of BSA eluted from 5 mm cellulose 
hydrogels cubes functionalized with HA. Hydrogels were functionalized by alternating 
calcium chloride and disodium orthophosphate solutions for one week, followed by one week 
of exposure to SBF fluid with 1 mM of citric acid. Two different elution buffers were used to 
examine how the BSA was binding to the HA crystals in the gels’ pores. Control gels used 
were of the same cellulose composition without HA functionality. In all cases, no adsorption 
was detected by the Nanodrop, indicating control gels had not bound any BSA. Similar results 
were found for hydrogels with HA formed from both alternating calcium and phosphate 






Table 4-1: Elution of BSA from HA cellulose hydrogels. 
 









5% cellulose 1 M NaCl 0.04 0.01 
5% cellulose + cellulose 2.5% 1 M NaCl 0.06 0.01 
5% cellulose + 2.5% cellulose + 5% ECH  1 M NaCl 0.05 0.01 
5% cellulose 1 M NaCl + 400 mM Na₂HPO₄ 0.29 0.02 
5% cellulose + 2.5% cellulose  1 M NaCl + 400 mM Na₂HPO₄ 0.48 0.01 
5% cellulose  + 2.5% cellulose + 5% ECH  1 M NaCl + 400 mM Na₂HPO₄ 0.38 0.03 
 
Over five times the amount of protein was eluted with a sodium chloride and phosphate salt 
buffer than with a sodium chloride salt buffer. This elution profile is a result of the binding 
characteristics of BSA to the HA functional groups. Predominantly, HA consists of three 
primary binding mechanics; (i) metal-chelating sites provided by the calcium ions for binding 
phosphates, (ii) cation exchange provide by the negatively charged phosphate ions, and (iii) 
small amounts of anion exchange can also be mediated by the positively charged calcium ions 
[255]. Only a small amount of BSA is bound to the ion exchange sites compared to the calcium-
based metal affinity active sites. This is because of BSA’s acidic nature, resulting in it having 
an overall negative charge at pH 7, therefore not having a great affinity for the cation exchange 
group [256]. For gels that were functionalized with HA before gelation, no BSA binding was 
achieved. The lack of protein binding was because of the cellulose covering the HA crystals 
restricting the proteins ability to access the binding sites. Even in gels with a high level of 
added HA (30 wt%), BSA was not bound. 
  
4.1.3 HA protein binding selectivity 
This work was completed in collaboration with Professor Steven Cramer at Rensselaer 
Polytechnic Institute (RPI) in Troy, New York. As the Solidscape printer was broken (before 
the Projet printer was purchased), only a limited number of templates were available to 
construct chromatography columns to take overseas.  Therefore, only one HA column was 
taken functionalized with alternating calcium and phosphate solutions instead of SBF with 
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citric acid. This column was made from SolidScape wax templates as described in 3.1. 
Cellulose composition for these columns was 6 wt% dissolved cellulose, 3 wt% undissolved 
cellulose powder, and 15 wt% ECH. Conditions for binding and elution used were based on 
research into hydroxyapatite selectivity and binding mechanics analysis by Hou et al. to be 
used as a comparison [139]. The same running buffers and elution gradient was used. Details 
for this bind and elute chromatography can be found in Section 3.5.3. Table 4-2 shows the 
elution order for model proteins from a 5 cm bed height 300 micron Schoen gyroid column 
functionalized with HA (two weeks of alternating calcium and phosphate solutions). 
 
Table 4-2: Retention time for model proteins from a 3D-printed 300 µm Schoen gyroid HA column. 
Protein Elution peak Standard deviation NaCl 
 
minutes minutes mM  
Ribonuclease B 5.9 0.07 197 
Beta lacto-globulin A 4.5 0.2 151 
Cytochrome C 10.3 0.06 344 
 
These experiments' results gave a different set of selectivities to those shown in the paper by 
Hou et al. using a commercial hydroxyapatite resin [139]. The resin they tested had an elution 
order from least to most retained of cytochrome C, beta-lactoglobulin A, ribonuclease B [139]. 
As shown in Table 4-2, the first eluted protein from the 3D-printed HA column was 
ribonuclease B followed by beta-lactoglobulin A and cytochrome C. An experiment was also 
completed with transferrin, a protein that should have been moderately retained at the 
equilibrated pH and salt concentration but did not bind at all. This unusual set of selectivities 
could be because of the mineralized HA's chemical composition (e.g., a large amount of 
chlorapatite or other calcium phosphate mineral instead of HA). Further analysis of the 
minerals composition and structure was required to determine if what had been synthesized 
is HA, as mentioned in previous papers [229, 231, 250, 257, 258]. Figure 4-7 shows the elution 




Figure 4-7. Elution profile of bovine cytochrome C from 5 cm bed height, 300 µm Schoen gyroid HA column. Linear 
gradient at 1 mL/min over 10 CV to 1 M NaCl 35 mM phosphate buffer pH 7. 
 
This broad elution peak is consistent with the 3D-printed column used and not its 
functionality. 3D-printed columns elute in larger volumes than traditional packed beds 
because of the large channel size (300 um) and 50% voidage within the column.  In previous 
work by Anne Gordon, elution peaks of BSA's from a similar DEAE column were equally as 
broad [15]. This peak broadness is similar to expanded bed chromatography, where because 
of the expansion required to passage cells, there is greater space between beads (higher 
voidage), and therefore, axial diffusion is higher [259]. Tailing was also observed for some of 
the proteins, most notably the larger globulin proteins (beta-lactoglobulin A and ribonuclease 
B). The protein's size affects its diffusivity, with larger proteins taking longer to diffuse out of 
the pores [248]. 
  
4.1.4 HA control 
Initial HA growth work also uncovered an unexpected result shown below in Figure 4-8. The 
growth of HA could be limited to just inside the pores of the cellulose hydrogel. This is 
particularly interesting as it could provide another level of selectivity by excluding particles 




Figure 4-8. SEM of HA crystal structure (inside of the red rings) grown on a 5 wt% cellulose hydrogel.  
 
The washing step with DI water between alternating solutions of calcium chloride and 
disodium orthophosphate caused this effect. By washing the cellulose hydrogel with DI water, 
the calcium ions bound to the free hydroxyl groups are removed and cannot create a crystal 
nucleation site when phosphate ions are introduced. Calcium ions bound inside the cellulose 
pores take longer to be removed as pore diffusion limits their migration out of the hydrogel. 
Therefore, controlling the length of time the washing occurs can control HA crystallization 
and where it occurs. This control can be seen in Figure 4-9, showing a relatively clean surface 
with a large amount of crystal growth below the surface. This 5 mm cube of cellulose hydrogel 




Figure 4-9: SEM image of HA crystal structure grown on a 6 wt% cellulose hydrogel cross-linked with 15 wt% 
ECH. Panel B shows a magnified in part of the crack in the red circle shown in A. 
 
Dependent on the length of washing time, the crystal growth can be limited far below the 
hydrogel's surface. Excessive washing (>60 seconds) resulted in no HA formation in small 
cellulose cubes (5 mm sides) as all the calcium ions were removed. The surface can also be 







Figure 4-10: SEM image of HA crystal structure grown on a 6 wt% cellulose hydrogel cross-linked with 15 wt% 
ECH without an intermediate washing step. 
 
Without a washing step, none of the Ca2+ ions are removed from the hydroxyl groups resulting 
in full surface coverage of nucleation sites. The entire surface is covered in a rough surface of 
crystals that fills the pores of the gel. This covering effect is similar to the HA growth 
facilitated by the SBF solution.  This result reinforces that how the crystals are seeded defines 
the crystal structure's growth. Control over where HA grows could not be achieved with the 
SBF method as the crystal growth continued to cover the entire surface even with a long (>60 
seconds) washing step. The citrate molecules favorably bind to the surface hydroxyl groups 
of the cellulose and become difficult to remove. 
 
Further work was completed on HA control. However, its benefit could not be shown for 
chromatography. The HA mineral did not bind the larger contaminates that would be 
excluded by the pores, such as cells, cell debris, and DNA, all of which are predominantly 
negatively charged [154, 260]. The HA’s cation exchange sites repel these negatively charged 
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contaminates anyway, so they do not bind during chromatography. Therefore, having the HA 
only inside the pores does not provide additional selectivity as excluded contaminates would 
not be bound anyway. Future works may use control of HA growth, but it has not been 
explored in this project. 
 
4.1.5 HA compositional analysis  
Based on the ability to control HA growth and the protein binding work completed at RPI, 
the mineral analysis was limited to the HA functionalization by alternating calcium and 
phosphate salt solutions. The mineral deposits of suspected HA were tested via EDS, FT-IR, 
SEM, and powder XRD, details of which can be found in Section 3.3. EDS compositional 
analysis showed the ratio of calcium and phosphate to be in the range of 1.5 to 1.8, depending 
on which salt solution was last in the cycle for seeding growth. Pure HA has a calcium to 
phosphate ratio of 1.67 based on its stoichiometric equation 𝐶𝑎5(𝑃𝑂4)3(𝑂𝐻)2. Upon repeats, 
with thoroughly washed gels, the ratio was found to be between 1.5 to 1.6. If the ratio is less 
than 1.67, the mineral may be known as calcium deficient HA. This data indicates a calcium 
phosphate mineral is present, but it may not all be HA, and some may be calcium deficient 
[232].  
 
Interestingly, initial EDS results showed a large amount of chlorine present in the sample. 
Chlorine could indicate the presence of chlorapatite instead of HA. Further repeats of this 
experiment showed that if the samples were not washed properly before freeze-drying and 
analysis, excess calcium chloride or di-sodium orthophosphate could be detected. However, 
even with excessive washing, chlorine was still detected in varying amounts. EDS results 
indicated while most of the sample is potentially calcium deficient HA, up to 1 to 3 wt% is 
likely chlorapatite. The pH of both alternating salt solutions was adjusted above pH 9 to 
prevent chlorapatite formation, confirmed by EDS results showing no chlorine present. In 
basic conditions, more free OH- ions are present and more favorably bind during mineral 
formation over Cl- [261]. The EDS results proved inconclusive, only indicating a calcium 




These EDS results for the calcium phosphate mineral presence were confirmed by FT-IR 
analysis shown in Figure 4-11. There are significant differences in the region of 450 to 700 and 
900 to 1200 cm-1. The peaks associated with PO4-3 are at 600, 570, and 1050 to 1100 cm-1, all of 
which can be seen in Figure 4-11 [228, 229, 231, 250].  
 
 
Figure 4-11: FT-IR transmittance results for HA cellulose and control cellulose hydrogels. Arrows indicate peaks 
associated with PO4-3 
 
Peaks specific to hydroxyl groups can be seen in the 600 to 650 cm-1 region which could 
indicate HA. Figure 4-12 shows the 400 to 700 cm-1 region of Figure 4-11 specifically looking 






Figure 4-12: FT-IR transmittance results for HA cellulose and control cellulose hydrogels. Zoomed in on 400-700 
cm-1 region. 
 
For pure HA samples, a peak at 630 cm-1 should be present indicating the hydroxyl group 
associated with the mineral. This is not present in pure chlorapatite samples as the hydroxyl 
group is replaced by a Cl atom [262]. This peak is also missing from Figure 4-12 but is 
consistent with all other papers where they have claimed to have mineralized HA onto 
cellulose structures. Because of the poor crystallinity of un-sintered mineralized HA this peak 
may not be able to be seen, hidden by shouldering of the broad 600 cm-1 peak. Figure 4-13 





Figure 4-13: FT-IR transmittance comparison between standard HA cellulose and those grown at pH 9. 
Magnified in on the 400-700 cm-1 region. 
 
Figure 4-13 shows that the peak around 600 cm-1 is broad, which could be caused by a stronger 
630 cm-1 peak. With the previous EDS results, it can be assumed not all the calcium phosphate 
mineral formed is pure and at least some of it is chlorapatite, except those grown under 
alkaline conditions. Although the peaks associated with HA are present in the FT-IR analysis 
the contradictory binding selectivities suggest that it is not HA but a different calcium 
phosphate mineral. There are multiple different calcium phosphate minerals with different 










4.1.6 Powder XRD  
 Figure 4-14 shows the results of XRD analysis of two different HA cellulose hydrogels. The 
analysis shows both samples are a combination of HA and octacalcium phosphate (OCP, 
𝐶𝑎8(𝑃𝑂4)6𝐻2 • 5𝐻2𝑂) [264, 265]. Peaks at 9.5, 9.8, 26, and 54 indicate OCP, while the peak at 
30 to 35 and 50 indicates HA [266, 267]. OCP is the precursor to HA in bone structures, being 
the initial mineral produced, converted into HA [268]. This analysis, alongside the FT-IR and 
EDS-SEM results, shows a mixture of calcium phosphate minerals (OCP, HA, and 
chlorapatite). Based on selectivity results, the predominant mineral is OCP, which has more 
calcium ions with a Ca/P ratio of 1.33. The reduction in calcium ions means more cation 
exchange sites than the metal chelating and anion exchange sites offered by the calcium ions. 
The additional phosphate sites would repel more negatively charged proteins such as BSA 
that predominantly bind to the calcium sites. Conversion of OCP into HA should benefit the 




Figure 4-14: XRD intensity peaks for two cellulose HA composites (standard HA and HA grown at pH 11).  








To convert OCP to HA a hydrolysis reaction needs to take place as follows: 
 
5𝐶𝑎8𝐻2(𝑃𝑂4)6. 5𝐻2𝑂 → 4𝐶𝑎10(𝑃𝑂4)6(𝑂𝐻)2 + 6𝐻3𝑃𝑂4 + 3𝐻2𝑂 
 
This reaction is catalyzed by tetracalcium phosphate (TetCP) in the correct ratio to form 
stoichiometric HA [264, 269]. This reaction occurs more rapidly at higher temperatures. 
Because of expenses associated with TetCP and time constraints, this conversion was not 
explored but future works should look at its effect on selectivity and binding capacity.  
 
The calcium phosphate crystals that have been mineralized inside of cellulose hydrogels  were  
shown to have two discrete binding mechanisms (cation exchange & phosphate binding) 
consistent with other HA media. While believed to be HA, characterization of the mineral 
using FT-IR, SEM-EDS and XRD showed it to be a mixture of OCP and HA with poor 
crystallinity. This mineral mixture caused a different set of protein selectivity during 
chromatography compared to traditional HA  media. Although not pure HA, the mineral 
mixture can still effectively bind and elute proteins and can be used for the purification of 















4.2 Viral diffusion  
The penetration depth of fluorescently tagged AAV particles into 5 mm cube blocks of 
cellulose hydrogels was examined under a confocal laser scanning microscope described in 
Section 3.4. Figure 4-15 shows the tagged viral particles' penetration into the cellulose 
hydrogels forming a thick fluorescent band. Note in Figure 4-15 there is a large amount of 
background noise or blurring.  Because the hydrogel is translucent, the fluoresces from below 
the hydrogel's surface refracted through and were visible on the top layer. This blurring in 
images and variation between samples caused these experiments' standard deviation to be 
high (≤ 20%). Measurements were taken from the edge of the gel to the highest intensity point. 
 
 
Figure 4-15: Confocal image of AAV particles tagged with Rhodamine red X diffused into 5 mm cellulose 
hydrogel blocks. A; 5 wt% cellulose + 15 wt% ECH functionalized with HA, two weeks’ growth B; 5 wt% 
cellulose hydrogel. The orange line defines the gels surface and the arrow show where the depth of penetration 
has been measured to. 
 
Table 4-3 shows the depth of penetration for various cellulose gel compositions and 
functionalities. The HA functionality used was alternating calcium chloride and disodium 
orthophosphate solutions over either one or two weeks. In a few cases, HA by alternating 
calcium and phosphate solutions was followed by exposure to SBF solution for another week. 
Comparatively, Wu et al. tested the diffusion distance of virus-like particles (VLP) tagged with 








50 to 1000 nm [158]. The VLP’s used for their work had a hydraulic diameter of 100 nm. The 
average depth of penetration observed was nearly five times greater than the 1 to 2 µm 
normally observed in standard chromatography media [158]. The VLP used by Wu et al. were 
four times larger than the AAVs used for this work. However, these particles are of a similar 
order of magnitude and should be able to be compared. 
 
Table 4-3: Diffusion depth over two hours of AVV 5 particles (1×1011 VP/mL) tagged with Rhodamine Red X into 
cellulose hydrogels of varying composition.  
Gel Composition Average penetration µm Standard Deviation µm 
Cellulose 5% 15.4 3 
Cellulose 5% + 2.5%  11.4 1 
Cellulose 5%+ 2.5% + 5% ECH 8.9 1 
Cellulose 5% -DEAE 10.4 1 
Cellulose 5% + 2.5% - DEAE 8.4 1 
Cellulose 5% + 2.5% + 5% ECH -DEAE 10.8 1 
Cellulose 5% + 15% ECH -HA -2 weeks  4.7 1 
Cellulose 6% HA- 1 week + 1 week SBF 11.1 2 
Cellulose 5% + 5% ECH – HA 1 week + 1 week SBF 6.7 1 
Cellulose 5% + 15% ECH - HA 1 week  11.9 3 
Cellulose 5% + 15% ECH - HA 1 week + 1 week SBF 7.2 1 
Cellulose 5% - HA 1 weeks  11.2 1 
 
The average penetration depth into a cellulose hydrogel was 15.4 ± 3 µm, over 700% deeper 
than traditional chromatography media [158]. The average penetration depth drops to ~10 µm 
for physically cross-linked cellulose hydrogels. Physically cross-linking cellulose hydrogels 
reduces the pore size distribution (0.1 to 2 µm), limiting accessible pores for AAV to 
penetrated [222]. A drop in penetration depth can also be seen for the gels functionalized with 
the anion exchange ligand DEAE. The viral particles have limited diffusion distances because 
of binding interactions between the negatively charged capsid of the AAV and the DEAE 
ligand [117]. The gels cross-linked with ECH (chemical cross-linker) have a lower penetration 
than expected even though they have the largest pore size distribution (5 to 15 µm) [222]. This 
low penetration suggests dead ends within the pore structure and that the pores are not fully 
interconnected. Poor interconnectivity can be caused by excessive cross-linking, as shown in 
other cellulose-based hydrogels [270, 271]. The 50% voidage of the 3D-printed 
97 
 
chromatography columns and the Schoen gyroid geometry results in the wall thickness being 
equal to the channels' hydraulic diameter. The stationary phase elements of the column are 
therefore thicker (200 to 300 µm) compared to packed bed beads (40 to 120 µm), which, if the 
virus fully penetrated, would take a long time to diffuse out of. This extended diffusion could 
potentially cause extended tailing during chromatography [272]. Functionalization of 
cellulose with HA results in crystal growths that fill the pores of the gels. The mineral blocks 
the pores of the hydrogel, restricting the virus's path. In all cases where crystal growth was 
longer than one week, the AAV penetration was reduced by nearly 50%. Therefore, it is 
important to limit crystal growth to provide enough functionality but still maximize viral 




4.3 Anion exchange functionalization 
4.3.1 Ligand density  
The original methods of functionalization for DEAE cellulose were able to bind and elute 
protein successfully [15]. DEAE functionalization was designed for agarose hydrogel 
columns, which limited the temperature of the reaction below 50°C to not dissolve or weaken 
the agarose structure [273, 274]. Optimization of this method for cellulose hydrogels required 
increasing the temperature during the reaction to drive it further to completion. The typical 
functionalization temperature for chromatography material ranges from 20 to 80°C [275-278]. 
The reaction temperature was increased from 30 to 80°C, which resulted in a higher ligand 
density, as seen in Table 4-4. Additional to optimizing the DEAE functionality, a quaternary 
amine (Q) anion exchange was also developed. Section 3.2 outlines a complete description of 
chemical reactions and methods for functionalities. Table 4-4 below shows the ligand density 
for the anion exchange functionalities tested during this work. HA functionalities could not 







Table 4-4: Ligand density of anion exchange functionalized 500 to 300 µm cellulose columns. 









DEAE  80  1.06 300 µm 30 
DEAE  229  3.02 300 µm 80 
Q 346 3.44 300 µm 80 
Q 256 3.36 400 µm  80 
Q 140 2.23 500 µm 80 
 
By adjusting the reaction temperature, ligand density increased over 300% for the DEAE 
functionalization bringing it into the higher range of packed bed resins [279-281]. Maximizing 
ligand density is also an important factor for increasing the potential binding capacity of 
proteins [282]. Although the ligand density is similar on micro equivalences per milliliter 
basis, it should also be considered based on the surface area, seen in Table 4-4 to compare 
against membrane technologies. The charge per cm2 is similar to that of anion exchange 
membranes used for viral purifications [283]. Although the charge per mL of resin changes 
between hydraulic diameters, it remains consistent as a function of surface area for 300 to 400 
microns. Therefore, it can be assumed that the functionalization does not fully penetrate all 
the cellulose hydrogel but just a partial distance into it. If the functionalization reached 
completion throughout the gel, the resin's charge density would be the same and not surface 
area dependent. If the surface area was increased further with decreasing hydraulic diameter, 
charge density per mL could exceed values for packed bed resins. 
4.3.2 Binding capacity  
The static binding capacity of both the Q ligand and the optimized DEAE ligand was 
determined using BSA as a model protein, details of procedures for this can be found in 





Figure 4-16:  Static binding of BSA at various concentrations onto a Q ligand functionalized, 400 µm Schoen gyroid, 
cellulose column (5% dissolved +50% added cellulose and 15% ECH) over time. 
 
 
Figure 4-17: Static binding of BSA at various concentrations onto a DEAE ligand functionalized, 400 µm Schoen 
gyroid, cellulose column (5% dissolved +50% added cellulose and 15% ECH) over time. 
 
The majority of BSA uptake occurs in the first two to four hours, on average 80%; however, 
reaching maximum binding for high protein concentrations takes up to 24 hours. 
Chromatography beads can reach equilibrium in two to three hours [284, 285]. Traditional 
chromatography beads have a diameter between 20 to 80 microns, an order of magnitude 
smaller than the printed columns (300 to 500 microns). Therefore, the protein has further to 
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travel via pore diffusion into the hydrogel to reach all potential binding sites. Because of the 
pore diffusion-limited nature of the system, equilibrium can take a longer time to reach higher 
protein concentrations that approach the static binding capacity (Qmax). 
 
Table 4-5 shows Qmax for each anion exchange ligand and varying column hydraulic diameter. 
One mL of each column variation was allowed to bind protein for 24 hours in a saturated  BSA 
solution (20 mL of 25 mg/mL) with protein uptake measured by Nanodrop. The Q ligand 
binds almost twice the BSA amount compared to a DEAE column of the same channel size. 
This capacity seems to be independent of the ligand density as both DEAE and Q ligands have 
similar densities. This difference shows the importance of having multiple anion exchange 
functionalities even for the same overarching binding style. Differences in ligand between 
DEAE and Q can be because of hydrophobicity, ionic strength, or effective pH range, which 
can play a large part in protein and nucleic acid binding [286-289]. The effects of pore size in 
these experiments should be minimal because of their size (5 to 15 µm) compared with the 
hydrodynamic diameter of BSA (3.49 nm) [222, 282].  
 
Table 4-5: Static binding capacity of 3D-printed columns of varying channel size and ligand functionality.  










DEAE  41  2 400  30 
DEAE  85  3 400  80 
Q 135 10 300  80 
Q 138 8 400   80 
Q 105 8 500 80 
 
A maximum binding capacity seems to be reached independently on the columns' surface 
area for 400 and 300 µm Q columns. This limit suggests the BSA has completely penetrated 
the stationary phase at 400 µm with no additional static binding improvement in reducing the 
hydraulic channel diameter. Therefore, the increase of ligand density from 400 to 300 µm does 
not provide any additional BSA binding capacity. The values for 400 and 300 µm Q columns 
are at the high end of packed bed resins for BSA binding capacity [106, 281, 290, 291]. 
Traditional chromatography columns are packed tightly and aim for a void volume between 
0.3 to 0.4 for optimal separation [292, 293].  This voidage maximizes the surface area and media 
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by fitting many spherical beads within a given volume. A further reduction of hydraulic 
diameter would increase specific surface however current 3D printers are limited by their 
resolution to produce such columns. However, based on the capacity results for Q ligands an 
increase in specific surface area may not increase static BSA capacity.  
 
4.3.3 Functionality selectivity of DEAE  
Table 4-6 shows the retention times for each model protein's peaks and how this corresponded 
to elution buffer salt concentration. Also shown is the model proteins isoelectric point (pI). 
The retention time was measured from the beginning of the run, including injection. 
 
Table 4-6: Selectivity of DEAE with model protein 
Protein Elution peak Standard deviation Salt pI 
 
minutes minutes M 
 
Amyloglucosidase 34.4 0.04 0.217 3.6 
HSA 31.0 0.2 0.165 5.2 
Transferrin 29.1 0.4 0.137 6.2 
 
Cytochrome C was also tested which is a basic protein that should not bind to the column 
because of its negative charge at pH 7. No binding occurred and was seen coming out during 
the flow-through of the wash step post-injection. The elution order was similar to other anion 
exchange resins [294]. Eluted peaks had a similar shape and broadness compared with those 













In this chapter, varying chromatography ligands were evaluated for their ligand density and 
static binding capacity. By increasing the reaction temperature for DEAE immobilization, the 
ligand density was increased by 300% and static binding capacity by 200%. Comparatively, 
the BSA Qmax values for 300 and 400 micron Q columns are in the top range for the static 
binding capacity of traditional packed bed media. However, these columns are pore diffusion-
limited, as shown by the extended time (24 hours) to reach Qmax values. The calcium phosphate 
mineral functionalization described was shown to be a mixture of HA and OCP. It binds 
various model proteins more so dominated by its cation exchange mode than its metal 
chelation sites. This combination of calcium phosphate minerals resulted in different 
selectivities than those shown by traditional HA media. Conversion of OCP into HA is 
possible, as shown in literature, but because time and cost constraints have not been explored 
in this work. Selectivity depositing of this mineral solely into the hydrogel's pores may also 
add another level of selectivity by excluding molecules too big to fit inside the pores. 
 
The cellulose hydrogel has a microstructure capable of penetration by AAV particles. This 
penetration allows the particles access to the internal surface area of the media. A larger 
surface area to access will improve the binding capacity of viral targets. For HA 
functionalities, consideration needs to be made on the length of time allowed for crystal 
growth. Larger crystals add additional potential binding sites but limit penetration depth. 
One to two week’s growth should allow for maximum penetration while still maintaining 











5  Purification of virus from crude and clarified lysate 
 
5.1 Introduction 
In chapter 4, chromatography ligands (Q and HA) were adapted for cellulose hydrogels, and 
static protein binding capacity was determined. Improvement to both ligand density and the 
resulting protein binding capacity should translate to an improved virus binding capacity. 
Determination of the mineral composition of HA explained the difference in protein binding 
selectivities compared to those found in the literature. HA has been previously shown to be 
effective for viral purification, especially for AAV serotype 9 [50, 295]. The stationary phased 
microstructure used for these 3D-printed columns (cellulose hydrogel) could be accessed by 
viral particles, as shown by CSLM diffusion experiments. A penetrable stationary phase 
should improve the columns' viral binding capacity by increasing the surface area, and 
therefore, the number of binding sites.  
 
In this chapter, various viruses were purified from clarified lysates and unclarified cell 
cultures by 3D-printed columns using FPLC. Dynamic binding capacities, recovery, and 
purity of each viral purification are assed and compared with current literature. Purifications 
use both anion exchange, and HA functionalized columns. M13 bacteriophage is purified 
directly from cell culture similar to expanded bed adsorption. Individual steps in the FPLC 
method are optimized to minimize processing time while maximizing recovery. The benefits 












5.2 Test scale column fabrication 
The prior work completed by Anne Gordon produced wax templates using a 3Z Pro 
Solidscape lost wax printer [15]. A new 3D system's ProJet MJP 2500W was purchased after 
the Solidscape printer could not be repaired. Comparatively, the new printer has a higher 
resolution and speed than the previous printer with improved capabilities. Test prints were 
completed to ensure fidelity between STL file, wax templates, and resulting cellulose 
hydrogels. The determination that these templates could be created at the same or a better 
standard allowed for the work's scientific contingency. A full comparison between printers 
and printing technology can be found in Chapter 6. Columns were made using the negative 
templating process as described in  Section 3.1.  
 
5.3 Purification from clarified lysate 
5.3.1 Purification of Adenovirus  
In collaboration with iBET (Lisbon, Portugal), a DEAE and HA functionalized 3D-printed 
cellulose column (300 µm, Schoen gyroid, 5 cm bed height, 1 cm diameter) was used to purify 
adenovirus and lentivirus from the clarified feedstock. Details of the method for purification, 
quantification, and purity can be found in Section 3.6.2, 3.7.1, and in our paper ‘3D-printed 
ordered bed structures for chromatographic purification of enveloped and non-enveloped 
viral particles’ [244]. This work was completed before DEAE ligand improvement, Q ligand 
development, and the Projet printer's acquisition, limiting both the length of the tested 
columns (5 cm) and the number available to use. As a result, because of the limited number 
of columns available, only one variation of a HA functionalized column was tested. The HA 
functionalization used was alternating calcium and then phosphate solutions for three weeks. 
This extended crystal growth was to maximize the amount of HA present in the column. 
Chromatographs from the purification of 1 mL of clarified adenovirus lysate using each of the 
functionalized 3D-printed columns are shown in Figure 5-1. The elution peaks are broad and 
asymmetrical because of the slow diffusion of the virus out of the column's pores. Tailing was 
previously suggested in Chapter 4 due to the accessible pore structure and the slow pore 
diffusion of large viral particles (40 to 200 nm). In both cases, the elution occurs over 10 to 15 




Figure 5-1: Chromatographs of adenovirus purification on DEAE (A) and HA (B) 3D-printed 300-micron Schoen 
gyroid column [244].   
 
The DEAE column was used to purify adenovirus from 1 mL of clarified lysate under varying 
load flow rates. The recovery of adenovirus from the elution peak was dependent on the load 
flow rate (linear velocity) of the clarified lysate, as shown in Figure 5-2. The maximum 
recovery of 69 ± 6% for the DEAE column and 64 ± 6% for the HA column occurred at the 
lowest load velocity (8 cm/h). These recovery values are similar to those reported in the 
literature for purification by traditional packed bed columns and anion exchange membranes 
[93, 296, 297]. The adenovirus recovery from the DEAE column halves when the load flow 
rate was increased from 8 to 23 cm/h suggesting a high residence time is needed to ensure the 
viral particles diffuse through the solution and contact the column walls and internal pores to 
bind. These flow rates are also considered low compared to those used by packed beds for 
adenovirus purification (100 cm/h) [120]. By comparison, a packed bed process would have a 
considerably faster processing time for clarified lysate than this 3D-printed column. Residence 
time increases will be possible as bed height is increased above 5 cm. longer bed lengths will 






Figure 5-2: Recovery of adenovirus based on the linear velocity during the load of the feedstock onto the column 
from qPCR results. Black bars show viral genomes found in elution while the grey bar represents viral genomes 
found in flow-through fractions [244].  
 
Two linear load velocities 8 and 38 cm/h were used to calculate a dynamic binding capacity 
at 10% (DBC10%) from the breakthrough curves Figure 5-3. Calculations for these values can 
be found in Section 3.7.4.2. The linear velocity of 8 cm/h gave a DBC10% of 1.9 × 1010 VG/mL for 
the DEAE column. A 4.75-fold increase in the linear flow rate resulted in a 60% drop in the 
DBC10% at a linear load velocity of 38 cm/h.  
 
 
Figure 5-3: Break through curves of adenovirus on both DEAE (A) and HA (B) 300-micron Schoen gyroid columns. 
load flow velocity of 8 cm/h (•, solid line) and 38 cm/h (▲, dashed line) where C is the virus concentration of flow-
through samples and C0 is the virus concentration of injected feed material [244]. 
 
Further analysis of the clarified lysate before and after purification can be seen in Figure 5-4. 
The Nanoparticle Tracking Analysis (NTA) results show a reduction in the size distribution 
of around 100 nm indicating some of the smaller and larger contaminants have been removed 
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during purification. The TEM images also show the purified adenovirus particles surrounded 
by less debris and foreign particulate. There are still contaminants present in the adenovirus 
solution indicating a further polishing step is required. However, this technology is designed 
as a capture step in the downstream process, aimed at high recovery and separation from 
large contaminates such as cells, cell debris, organelles, and DNA. A high purity, free of 
smaller contaminants such as proteins and endotoxins, would be desirable but downstream 
processes typically require at least one or two additional purification and “polishing” steps 
[64, 84, 298]. The TEM images also show that the adenovirus's morphology is intact, and the 
process has not damaged the virus which could cause loss of infectivity [122, 299, 300]. 
Western blot analysis was also used to confirm the presence of proteins that make up the 
adenovirus structure (hexon and penton) and showed good protein clearance in the eluate.  
 
Figure 5-4: Characterization of purified oncolytic adenovirus. NTA profiles from (A) DEAE column purification 
and (B) HA column purification. The solid line represents the initial virus loaded on the columns and the dashed 
line the purified virus. (C) Western blot of purified oncolytic adenovirus from both 3D-printed columns. M: 
Molecular weight markers; Lane 1: Virus eluted from the DEAE column; Lane 2: Virus eluted from the HA column. 
Hexon, Penton IIIa, V, VI are Adenovirus capsid proteins.  (D) Transmission electron microscopy images of initial 




5.3.2 Purification of Lentivirus 
The initial work with adenovirus was used to set the flow rate conditions for lentivirus 
purification to maximize the potential recovery. A recovery of 57% for infectious particles was 
obtained from the elution peak (approximately 9 mL) from a 1 mL load of clarified lysate at 8 
cm/h. This is at the higher end of the range of lentivirus recoveries from a packed bed or 
membrane chromatography techniques [65, 124]. Figure 5-5 shows the elution profile and 
break-through curve for lentivirus purified on the DEAE column. A linear velocity of 8 cm/h 
gave a DBC10% of 2.0×109 PP/mL. As with adenovirus, the elution profile of lentivirus exhibits 
significant tailing, which can be attributed to the large viral particles' diffusion out of the 
stationary phase pores. 
 
Figure 5-5: Performance evaluation for Lentivirus. (A) Breakthrough curve for the DEAE 3D-printed column. The 
load flow velocity was 8 cm/h, where C is the virus concentration of flow-through samples and C0 is the virus 
concentration of injected feed material. Physical particles concentration was determined by p24 LV protein 
detection. (B) Chromatographic profile of Lentivirus purification in bind-and-elution mode [244].  
 
The initial results purifying both adenovirus and lentivirus showed comparable recovery to 
the current state-of-the-art purification methods. However, although recovery is comparable, 
the linear load velocities required for purification from clarified lysate are significantly slower 
(>10×). After this work, the Projet printer was purchased to produce longer column templates 
and therefore longer hydrogel columns. Additionally, anion exchange ligand densities were 
improved and a Q functionality was developed. Longer columns with the higher ligand 
density Q functionality have been used for both the AAV and M13 purifications. This was to 
increase residence time in the system and allow for more binding sites for the viral particles. 
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For details regarding the differences in ligand density and static protein binding capacity for 
these functionalities see Chapter 4. 
 
5.3.3 Purification of AAV serotype 9 
Samples of AAV serotype 9, provided by South Western Medical Centre (Texas, USA), were 
taken from a downstream process post clarification.  Although cells and other large debris 
had been removed from the solution, the viral particles remain in the culture fluid. This 
culture fluid contained 500 mM NaCl giving a conductivity greater than 60 mS/cm. This 
conductivity level prevents the use of ion exchange to bind the viral particles because of the 
excessive counter ions in the solution. Three options were considered; (i) to use HA to bind 
the virus using only calcium coordination sites, (ii) to dilute the fluid 10× to reduce 
conductivity below 7 mS/cm, and bind the virus with HA using both the calcium coordination 
sites and the phosphate cation exchange sites. (iii) to dilute the fluid 10× to reduce conductivity 
below 7 mS/cm and bind the contaminates using anion exchange, leaving the purified virus 
in the flow-through. Full details for purification, quantification, and purity analysis can be 
found in Sections 3.6.3 and 3.7.3.  
 
Table 5-1 shows the recovery from varying load volumes for direct purification from clarified 
lysate on a HA column (20 cm bed height by 1 cm diameter, 300 micron Schoen gyroid). The 
load flow rate was set to the minimum possible by the AKTA Start at 76 cm/h to maximize the 
eluate recovery.  For a 1 mL load, recovery of 12% was achieved with a binding capacity of 
3.28×108 VG per mL of the column. Additionally, recovery drops off rapidly for load volumes 
above 1 mL, showing that the maximum binding capacity is reached quickly because of the 
high salt concentration (500 mM NaCl) within the clarified lysate, limiting the binding of viral 








The load's conductivity was reduced by diluting the sample 10 fold to allow the virus to bind 
to the cation exchange sites. For a 1 mL load, recovery of 50 ± 5% was achieved for a binding 
capacity of 1.34×109 VG/mL of the column. While this is a significant increase in both recovery 
and capacity, it is still too low for a capture step in the downstream process. Although 
comparable to older purification methods (CsCl density gradients), recoveries for AAV9 are 
now up above 70% for ion exchange with capacities in 1012 VG per mL of resin [50, 295]. qPCR 
results have a high variation because of the small DNA concentration present in the recovered 
samples, with some samples being at the limits of acceptable detection levels.   
 
Table 5-1: Recovery of AAV 9 from undiluted culture fluid using 3D-printed HA chromatography under various 
load volumes. 
Load volume Recovery Standard deviation Total titer 
mL % % VG 
1 12 4.9 5.13E+09 
2 7.2 2.7 6.17E+09 
3 6.8 3.8 8.81E+09 
5 0.31 1.9 3.67E+09 
10 0.34 7.9 7.94E+09 
15 0.31 13 1.10E+10 
20 0.19 4.7 9.12E+09 
 
Figure 5-6 shows the chromatographs of AAV9 purification with varying load volumes of 
clarified cell culture using a 3D-printed HA column. Peaks were eluted in volumes between 
10 to 16 mL with large flow-through peaks compared to elution. As seen in both adenovirus 
and lentivirus the elution’s exhibit tailing because of the virus’s slow diffusion out of the pores 




Figure 5-6: Combined chromatograph of AAV purification from 20 cm HA column under varying load volumes 
at 76 cm/h of undiluted culture medium ( 1×1010 VG/mL). 
 
HA resins used in packed bed chromatography have a high crystallinity or are in a ceramic 
form achieved by sintering at temperatures greater than 400°C [301]. This heat-treating 
process not only affects selectivity but increases the binding capacity of the resins [301]. As 
the HA used in this work is deposited onto a hydrogel matrix heat treatment is not possible 
without the destruction of the stationary phase.  Further improvement of this functionality 
may be possible as previously mentioned in Chapter 4, by thermal conversion into pure HA. 
Changing the HA functionalization by reducing or increasing the time the mineral is grown 
for was considered. As shown in the viral penetration study, a decrease in HA 
functionalization time to one week would double the potential penetration depth achievable 
by AAV particles. However, the capacity of the column was considered so low (two orders of 
magnitude below the state-of-the-art) even by doubling capacity this purification method 
would not be comparable.  
 
Instead of using bind and elute chromatography, the stationary phase can bind contaminants 
and allow the flow-through of the viral particles. 50 mL of 10× diluted clarified AAV9 cell 
culture was passed through a Q functionalized column (10 cm bed height by 1 cm diameter, 
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300 micron Schoen gyroid). As the lysate flows through the column, the number of viral 
genomes detected by qPCR stabilized between 6×109 and 4.5×109 per mL after an initial 
amount flown through (10 to 15 mL). The overall recovery from 50 mL of 10× diluted load was 
80 ± 5%. This suggests some of the viral particles are either being bound or trapped within the 
column. Post flow through a 1 M NaCl, 10 mM phosphate buffer pH 6.5 was used to elute off 
any bound virus. qPCR of this elution was inconclusive, indicating some DNA material 
present but not enough to accurately quantify. It can therefore be assumed some AAV was 

























 Figure 5-7 shows an SDS-PAGE stained with Coomassie Brilliant Blue of AAV9 samples from 
the 3D-printed Q column at different points in the flow-through. A reduction in protein 
contaminates is observed, but it is hard to distinguish because of the 10-fold dilution required 
for the anion exchange column to bind contaminates. The remaining bands seen in 5 and 4 are 
potentially capsid proteins (VP2) from the AAV [302]. The lack of bands before lanes 5 and 4 
suggests that some AAV is bound to the column. Comparatively, to the state-of-the-art 
purification from the clarified lysate, AAVX and AAV capture series resins offer 99% recovery 
for up to 1013 VG/mL over the range of AAV serotypes [6]. These resins have much higher 
recovery and load capacity than what is currently possible with 3D-printed columns. This is 
because of the strong affinity AAV particles have for the camelid antibody used as the ligand 
on these resins.  
 
 
Figure 5-7: SDS-PAGE gel of AAV9 load and flow through of AAV9 on 10 cm 300-micron Schoen gyroid Q column. 




L F1 4 3 F2 1 2 L 5 
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5.4 Purification from crude cell culture 
Purification of M13 bacteriophage directly from cell culture was completed with three 
different bed height (5, 10, 15 cm) Q anion exchange columns (1 cm diameter, 300 µm Schoen 
gyroid). Details of culturing, chromatography, SDS-PAGE, and quantification can be found in 
Sections 3.6.1 and 3.7.2. 
 
3.1.1 Purification of M13 bacteriophage 
The recovery of M13 bacteriophage particles from 2 mL (0.5 CV) of crude cell culture over 
varying load flow rates is shown in Figure 5-8. The effect of flow rate on the recovery of M13 
bacteriophage is significant, losing over 20% for an increase from 76 to 153 cm/h. If the load 
flow rate is too high, the M13 particles do not have enough time to diffuse through the liquid 
to contact the column's solid phase. Therefore, the residence time of this style of 
chromatography media is an important variable to consider. Minimizing the flow rate to 
lengthen residence time through the column during loading should maximize recovery. The 
highest recovery was 69 ± 4% for 3.1 x 1011 pfu/mL of resin for a 2 mL load at the lowest flow 
rate (76 cm/h).  
 
Figure 5-8: The recovery of M13 bacteriophage (2 mL load of 1×1012 pfu/mL) from cell culture under varying load 




While maintaining the lowest possible flow rate on the ÄKTA start (76 cm/h), the load volume 
was adjusted to measure its effect on the recovery. Figure 5-9 shows the recovery drops to a 
plateau (between 1 to 2 CV) as load volume increases before starting to decrease again.  These 
two distinct areas in Figure 5-9 suggest two different binding mechanisms are occurring 
within the system. The initial binding of phage particles is thought to occur on the channel 
walls (surface binding), followed by phage diffusion and binding inside the stationary phase 
pores (pore binding). The pore binding occurs slower than the initial surface binding resulting 
in the plateau seen in Figure 5-9. 
 
 
Figure 5-9: The recovery of M13 bacteriophage from crude cell culture at 76 cm/h under varying load volumes 
(1×1012 pfu/mL) from a 5 cm bed height, 300 micron Schoen gyroid column. 
 
A repeat of this experiment with a bed height of 10 cm was completed, shown in Figure 5-10. 
The same trend is seen with a plateau region between 0.75 to 2 CV. Interestingly, the recovery 
and capacity for 0.5 CV of load on the 10 cm (71 ± 6% for 3.2 x 1011 pfu/mL of resin) was similar 
to that of the 5 cm column (69 ± 4% for 3.1 x 1011 pfu/mL). Although a slight recovery 
improvement is shown, surface binding still dominates and is less affected by increased 
residence time. However, an increase is seen in the plateau region (the area dominated by 
pore diffusion); for the 5 cm column, it occurs at a recovery of ~40%, while the 10 cm column 
occurs higher at ~50%. The increase in column length effectively doubles the residence time 
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for the phage particles passing through. This increase in time allows for more of the slower 
pore-based binding to occur, resulting in a higher recovery rate during this period. If these 
columns were solely limited by diffusion, particles of M13’s size would take many hours to 
reach the walls from the center of the bulk needing to travel up to 150 µm. An investigation 
into the flow-through gyroid structures by magnetic resonance imaging showed fluid streams 
spitting and recombining from one unit cell to the next [303]. Therefore, this splitting and 
recombining are thought to aid in transporting viral particles from the bulk to the adsorptive 
walls through radial mixing. 
 
Figure 5-10: Recovery of M13 bacteriophage from cell culture under load volumes at 76 cm/h from a 10 cm bed 
height, 300 micron Schoen gyroid column 
 
By minimizing the load volume to 0.25 CV to maximizing surface binding, the recovery 
increased to 89.7% ± 6% for 1.4 x 1011 pfu/mL of resin. Because of the large size of the ordered 
channels within the 3D-printed columns, the pressure drop (between 0.01 and 0.02 MPa at 611 
cm/h) is minimal compared to a packed bed [16, 304]. Therefore, by maintaining the residence 
time in longer columns (>50 cm) by using higher flow rates, it will be possible to process larger 
volumes while maintaining a high recovery and similar processing time. The chromatograph 
for this purification is shown in Figure 5-11. The elution peak is tailing, as seen previously in 
chromatographs of AAV, lentivirus, and adenovirus. The tailing seen in Figure 5-11 is caused 






Figure 5-11: Chromatograph of 0.25 CV load on a 10 cm bed height, 300 µm Schoen gyroid column at 76 cm/h. 
 
5.4.1 Purity 
 The SDS-PAGE results (stained with Coomassie Brilliant Blue) in Figure 5-12 show a clear 
reduction in HCP visible on the gel between the load (lane 1) and the elution’s (lanes 2 to 7). 
OD600 measurements of elution samples were also compared to the initial cell culture load 
(OD600 values between 0.8 and 1). Values for OD600 of between 0.01 to 0.02 absorbance 
suggest low turbidity for the eluted samples. Both of these results indicate that further 
purification or polishing by packed bed chromatography should be possible without 
significant fouling caused by large contaminates such as cells or cell debris common in crude 
load material. Crude load material containing solids or large particulates can cause fouling, 
tailing, and a reduction in dynamic binding capacity for packed bed columns [305, 306]. The 
combined capture and clarification step demonstrated by this 3D-printed column purification 
would eliminate the need for centrifugation or filtration to remove solids. Secondary 





Figure 5-12: SDS-PAGE gel of M13 elution’s from a 10 cm bed height column based on varying load volumes; L – 
Ladder; 1- load; 2- 0.25 CV; 3 – 0.5 CV; 4 – 1.25 CV; 5 – 1.75 CV; 6 – 2.5 CV; 7 – 2.75 CV. 
 
 
5.4.2 Expanded bed adsorption process comparison 
Ling et al. performed an EBA purification of M13 bacteriophage to show its advantage over 
the traditional PEG/NaCl precipitation method [307]. Their purification gave a recovery of 
82.86% for 3.1 x 1011 pfu/mL of resin compared with a 36% recovery using PEG/NaCl. This 
EBA process was used as a model to compare with 3D-printed column purification. Table 5-2 
outlines the key results and processing conditions for each method. For similar operating 
conditions, purification using a 3D-printed column achieved a recovery rate of 87.7% ± 5% for 
1.49×1011 pfu/mL of resin. Although a higher recovery was achieved, a potential reduction in 
the EBA process's load volume may have yielded a similar result. Load volume was 
minimized to ensure a high recovery as capacity can be adjusted in scale-up. As previously 
mentioned, lengthening the column and increasing load velocity to maintain residence time 
L 3 2 1 4 5 6 7 
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should be possible because of the minimal pressure drop over the 3D-printed column. 
Maximizing recovery is critical for high-value targets such as gene therapies, as costs to 
culture recombinant viruses are a large majority of production costs [308]. High recoveries are 
also critical for early downstream processing steps like capture because of the follow-on effect 
in subsequent steps. Improving recovery rates for clarification and filtration steps has also 
been acknowledged as a potential area of process improvement [309]. There is also a 
considerable difference in elution volume between the EBA and 3D-printed column processes. 
The EBA process elutes in 300% more buffer than what was required for the 3D-printed 
column. However, this is because their elution occurred while the bed was expanded [307]. 
This choice in mode caused their elution volume to be higher than a packed mode elution 
because of the flow rate required to maintain expansion [164].  
 
Table 5-2: Comparison of key features between EBA and 3D-printed column ( 6% cellulose +50% added and 15% 




Recovery (Yield) 87.75 ± 5% 82.86% 
Resin material Cross-linked cellulose, 300 µm 
diameter Schoen gyroid 
Streamline DEAE 
pfu/mL of resin 1.49E+11 3.17E+11 
linear velocity (cm/hr) 122 250 
residence time (min) 7.4 7.4 
Elution volume (CV) 1.53 4.63 





The chromatograph of this purification is shown in Figure 5-13, which has a similarly shaped 
elution peak to Figure 5-12. The 3D-printed column purification was completed in 70 minutes, 





Figure 5-13: Chromatograph of 3 mL load on a 15 cm, 300 µm Schoen gyroid column at a load flow rate of 122 
cm/h. 
 
Figure 5-14 shows the time for each step in the compared processes. Conventional purification 
requires repeated cycles of PEG salt precipitations and centrifugations, which are time and 
labor-consuming. EBA adsorption can be completed in a fraction of the time. However, this 
does not account for the setup, maintenance, or cleaning of the column. Purification by 3D-
printed chromatography can be completed faster than EBA because of the ability to vary the 
flow rate at each step of the process. The equilibration and wash steps can be completed at 
high flow rates to minimize processing time (611 cm/h). Flow rates could have been increased 
further but were limited to the ÄKTA Start's hardware's maximum flow rate. For the same 
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column tested on an ÄKTA Pure capable of flow rates up to 20 mL/min, a back pressure of 0.1 
MPa was observed for a linear velocity of 3055 cm/h. Because of the physical containment 
level required to work with M13, the only available chromatography system was an ÄKTA 
Start. 
The flow rates for EBA directly relate to the degree of bed expansion and operational 
performance. Flow rate is optimized depending on the load material, degree of expansion 
required, adsorbent used, and target biological. Expansion is typically between two to three 
times the original packed bed height for optimal performance. During the EBA setup, the 
fluidized bed needs time to become stable before sample loading. The bed also requires re-
stabilization if the flow rate is changed during operation. The degree of expansion limits EBA's 
maximum flow rates and discourages flow rate changes during operation. Time is also 
required for EBA setup (bed fluidization) before the purification can commence. The initial 
expansion can take 30 to 40 minutes to stabilize before the flow rate is adjusted to reach the 
correct degree of expansion, followed by another 30 to 40 minutes to re-stabilize [310]. 
Fluidization is an iterative process until the desired expansion is achieved. The overall setup 
and running of an expanded bed system is a complex process and requires expertise. In 
comparison, this 3D-printed column can be operated with traditional packed bed hardware 
without any additional setup time or specialized equipment. The monolithic style stationary 
phase also does not require any specialized packing technique, being able to be slide inside a 
conventional casing designed for a packed bed column. 3D-printed columns do not suffer 
from the same issues, such as channeling and bed collapse, because of their self-supporting 




Figure 5-14: Comparison between the individual steps of M13 purification and the time required for each for an 
EBA process, the conventional technique and a 3D-printed column [307].  
 
5.4.3 Column cleaning and fouling mitigation 
Notably, no build-up of cells or other debris was observed at the column's inlet or outlet under 
visual inspection post purification even after multiple cycles (>10). Effective CIP and 
sanitation are crucial for meeting goods and manufacturing regulations and FDA guidelines. 
The build-up of cells or lipids at the inlet or outlet was a common EBA issue, which affected 
its adoption in the industry[14, 167]. 
 
 The column's initial cleaning method was based on the CIP used for traditional anion 
exchange packed bed resins [281, 290, 311]. The column was stripped with 1 M NaOH over 8 
CV at 1 mL/min, followed by 8 CV of 1 M NaCl and a flush of DI water. Figure 5-15 shows 
how the recovery of a 2 mL load at 76 cm/h on a 10 cm column (300 µm Schoen gyroid, 1 cm 
diameter) decreases after multiple purifications using a CIP system like packed bed resins. 
The recovery rapidly decreases over 10 to 30 purifications using this CIP method. This 
recovery decrease indicates that fouling has occurred, and the cleaning cycle is not adequate 





































Instead of basing cleaning on volume, a timed method was implemented. 1 M NaOH was 
passed through the column at 76 cm/h for one hour, followed by a flush of 1 M NaCl (611 
cm/h for 5 minutes) and then DI water (611 cm/h for five minutes). This slower process lets 
the NaOH penetrate the 300 µm walls of the column to break up any biological material 
causing the fouling (DNA, protein, cell debris) and then diffuse out of the pores to be flushed 
from the column. This CIP method was implemented after 34 cycles, which quickly reversed 
low recoveries from the column because of fouling. Removal of fouling is shown in Figure 5-
15, where at 35 cycles and onwards, the recovery goes back to ~90%. The ability to reverse this 
fouling shows these columns' potential longevity even under heavily contaminated feed 
streams and rigorous CIP methods.  
 
 
Figure 5-15: Recovery of M13 from a 2 mL load at 76 cm/h using a 10 cm bed height, 300 µm Schoen gyroid column. 
Recovery of repeat purifications using the same column are shown after numerous trials. Red line indicates where 









In this chapter, a range of viruses was purified from clarified cell lysates and crude cell culture. 
Most notably, purification of lentivirus and M13 bacteriophage showed high recoveries 
compared to the art's current state. Because of the column's mass transfer limitations, to 
maximize recovery, loading of the column needs to be completed at a minimal flow rate (< 76 
cm/h). The slower flow rate gives viral particles the maximum amount of time to diffuse 
through a solution and contact the column's walls and internal pores to bind. Alternatively, 
to minimizing the load flow rate, bed height can be lengthened to increase the residence time. 
Higher residence time improves pore binding as shown for M13 bacteriophage where the 
plateau region (pore binding) of recovery increased (+10%) for a bed height increase from 5 to 
10 cm. 
 
Purification of AAV serotype 9 was possible by both HA and anion exchange but was not 
comparable to the current state of the art in recovery or capacity.  Although the HA 
functionality can bind and elute viral particles, its capacity is low compared with the 
optimized Q and DEAE anion exchange ligands. An investigation into an affinity style ligand 
is thought to improve both capacity and recovery for AAV. 
 
3D-printed columns are a simple alternative to an expanded bed chromatography for the 
purification of M13 directly from cell culture. The 3D-printed column purification has 
comparable recoveries, but was able to be completed three times faster than EBA. The ability 
to freely adjust flow rate allows for each step within the process to be optimized, saving time. 
This advantage over expanded bed chromatography alongside ease of use and setup shows 
this technology’s potential benefits for downstream virus processing. The low-pressure drop 
over 3D-printed columns could also be exploited further with higher flow rates and longer 
bed heights. An effective CIP process to minimize column fouling was required to prevent 
build-up over multiple purification cycles. An extended caustic wash was used to break up 
any biological material bound to the column. No reduction in recovery or capacity could be 
seen after CIP changes were made, even after numerous purifications (40+). 
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6   Advancement of 3D printing and upscaling 
 
6.1 Introduction 
Chapter 5 showed that purification of viruses and viral particles using 3D-printed 
chromatography columns was possible, achieving high recoveries comparable to current 
packed bed standards. Furthermore, this technology's benefit over expanded bed adsorption 
was shown in faster processing time, ease of use, and high recovery. For this technology to be 
adopted by the industry, it must be scalable and process commercial volumes of feedstock. 
Emerging technologies such as monoliths experience issues reaching preparative or pilot-
scale because of inconsistent processing and limitations in current fabrication methods [10, 
312, 313]. Current pilot-scale packed bed chromatography columns have bed volumes 
between 400 mL up to 25 L, capable of processing liters of feedstock per batch process [314]. 
For this technology, a pilot-scale column's goal would be 5 cm in diameter by 50 cm bed 
height, equivalent to a volume of 980 mL. This chapter looks at the 3D-printing technology 
used for templating and if scale-up is currently possible with this method. 
 
This chapter investigates the size of wax templates producible on the 3D-systems ProJet MJP 
2500w printer and unique ways of making larger columns. The entire templating process is 
examined, focusing on the most time-consuming steps and those that limit column size. 
Currently, the longest step of the templating process is in support wax removal which is 
expected to lengthen exponentially as the column's size increases. Determining the current 
process limits will help guide future work on upscaling while informing what is possible now. 
Design of specialized equipment to aid a larger templating process was also required for 
support wax removal and cellulose infusion into templates. A unique column stacking 
method is examined as an alternative to needing a single-piece monolithic column. Residence 
time distribution (RTD) was used to compare performance between a single piece column and 





6.1 Methods & materials 
Materials used for Chapter 6 of work have previously been mentioned in Chapter 3 and are 
the same used for the printing and creation of 3D-printed columns as outlined in Section 3.1.1 
and 3.1.4. 
6.1.1 Printer comparison 
Product information for both the SolidScape Pro 3z and the 3D Systems ProJet MJP 2500w 
wax 3D printers were obtained from the manufacturers to compare specifications. Printing 
time and file size data from the SolidScape printer were then compared with the experimental 
data from the ProJet printer. A base case was used to compare printers, a 1 cm diameter by 5 
cm long, 300 µm Schoen gyroid column. The time required to print, the number of individual 
templates made in one print, and the printer's slicer software's maximum file size were all 
recorded. 
 
Trial prints of smaller hydraulic diameters were tested with the ProJet printer. 150, 200, and 
250 µm Schoen gyroid templates (1 cm diameter by 5 cm long) were produced. Post printing 
templates were placed in a beaker of IPA stirred at room temperature to remove the support 
wax (Figure 6-1). IPA was replaced every 48 hours for between 7-20 days until support wax 
had been removed. Templates were then dried in a fume hood for 24 hours before being gelled 
using the standard method described in 3.1.4. After gelation, columns were boiled in a beaker 
with a drop of liquid hand soap for up to 100 hours to remove build wax from the cellulose 
structure. After removal of build wax, three of each channel diameter were snap-frozen, 







Figure 6-1: First support wax removal method. A beaker is filled with IPA and placed on top of a temperature 
controlled hot plate (30-40 °C). 
 
6.1.2 Slicer file size  
Various sized 300 µm hydraulic diameter Schoen gyroid template STL files were made using 
the Matlab TPMS generation program described in 3.1.2 and attempted to be loaded in 3D 
sprint slicer software used by the ProJet MJP 2500W printer. Determination of file size and 
compatibility of the printer was recorded.  
 
A patterning technique was used to avoid the file size limitation of the 3D sprint slicer 
software used by the ProJet MJP 2500W printer. The TPMS geometries (Schoen gyroid) used 
for these 3D-printed columns are periodic along the x, y, and z-axis. Therefore, each unit cell 
is identical to the next and can be patterned along each axis. Patterning can be done within 
the 3D systems software “3D sprint” where a circular slice, one unit-cell thick, can be 
patterned along the y axis to increase the column's length. This pattern by-passes the 
computer and software's file size limits, allowing for larger columns to be printed. Using this 
method, a 5 cm diameter by 20 cm long, 300 µm Schoen gyroid template was printed on the 
Projet printer. Because of this template's size, support wax removal was attempted by leaving 
it inside a glass jar with 2 L of IPA. The jar was left stagnant to slowly dissolve away the 
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support wax, with the IPA being replaced every five days for one month. The template was 
then visually assessed for damage and dissected to determine if the support wax had been 
completely removed. 
 
6.1.3 Segmentation method 
Dividing up a column template into multiple smaller pieces (column segmentation) was used 
as an approach to upscale this technology. Two methods of column segmentation were tested 
to achieve larger structures and reduce overall column production time. The first was to 
produce smaller pieces (1 cm in length by 1.5 cm in diameter) of column template (plugs) with 
locater keys along the edge of each (Figure 6-2). A modified column casing was then used to 
line these smaller plugs together in the correct orientation using the template's locator key. 
These plugs were then gently forced together and gelled as a single-piece column described 
in Section 3.1.4. Post-processing occurred similar to a standard column, with the build wax 





Figure 6-2: 3D model locator on plug (left) and locator slot on column casing (right) 
 
The second method was to again make smaller plugs (1 cm diameter by 2 cm long) without a 
locator key. The smaller plugs would be gelled individually in short casings to make smaller 
pieces of cellulose column. These plugs were then stacked together inside the appropriate size 
SNAP casings to the desired bed height. The plugs were stacked randomly inside the casing. 
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6.1.4 Column tracer study 
One cellulose column 10 cm long (1 cm in diameter, 300 µm Schoen gyroid) or 4 × 2.5 cm long 
were placed in SNAP glass casings fitted with plastic pistons containing 20 µm glass frits (S-
10/125-PPSS-OV-FP20). The column was attached by plastic tubing and fittings to an ÄKTA 
Pure chromatography system. Tracers of 1% acetone were injected, 0.5 mL per trial (6% of the 
column volume), into the column at different flow rates between 0.1 and 4 mL/min. Unicorn 
5.4 software was then used to measure the 280 nm absorbency response from the ÄKTA’s 
detectors. Peaks were then normalized and analyzed to compare asymmetry and HETP 
values. Asymmetry was determined by the half-peak method (equation 6-1). Where 𝑎 and 𝑏 




Figure 6-3:  Example of a tracer elution peak from a packed bed chromatography column [160]. 
 
 




The HETP values were also calculated from the normalized peaks using equation 6-2. Where 









2      (6-2) 
 
Sample calculations can be found in Appendix A 
 
6.1.5 Support wax removal advancement 
The first iteration of a support wax removal rig (Custom support wax removal rig version 1) 
is shown in Figure 6-4. This rig was designed to have a consistent and repeatable method for 
support wax removal from longer column templates too large for beakers. A cylindrical tube 
with a mesh grate at the bottom and top held the template in place while a peristaltic pump 
(Master flex Console drive) pumped IPA from a tank up through the cylinder. The flow rate 
was set to 40 mL/min, which was the highest possible by the pump. No heating was applied 
to this rig because of the wearing down of the peristatic tubing over long runs (>24 hours) and 
IPA's flammability. The glass tube could only fit single columns up to 3 cm in diameter and 
20 cm long. Templates of various channel diameters and column diameters were printed at a 
length of 15 cm. Individual trials of each of these templates used a fresh 1.5 L of IPA 
recirculated through the rig at 40 mL/min. Templates were removed each day and had 0.5 cm 
cut off from one end to visually determine if support wax remained inside. Templates were 
then returned to the rig for a further 24 hours if support wax remained. Upon determination 
of complete support wax removal, a repeat trial was completed, with the template being left 
undisturbed in the rig for the predetermined length of time to confirm prior results. Figure 6-




Figure 6-4: Custom support wax removal rig version one. IPA recirculation by pump up through holder over 
column template and back to tank. 
 
 
Figure 6-5: Support wax removal rig version one. Brown bottle is filled with IPA and the Master flex console 




The second iteration of a support wax removal rig (Custom support wax removal rig version 
2) was designed for template 'plugs' as described as a part of the column segmentation 
method. These plug templates were 5 cm in diameter by 2 cm thick, 300 µm Schoen gyroid. 
The second version (Figure 6-6) of the support wax removal rig was developed alongside 
Craig Stocker (undergraduate student contributing as part of his final year project). The tank 
was 30 cm in diameter, and 20 cm deep with six 3D FDM printed mesh cages (Figure 6-7) 
arranged evenly in a circular pattern around the tank's sides. The mesh cages are held in place 
by the lid on top of the tank. IPA is stirred inside the tank by an overhead mixer, and the 
temperature is controlled through a temperature probe connected to the hot plate. The mesh 
cages can hold columns up to 5 cm in diameter by 15 cm long templates. Templates of varying 
sizes and hydraulic diameters had their support wax removed using this rig as described in 
their relevant experiments.  
 
 
Figure 6-6 Custom support wax removal rig version 2. A stirred tank containing IPA sitting on top of a hot plate 






Figure 6-7: Custom 3D-printed mesh cages for holding wax templates inside support wax removal rig version 2.  
Pins fit through the smaller holes to hold templates. 
 
 
The following series of experiments using the second iteration of the support wax removal rig 
was designed to optimize the wax removal from 2 cm by 5 cm, 300 µm hydraulic diameter 
Schoen gyroid template.  
 
1. Timed support wax removal 
The second support wax removal rig with filled with 8 L of fresh IPA before each trial. Five 
wax templates were placed in the mesh cages for each experiment and submerged into the 
IPA within the tank. The temperature was controlled using a probe connected to a hot plate 
beneath the tank. A fixed stirring rate of 400 rpm was used for these experiments. Three 
temperatures were tested 40°C, 35°C, and room temperature (~22 °C). One template was 
removed from the rig at regular one-hour intervals after starting the experiment and left to 
dry overnight inside a fume hood. Each disc's mass was recorded at the experiment's start and 
then after each had dried the next morning. These measurements allowed the mass change of 
the disc because of support wax removal to be quantified. Each morning, the templates would 
134 
 
be reloaded into the rig to repeat the cycle until the templates' mass change had stabilized 
over three or more hours. The template removed first on the previous day would be the last 
to be removed on the following day. Visual inspection of the templates was also performed to 
detect any damage. After support, wax removal templates were cut in half to examine their 
cross-sections to ensure complete support wax removal. 
 
2. Adjusted template thickness  
5 cm diameter, 300 µm Schoen gyroid templates of varying thickness (0.8, 1, 1.2, 1.4, 1.6, and 
1.8 cm) were placed inside the mesh cages in the tank. The tank was filled with 8 L of fresh 
IPA and stirred at a constant rate of 400 rpm. No heating was used for this trial. The trial was 
left to run for 72 hours before the templates were removed, visually inspected, and left to dry 
for 24 hours inside a fume hood. Upon drying, the templates were weighed before the process 
was repeated until either the templates cracked or no mass change was observed between 
cycles.  
 
Following the results of the adjusted template thickness experiment, the mixing conditions 
were changed. First, a new holder was designed that held the template vertically, as shown in 
Figure 6-8. For each trial, two of these holders containing 1 cm thick (5 cm diameter, 300 µm) 
templates were placed into the tank with 8 L of fresh IPA. The first trial used a fixed mixing 
rate of 400 rpm, while the second was fixed at 900 rpm.  The templates were removed from 
the tank after 72 hours and left to dry for 24 hours inside a fume hood. Upon drying, the 
templates were weighed before the process was repeated until either the templates cracked or 
no mass change was observed between cycles. 
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Figure 6-8: Second design of wax removal template holder for 5 cm diameter templates. 
 
3. Decreasing template diameter 
After determining results from adjusting the thickness of the template, a similar trial was 
completed with varying column diameters of a set thickness (1 cm). Two of each template of 
varying diameter (2, 3, and 4 cm) were placed inside the originally designed mesh cages inside 
the tank. The tank was filled with 8 L of fresh IPA and stirred at a constant rate of 400 rpm. 
The trial was left to run for 72 hours at room temperature before the templates were removed, 
visually inspected, and left to dry for 24 hours inside a fume hood. Upon drying, the templates 
were weighed before the process was repeated until either the templates cracked or no mass 
change was observed between cycles. 
 
4. Increase of hydraulic channel diameter  
The last test of the second support wax removal rig was a repeat of the timed support wax 
removal experiment with templates (5 cm diameter by 1 cm thick) of varying hydraulic 
channel diameters (500, 400, and 350 µm). Four wax templates were placed in the mesh cages 
for each hydraulic diameter and submerged into the IPA within the tank. The temperature 
was controlled using a probe connected to a hot plate beneath the tank. A fixed stirring rate 
of 400 rpm was used for all of these experiments. Two temperatures were used in individual 
repeats of this test at 40°C and room temperature (~22 °C). For the trial at 40°C, templates were 
removed from the rig at regular two-hour intervals after starting the experiment and left to 
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dry overnight inside a fume hood for 24 hours. Each disc's mass was recorded at the 
experiment's start and then after each had dried the next morning.  Measurements were 
repeated until the mass of the templates had stabilized or the template had cracked. This 
method was repeated for the room temperature trial, except templates were removed at 24-
hour intervals instead of two hours.  
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6.1.6 Column plug template filling rig  
 The cellulose infusion rig designed alongside Craig Stocker (undergraduate student 
contributing as part of his final year project) is shown in Figure 6-9 below. This rig is 
attempting to replicate filling wax templates with dissolved cellulose solution at a larger scale. 
The rig was also designed to fill either multiple larger (>2 cm diameter) column templates at 
a time or a single template.  
 
Figure 6-9: 3D Solidworks model of the custom wax template cellulose infusion rig. 
 
The tank holds up to 3 L of dissolved cellulose solution kept cold by an ice bath recirculated 
through the tank's jacket. The rig was also designed for eventual use with other polymer 
solutions such as dissolved agarose that would need to be kept warm using a heated water 
bath to prevent premature gelling. The flow of solution through the pipework is driven by air 
pressure (100 PSI) in the head. This pressure is supplied by an airline and controlled by a 
regulator valve. Manual ball valves were used to stop and start the solution's flow, with one 
before each of the template holder attachments.    
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 Template holders were designed and 3D-printed out of resin to be attached to the cellulose 
infusion rig's arms. The design could be altered to hold varying sizes of wax templates. They 
are attached by female Cam Lock fittings that screw into the 3D-printed holder and connected 
to the rig's pipework's male Cam Lock fittings. Figure 6-10 shows the design of one of these 
template holders below. The holders' tapered slides are to minimize air pockets forming and 
allow for an even distribution of solution through the template. 
 
 
Figure 6-10: 3D Solidworks model of the custom template holders for cellulose infusion rig. The external image 
shows the outside of the template while the cross-section shows it internal structure. 
 
A top and bottom casing are held together by an external clamp (Figure 6-11), which seals the 
O-ring. The Luer Lock attachment on the top casing can be sealed with a cap to prevent 
cellulose solution from leaking out after infusion has been completed. A screw cap that fits 







Figure 6-11: Printed template holder for the cellulose infusion rig showing female Cam attachment and clamp 
holding the top and bottom casing together. 
 
A four-way splitter value (Figure 6-12) attached to the bottom of the tank, with identical length 
pipework, can be used to fill multiple templates simultaneously. The rig can also be 
rearranged using Cam Lock fittings to fill one or any number of templates up to five at a time. 
Clamp 




Figure 6-12: 4-way splitter attachment for cellulose infusion rig. Each arm has its own Cam fitting for holder 
attachment.  
 
Figure 6-13 shows the rig set up to fill one template at a time. The bottom pipe was used as a 
purge valve to empty the tank after the infusion has been completed. The rig was operated 
inside a fume hood because of the volatility and toxicity of the chemical cross-linker ECH. 
This requirement for the rig's operation prevented the 4-way splitter valve from being tested 
because of the lack of space inside the fume hood. Upon confirmation, the rig works a more 




 Figure 6-13: Cellulose template infusion rig setup without 4-way splitter pipework.  Blue line: air connection; 
Green line: recirculated water for jacket.  
 
6.1.7 Cellulose infusion operational testing 
Two different sized templates were used to determine if the rig performed as designed. In the 
first test, 1 kg of 6% dissolved cellulose solution (as described in Section 3.1.1) was combined 
with 30 g of cellulose powder in an overhead mixer at 8000 RPM for five minutes. No chemical 
cross-linker was used in case the rig leaked or did not have enough pressure to force the flow 
of the cellulose solution. The solution was then sieved to remove any large clumps of the 
remaining powder. Only a very small number of clumps were removed compared with a large 
amount of cellulose added. Cellulose lost in clumps was considered minor and would not 
affect the desired cellulose composition. The rig was set up as previously shown in Figure 6-
13 to gel a single 5 cm diameter by 1 cm thick, 500 µm Schoen gyroid template. The rig's tank 
was cooled with the recirculating ice bath 10 minutes before infusion. The cellulose solution 
was poured into the tank, lid closed and wing nuts tightened. The ball valve from the tank to 
the template holder was opened and the air regulator slowly adjusted to pressurize the tank 
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and force the solution up through the template. The ball valve was then closed once the 
solution started to flow out of the holder's top. The top of the holder was then capped and 
removed from the arm. The holder's bottom was plugged and placed in a water bath at 50°C 
for four hours. Post gelation, the infused template was removed from the holder and lightly 
scrapped to remove excess hydrogel. The infused template was then boiled in water with a 
drop of liquid hand soap for 8 hours. After build wax removal, the resulting hydrogel piece 
was visually examined and dissected to identify defects. 
  
The second experiment used a 5 cm diameter by 6 cm thick, 500 µm Schoen gyroid template. 
The previous experiment was replicated with the addition of 100 grams of chemical cross-
linker (ECH) mixed in with the cellulose powder by the overhead mixer for five minutes. Post 
gelation and build wax removal, the hydrogel piece was visually examined and dissected for 
defects. 
 
The final experiment was a repeat of the second experiment with two templates infused one 
after the other. Upon the filling and removing the first holder, a second holder was attached 
to the rig, and the ball valve reopened to fill the second template. Post gelation, the templates 
were visually examined and dissected for defects. All three resulting hydrogel structures with 
chemical cross-linker were sliced into 0.5 cm thick discs, freeze-dried, and examined under 




6.2 Results and discussion 
6.2.1 Printer advancement 
SEM was used to ensure the template structure from the Projet printer was transferred to the 
cellulose hydrogel through the templating process. Multiple columns of varying channel sizes 
(500 to 200 µm) were freeze-dried according to Section 3.3.1 then fractured to examined the 
internal cross-section under SEM according to Section 3.3.2 Figure 6-14 shows the resulting 
cellulose hydrogel structure from a wax template produced by the 3D Systems printer.  
  
Figure 6-14: SEM image of a cross-section of a freeze-dried 300-micron hydraulic diameter, Schoen gyroid cellulose 
column made from a wax template printed on the 2500w ProJet wax printer.  
 
Cleary defined channels can be seen in Figure 6-14 alongside the microstructure of the 
cellulose hydrogel that makes up the solid phase. On inspection, the shape of the resulting 
structure matched the requested Schoen gyroid defined by the STL file sent to the printer. This 
determined that a similar quality TPMS column could be produced with templates from the 






6.2.2 Resolution and speed 
The Solidscape 3Z pro was purchased in 2015, while the Projet 2500w was purchased recently 
in 2020. Table 6-1 shows the manufactures specifications for each model. Interestingly, the 
Solidscape printer's resolution in dots per square inch (DPI) is higher than the Projet printer. 
The DPI difference means the Solidscape printer places a much finer set of wax droplets than 
the Projet. Additionally, the layer thickness is lower for the Solidscape printer, allowing it to 
fit over twice the amount of layers into a single structure. However, the actual accuracy of the 
SolidScape printer is significantly worse. The Projet printer's accuracy is 500% greater, 
allowing it to produce much finer features than the SolidScape, even with a lower DPI and 
higher layer thickness. The larger layer thickness of the Projet also allows for a quicker print 
time as it lays down more wax in each pass, reducing the total overall passes required to 
produce a structure. The Projet build volume is 450% larger, allowing for the production of 
not only bigger parts but multiple parts simultaneously. 
 
Table 6-1: Comparison of 3D wax printer manufacturers specifications. 
 Solidscape 3Z pro Projet 2500w 
Resolution DPI 5000 1600 
Accuracy (mm) 0.0254 0.005 
Layer thickness (µm) 6.4 16 
Build volume (mm) 152.4 X 152.4 X 101.6 298 x 183 x 203 
 
A base case print of a 1 cm diameter by 5 cm long, 300 µm Schoen gyroid column was used to 
compare each printer's resolution, speed, and capacity. Table 6-2 shows the data from these 
tests and the original data from the SolidScape printer. The Project is not only faster (22.5×) 
but can produce multiple parts at the same time. The increased speed results in a capacity 
increase of 4500%. This capacity increase overcomes a considerable hurdle for this technology 
in the ability to produce columns rapidly. For commercialization of these columns, they need 
to be produced on a large scale and quantity. This capacity improvement shows the potential 
for a commercial-sized process of lab-scale columns.  However, as with all 3D printing 




Table 6-2: Comparison of printing a 1 cm diameter by 5 cm long Schoen gyroid column. 
 Solidscape 3Z pro Projet 2500w 
Time (hours) 36 - 48 1.6 
Volume (number of parts) 1 20 
Resolution (minimum hydraulic diameter µm) 300 150 
 
The improvement in resolution and reduction in hydraulic channel diameter is important as 
it reduces the potential diffusion distance for target biologicals during chromatography. 
Additionally, a reduction of hydraulic diameter inversely relates to an increase in specific 
surface area. However, although templates with smaller hydraulic diameters are possible, 
they need to be translated into hydrogel columns. 
6.2.3 File size limitations 
Advancements in printing technology have improved the speed and number of simultaneous 
prints; however, limitations that affect large-size templates still exist. The preparative 
software (slicer software) and computing power limit the file size the wax printers can handle. 
The slicer software ModelWorks used by the SolidScape Pro 3Z could process files up to 500 
MB, while '3D Sprint' used by the Projet 2500w has a higher capacity of 7 to 8 GB. Even with 
this improvement, printing larger columns' is an issue as the file sizes rapidly become too 
large for the printer's slicer software to handle. Table 6-3 shows the file size for 300 µm Schoen 
gyroid columns of the same resolution but varying column size. A commercial-sized packed 
bed column can be between 45 cm in diameter by up to a bed height of 80 cm [317]. The file 
size for a 3D-printed column that size would be multiple terabytes, far greater than standardly 











Table 6-3: Comparison of STL file size a 300 micron Schoen gyroid in gigabytes. 
 Diameter cm 
Length cm 1 1.5 2 2.5 
5 0.8 1.9 3.4 5.2 
10 1.7 3.8 6.8 10.5 
15 2.5 5.7 10.1 15.7 
20 3.4 7.6 13.5 21.0 
 
A patterning method was used to avoid file size limits to print larger templates described in 
Section 6.2.3. Figure 6-15 below shows the largest column printed to date (50 mm diameter by 
200 mm long, Schoen gyroid 300 microns’ hydraulic diameter channels). This template was 
the largest possible by this technique using the 3D Sprint software. Even by patterning, the 
software would crash when a file was copied too often, preventing larger structures from 








Figure 6-15: Wax print of a Schoen gyroid template (50 mm diameter by 200 mm long, 300-micron hydraulic 
diameter channels).  
 
6.2.4 Support wax removal 
Printing of the wax templates is the first of four steps in the cellulose column production 
process. As both the templates' size increases and the hydraulic channel diameter decreases, 
removal of support wax becomes more difficult.  Two factors were considered to reduce the 
time required to clear all of the template channels of support wax; IPA temperature and 
mixing velocity. The supplier of the printer recommended the increasing temperature to 
reduce processing time [318]. An increase in mixing velocity should help move the saturated 
IPA away from the dissolving wax's surface, aiding dissolution [319]. The temperature of the 
IPA could be increased to a maximum of 40 °C. At temperatures higher than this, the wax 
templates became soft and quickly distorted in shape. A similar issue was found with the 











The force generated on the ends of the template during high-velocity mixing caused the 
structure to warp and bend predominantly for longer templates (> 5 cm length, 1 cm 
diameter). Warping happened faster at higher IPA temperatures. If the IPA was not heated, 
warping could be minimized; however, the length of time for support wax removal would 
increase (~4× slower room temperature than at 35°C). Based on these initial observations, a rig 
was designed to better support the templates during this process. A description of this rig and 
the experimental method of testing is described in Section 6.2.4. In this first version, a narrow 
tube is used to hold the template vertically while IPA is slowly (40 mL/min) pumped from the 
bottom up. This slow directional flow along the axis prevented warping and could remove 
support wax from long (20 cm) 300-micron structures in under 48 hours. For comparison, a 
column of the same diameter and hydraulic diameter 10 cm long took 20 hours to process at 
35°C. Although slower because of the lack of heating, these structures previously could not 
have their support wax removed because of their length and warping.  The size of the column 
diameter limits the design. It had to be narrow enough to support the template but large 
enough to accommodate varying column diameters. Therefore, multiple cylinder sizes would 
be needed to be used depending on the dimensions of the template. 
 
The time required rose when removing support wax from larger diameter structures and 
those with hydraulic diameters smaller than 300 µm. In both cases, the time required to 
remove the support wax increased, as seen in Table 6-4. The time for support wax removal 
comparing a 1 cm column (300 µm Schoen gyroid) to a 2 cm column of the same internal 
geometry requires 700% longer. Extrapolating this result suggests a pilot-scale size column (5 
cm diameter, 15 cm long) would take two or more months to process. This length of time is 









Table 6-4: Time taken for support wax to be removed from varying wax templates of a nominal length (15 cm, 
second iteration support wax removal rig). 
Channel diameter Column diameter Time 
µm mm hours 
300 10 48 
300 15 168 
300 20 336 
250 10 120 
200 10 288 
 
As well as the length of time taken to remove support wax from some structures, damage to 
the template was noticed on 150 µm hydraulic diameter channel templates. Figure 6-16 shows 
an example of this cracking on a piece of 150 µm Schoen gyroid template. Additionally, the 
purple support wax had noticeably whitened. The IPA was also bright purple after support 
wax removal suggesting the dye had leached out during the process. This cracking ruins the 
template as during infusion, it will fill with the cellulose solution creating an axial wall 
through the column, disrupting the channels. Similar cracking was also observed after the 
attempted support wax removal from 5 cm diameter by 20 cm long, 300 µm Schoen gyroid 
template. Figure 6-17 shows the extent of this cracking. Further investigation of this cracking 
phenomenon is presented later in this chapter. 
 
Figure 6-16: 5 cm long piece of 1 cm diameter, 200 µm Schoen gyroid template post support wax removal 











6.2.5 Build wax removal 
Post support wax removal and cellulose hydrogel injection, the remaining build wax needs to 
be removed from the structure. Similar to support wax removal, this process takes longer the 
smaller the hydraulic diameter of the channels. These column templates were gelled are 
described in Section 3.1.4 and analyzed under SEM (Section 3.3.2). The narrower channels 
seem to slow the migration of molten wax out of the structure during boiling. The time 
required to fully remove wax from a 300 micron Schoen gyroid compared to a 200 micron 
Schoen gyroid (1 cm diameter by 5 cm long) is nearly four times greater (80 hours). Figure 6-
18 shows a cross-section of a 200 micron Schoen gyroid column with trap build wax inside the 





Figure 6-18: SEM cross-section image of a 200 micron Schoen gyroid with build wax trapped inside of the 
channel network.  
Pockets of wax that are trapped within the structure require excessive boiling to remove. Build 
wax removal is another potential bottleneck in the process, as larger columns with small 
hydraulic channel diameters will increase the amount of time to clear wax. Build wax removal 
from these small channel diameters (200 microns) is possible as shown in Figure 6-19. 
 
 





Figure 6-19: SEM image of a 200 micron Schoen gyroid cellulose column cross-section. 
 
6.2.6 Segmentation of columns 
As the ProJet wax printer could not print templates larger than 5 cm by 20 cm, as shown in 
Section 6.2.3 because of the slicer software, a segmentation method was proposed as an 
alternative to single-piece columns.  Larger columns could be created by dividing up the 
desired column length into smaller printable pieces. Two different methods were tested, 
template segmentation with combined gelling and template segmentation with individual 
gelling. Details of these two methods can be found in Section 6.1.3. The time required to 
remove support wax should be reduced by limiting each template's length to 2 cm while 
minimizing potential warping. 
 
6.2.7 Combined gelling 
Multiple segments of the template were stacked together to be gelled as one piece as described 
in Section 6.1.3. Figure 6-20 shows the plug templates inside of the casing used to gel them 
together. They have been tightly pressed together, but gaps between them can still be seen. In 
a previous attempt, excessive force was used during loading into the casing to minimize these 





Figure 6-20: Image of wax templates inside casing used to hold them during cellulose infusion and gelling. A 
front view; B Side view.  
 
During the infusion process, the pressure applied by the syringe forced the segments tightly 
together. However, the cellulose solution still seeped its way between them. This seeping 
resulted in a combined structure with slices of solid hydrogel between segments. The 
unwanted hydrogel blocked the axial flow through the column. Increased pressure on the 
templates to minimize seeping was tested in a repeat experiment. However, the paraffin-
based build wax deforms under the additional pressure shown in Figure 6-21. The templates' 
rough face surface has contributed to the gaps the solution filled between the templates. 
Shaving the surfaces of the templates was suggested post support wax removal. However, 
this would misalign the TPMS structure channels unless a perfect unit cell was removed from 






Figure 6-21: Image of wax templates gelled together showing the gaps of cellulose between each template 
blocking channels. 
 
An alternative segmentation method was used to avoid channel blocking resulting from 
combined gelling. The smaller 2 cm thick templates were gelled separately to be stacked onto 
each other inside the column casing after building wax removal. Figure 6-22 shows a 
combination of these ‘plugs’ inside of a casing. The plugs were shrunk in IPA and slide inside 
the casing one at a time. Each plug was re-swelled with water before the next plug was 
inserted. Each plug was placed as close to the previous as possible to minimize the gaps 
between them. Initial flow testing of this stack of plugs showed no difference in pressure drop 
between this and an equivalent single-piece column (0.02 MPa). Therefore, it was concluded 
potential misalignment of the plugs was not significantly affecting flow or blocking channels. 














6.2.8 Column stacking  
6.2.8.1 Tracers analysis 
A tracer analysis was completed to determine if there was a significant performance drop 
between a single piece or a combination of four separate plugs. Details for this method can be 
found in Section 6.1.4 RTD profiles were determined from 1% acetone tracers at varying flow 
rates through a 10 cm bed height, 1 cm diameter, 300 micron Schoen gyroid column. The same 
column was then cut into four individual 2.5 cm plugs and stacked back inside the same SNAP 
casing. The same tracer experiment was then repeated. Figure 6-23 below shows the 
normalized peaks from these tracers overlapped. 
 
Figure 6-23: 1% Acetone tracers at varying flow rates through a 10 cm 300 µm hydraulic diameter Schoen gyroid 
in a single piece and in four separate plugs.   
 
The overlap of all four flow rates matches between the two variations of the same column. 
The overlapping peaks show minimal disruption by segmenting the column into multiple 
pieces. To further analyses these peaks, Asymmetry and the HETP values were found and 
compared; details of these calculations can be found in 6.1.4, and sample calculations can be 
found in Appendix A. Figure 6-24 shows how asymmetry values compare between the single 
piece and multiple plugs for the acetone tracers. For all peaks shown, the asymmetry values 
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are within the recommended values for packed bed columns (0.8 to 1.8) [160]. The best 
symmetry is achieved not at the lowest flow (15 cm/h) rate but a higher 76 cm/h. 
 
 
Figure 6-24: 10% Asymmetry values calculated from 1% acetone tracer peaks (10 cm, 300-micron Schoen gyroid, 
single column and 2.5 cm stacked plugs) from Figure 6-7.   
 
The HETP values for each peak can be seen in Figure 6-25 below, as with packed bed columns, 
as the flow rate is increased, the performance decreases. However, this does not follow the 
tick shape of a traditional Van Deemter plot. The Van Deemter equation consists of three 
factors, A, B, and C, as shown in Equation 6-7, where u is fluid phase velocity [320]. A is related 
to eddy dispersion, B is related to molecular diffusion, and C is related to mass transfer. 
 
    𝐻𝐸𝑇𝑃 = 𝐴 +
𝐵
𝑢
+ 𝐶𝑢,      (6-7) 
 
Based on the shape of Figure 6-25, it would suggest that the dominating factor is the mass 
transfer term C. The mass transfer can therefore be assumed to be the limiting factor for plate 
height. The large hydraulic diameter (300 µm) of the channels causes poor mass transfer 
within the column. A similar trend is seen in EBA because of the expansion required to 
passage solids, where again the C term is dominant for the Van Deemter plots [321]. A 
reduction in the hydraulic diameter of the channels should reduce HETP values. However, 
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channels still need to be large enough to passage solids for capture recovery from crude cell 
lysates. Hydraulic diameter is limited by the current 3D printing technology, which dictates 
the smallest possible channel diameter possible, being ~200 µm. As advancements are made 
with 3D printers, the minimum printable hydraulic diameter is expected to reduce.  
 
 
Figure 6-25: HETP values calculated from 1% acetone tracer peaks (10 cm, 300-micron Schoen gyroid, single 















6.2.9 Pilot scale column creation 
The segmentation method was shown not to affect the performance of 3D-printed columns on 
a small scale. It also provides a potential method for upscaling this technology, circumventing 
printable templates' size limits because of the slicer software and long templates' warping. 
Therefore, a new support wax removal rig was designed for 'plug' templates up to 5 cm in 
diameter by a given thickness up to 10 cm. A 2 cm diameter column could successfully have 
its support wax removed without heating based on previous experimentation. A 2 cm 
thickness was used as a starting point for this work, hypothesizing that heating would shorten 
the time required. If the templates need to be thinner than 2 cm, more will be required to be 
stacked together to reach the desired column length. Therefore, there is a potential trade-off 
between the time taken to create one plug versus how many total plugs are needed for a 
column. Table 6-5 shows which templates were used in each test of this rig. Experiments are 
described in Section 6.1.5. Each test followed the previous to determine if upscaling by 
segmentation was possible with current technology.  
 
Table 6-5: list of the various templates used for testing of the second support wax removal rig. 
 Thickness Channel hydraulic diameter Diameter 
 cm µm cm 
Test 1 2 300 5 
Test 2 0.8, 1, 1.2, 1.4, 1.6 and 1.8 300 5 
Test 3 1 300 4, 3 and 2 
Test 4 1 350, 400 and 500 5 
 
 
6.2.10 Test 1 - Effect of temperature  
Three different temperatures (40°C, 35°C, and room temperature) were tested to remove the 
support wax from the plug templates. All three of the temperatures tested resulted in cracking 
of the wax template after different periods. This cracking occurred in all three cases at a mass 
removal between 30 to 35% of the starting mass. For higher temperatures, this happened 
earlier as support wax removal occurred at a faster rate. At 40 °C, cracking occurred within 
two hours compared to room temperature, which took up to 24 hours. Templates were broken 
open to see how far the support wax removal had progressed. Figure 6-26 shows the cracks 
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found on these templates' external surfaces, while Figure 6-27 shows the template's internal 
structure after being cut in half. The lighter purple front around the outside of the template 
shows the distance support wax removal had reached. A similar depth of support wax 
removal (3 to 4 mm) occurred before cracking was noticed in all cases. 
 
 
Figure 6-26: Plug wax template (2 cm thick by 5 cm diameter, 300 µm Schoen gyroid) side view showing cracking 
seen post dissolution. Wax removal occurred at room temperature over 5 days. 
 
 
Figure 6-27: Plug wax template (2 cm thick by 5 cm diameter, 300 µm Schoen gyroid) cross-section view showing 
IPA front of support wax removal. Wax removal occurred at room temperature over 5 days. 
 
The purple support wax was whitened during the support wax removal process. The 
whitening indicates again that the dye of the build wax has leached out into the solution. This 





cracking. Based on these initial results, the template size was reduced to find a point where 
cracking would not occur. 
 
6.2.11 Test 2 - Template thickness 
The support wax from various thickness (0.8 cm to 2 cm) templates (5 cm diameter, 300 µm 
Schoen gyroid) could not successfully be removed from any of these structures without 
cracking, even those thinner than the 1 cm diameter columns. The template's position within 
the tank was modified to increase the surface area exposed to IPA flow. A new template mesh 
cage was designed to allow the template's cross-section to be normal to the tank's flow. The 
rig was tested with two normal-facing templates shown in Figure 6-7 with optimal conditions 
(room temperature, fresh IPA). Both templates cracked before the support wax had dissolved.  
 
Interestingly, the template had a similar support wax removal pattern to those dissolved in 
the original template holder when dissected. Figure 6-28 shows a cross-section of one of the 
templates that cracked during support wax removal using the new holder. Even though the 
flow was directed at a different part of the structure, the support wax removal pattern was 
the same. This pattern suggests that the IPA flow does not affect the support wax removal 
process. The mixer's speed was increased from 400 rpm to 900 for a repeat of this trial. Again 
the template cracked, and upon dissection, had a similar removal pattern inside the template. 
The small size of the channels within the structure slows the IPA's velocity and eventually 
stagnates because of the dead ends due to support wax. Therefore, most support wax 
dissolving is limited by diffusion, not convection of saturated IPA away from the solid 
support wax. As the system is diffusion-limited, increases in the IPA temperature will speed 





Figure 6-28: Cross-section of wax template after cracking during support wax dissolution at 900 rpm.  
 
6.2.12 Test 3 - Column diameter 
Previous experimentation with the first support wax removal rig could remove support wax 
from 2 cm diameter columns (15 cm long, 300 µm Schoen gyroid) with cracking occurring. 
Therefore, instead of varying template thickness, the diameter was altered.  Templates (1 cm 
thick, 300 µm Schoen gyroid) with diameters between 5 and 2 cm had their support wax 
removed using the second iteration rig. Table 6-6 shows the templates larger than 3 cm in 
diameter cracked before the support wax could be removed. The template diameter variation 
seems to have a greater effect on preventing cracking than changing the thickness of the 
template.  Altering of the diameter suggests the cracking may depend on the template's 
circumference surface area rather than its length. 
 
Table 6-6: Results of support wax removal trial on various template diameters.  











6.2.13 Test 4 - Hydraulic diameter 
Based on previous results indicating support wax removal was diffusion limited, the channels' 
hydraulic diameter within the templates was increased. The increase in channel hydraulic 
diameter increases the template channels' wall thickness, potentially increasing its resistance 
to stress during support wax removal. Table 6-7 shows repeat trial results removing support 
wax from varying hydraulic diameters (5 cm diameter, 1 cm thick, 300 µm Schoen gyroid). 
The Schoen gyroid templates with a hydraulic diameter of above 350 µm did not crack during 
the support wax removal process. For both temperatures tested (room temperature and 40°C), 
the same result occurs, indicating if the template cracked during support wax removal at 40°C, 
it would crack at room temperature. The effect of temperature only decreases the time taken 
to reach the cracking point or complete support wax removal for templates. 
 
Table 6-7: Results of support wax removal trial on various template channel hydraulic diameters.  
 






Figure 6-29 shows the mass change for a 5 cm diameter by 1 cm thick, 500 µm Schoen gyroid 
template over 4 hours in the second support wax removal rig at 40°C. The mass loss stabilized 
after two hours, indicating that no support wax was left. The template was fractured post 
drying to visually confirm that all the channels were clear of support wax. Comparing the 
weight of build wax used (specified by the printer) to that of the template (post support wax 
removal) shows a 50% reduction in mass. This weight reduction in the build wax suggests 




Figure 6-29: Change in mass over time of templates (5 cm diameter by 1 cm thick, 500 µm Schoen gyroid) at 40°C 
inside support wax removal rig.  
 
To continue upscaling work creating larger cellulose column pieces, 500 µm hydraulic 
diameter templates were used as most smaller hydraulic diameter templates cracked during 
testing. The build wax formulation is mostly unknown and not disclosed by the producer. The 
MSDS sheet provided with the wax says it is 60 to 90% paraffin [322]. A more detailed study 
into the wax materials, dissolution process, and other potential solvents would be required to 
understand if cracking could be prevented in larger (>3 cm diameter) 300 µm hydraulic 
channel diameter templates. The dissolution process analysis was outside of this work scope, 
where the goal was to show what is currently possible with current 3D printing technology. 
A larger 500 µm Schoen gyroid template (5 cm diameter by 6 cm thick) was produced and had 
its support wax successfully removed without cracking (5 hours at 40°C) inside the second 
support wax removal rig. Figure 6-30 shows a comparison of a 500 micron Schoen gyroid 





Figure 6-30: Side by side comparison of 500 µm Schoen gyroid template (5 cm diameter by 6 cm thick) pre 
(purple) and post support wax removal (white/violet). A: top view; B: side view. 
 
A reduction in size and change in build wax color between template pre and post support 
wax removal is shown in Figure 6-30—the wax template shrunk by 28.4% by volume and 50% 
by mass. The supplier of the wax states shrinkage at 40°C in IPA is 2% by volume, but they 
do not specify over what period. However, they suggest support wax removal should only 
take one hour [323]. The extended time (5 hours at 40°C) in IPA to completely remove support 
wax could result in the greater shrinkage seen in these templates than what was reported by 
the manufacturer. This shrinking effect may also cause the cracking found in templates with 
smaller hydraulic diameters and larger template diameters. The surface may be under tension 
if shrinking occurs on the template's surface before the internal support wax is removed. 
Surface stress is a common occurrence in concrete curing where the surface cracks as the 
concrete dries because of water loss shrinking at the exposed surface [324]. Cracking happens 
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more frequently with objects that have a high surface area to volume ratio [325]. As the 
template's channel size decreases, the surface area to volume ratio increases. This increased 
surface area to volume ratio could explain why templates with smaller channel diameters 
crack while templates with larger channels do not. Based on the results of support wax 
dissolving, the limits of the current process have been shown. Testing of the cellulose infusion 
rig took place with 500 µm hydraulic diameter Schoen gyroid templates. 
 
6.2.14 Cellulose injection rig operation 
The cellulose infusion rig used for these experiments is described and operated according to 
Section 6.2.14. Figure 6-31 shows the resulting cellulose structure produced from the first trial 
with a 5 cm diameter by 1 cm thick template. An air bubble was trapped on top of the template 
caused by the template's loose-fitting within the holder. The cellulose traveled up and around 
the sides of the template, trapping air. This air bubble prevented the entire template from 
being infused with the solution, which left the large cavity seen in Figure 6-31. For the second 
trial, the tolerance between the holder's sides and the template was reduced (2 mm to 0.5 mm) 
to be a tighter fit to the template's sides. The first trial showed the rig was operational and the 




Figure 6-31: Result of first trial of cellulose infusion rig post wax removal, showing the resulting level of cellulose 




Another 5 cm diameter by 6 cm thick template was infused using the previous trials' method. 
Additional to the physical cross-linker, 10 wt.% chemical cross-linker (ECH) was included in 
the hydrogel formulation. The cooling jacket was used with an ice bath to keep the solution 
as close to 0°C as possible during infusion to prevent premature gelling [222]. Figure 6-32 
shows the chemically cross-linked column piece post-build wax removal. The build wax 
removal for this template took only 8 hours because of the channel size (500 µm). The larger 
hydraulic diameter of the channels within the column piece provided less resistance for wax 
migration out of the structure. Although not explored because of the cracking of 300 µm 
templates, build wax removal should be investigated in future work once larger templates 
with smaller channels can be produced.  The cellulose column piece resulting from the 
infusion process has rough edges resulting from minor damage to the template during 
support wax removal and the boiling for build wax removal. Apart from these minor surface 
defects, the template's overall structure and size are reflected in the resulting hydrogel. 
 
 







Figure 6-33 shows a cross-section of this gelled column piece showing the internal structure. 
There were no internal cavities within the structure confirming complete cellulose infusion. 
Figure 6-34 shows an SEM image of a slice from the chemically cross-linked cellulose columns. 
The periodic shape of the channels shows the structure from the template has been transferred 
to the hydrogel.  This stackable column piece represents a 15× volumetric increase in a 
producible single-piece 3D-printed column size. 
 
 
















Figure 6-34: SEM image of a freeze dried slice from one of the 5 cm diameter by 6 cm thick, 500 µm Schoen 
gyroid cellulose hydrogel columns.   
 
Multiple column templates could be filled at once by changing template holders during 
operation. Two holders were successfully filled, capped, and gelled within five minutes from 
starting the infusion process. Additional templates could have been filled if available. Based 
on the volume of solution used to fill two templates (~600 mL), up to 8 or more could be 
potentially filled in one run. Therefore, in two full runs of this rig, assuming all templates are 
filled correctly and are undamaged, enough ‘plugs’ would be created to stack a column 5 cm 
in diameter by 72 cm bed height. Table 6-8 summarizes the process steps for creating these 
column pieces and their times. Build wax removal currently is performed in a 1 L beaker on 
top of a hot plate, which multiple of these could be set up to run in parallel. Therefore, the 
total time to make a batch of 5 × 5 cm diameter, 6 cm long, 500 µm Schoen gyroid pieces would 







Table 6-8: Summary of processing steps for creation of a 5 cm diameter by 6 cm long, 500µm Schoen gyroid 
column piece.  
Step Number per batch Time per batch 
  hours 
Template printing 5 6 
Support wax removal 6 5 
Cellulose infusion 8 1 
Build wax removal 1 8 
Total  20 
 
This simple, straightforward process does not require complicated machinery to produce 3D 
chromatography columns at a pilot scale in under 24 hours from start to finish. With further 
process optimization, larger columns with smaller hydraulic diameters may be possible. This 
upscaling method is potentially a pathway for industrial scaling of this technology, testing 





In this final chapter, 3D-printed chromatography columns' scalability via a templating 
method using current technology was investigated. Advancement in printing technology has 
shown a significant improvement in capacity, speed, and resolution over the past five years. 
The largest single-piece template (5 cm by 20 cm, 300 µm Schoen gyroid) was printed on the 
ProJet 2500W printer using a patterning technique to avoid the slicer software's file size 
limitations. A stackable segmentation method was developed to circumvent the need for 
single piece chromatography columns, allowing columns of the desired length to be created 
from multiple smaller 'plugs.' Comparing a single piece column's performance to a column 
made from multiple smaller plugs showed no drop in the performance. Additionally, the best 
performance of these 3D-printed columns was found at the lowest possible flow rate. This 
result showed these columns are mass transfer limited because of the large size of the 
structure's channels. 
 
Although larger plug templates can be printed on commercially available wax printers, post-
processing of these templates (support wax removal) limits the size of viable templates and 
the hydraulic diameters of internal channels. Shrinking based cracking during support wax 
removal was found to damage templates rendering them unusable for the templating process. 
The process seems to be diffusion-limited with increases in IPA temperature during elution 
speeding wax removal. However, templates too large or with small hydraulic diameter 
channels will crack at low and high temperatures. Support wax removal is the major 
bottleneck for this technology as printing without support wax is currently not possible. 
 
A cellulose infusion rig was tested using 500 µm hydraulic diameter plug templates. Air 
pressure was used instead of a pump to force the dissolved cellulose solution through the 
templates. Multiple 5 cm diameter by 6 cm long, 500 µm Schoen gyroid templates could be 
filled at once. Upon build wax removal, cellulose hydrogel columns were found to have the 
template's desired internal channels. These larger hydrogel pieces mark a 1500% increase in 
the size of a single piece of 3D-printed hydrogel column. The stacking of these column pieces 
will allow for creating a 5 cm diameter pilot-scale column of any desired length. The total 
processing time for up to 5 of these parts is 20 hours. 
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7 Conclusion and recommendations for future work 
 
7.1 Conclusions 
The work present in this thesis displays how 3D-printed chromatography columns can be 
used for the capture step in the downstream processing of viruses. Cellulose hydrogels were 
formed into monolithic structures with custom-designed internal channels by a negative 
templating method. Three different functional ligands (DEAE, Q, and HA) were attached to 
the cellulose hydrogel by covalent or hydrogen bonds. These ligands were then used to bind 
and elute target viruses to separate them from contaminates found in their feed streams.  
Upscaling of the columns was achieved with currently available wax printing technology. 
 
In chapter 4, the cellulose hydrogel was investigated for use as the 3D-printed 
chromatography columns' stationary phase. The hydrogel pores were large enough to allow 
diffusion of virus-like particles to an average depth of 10 µm, 500% deeper than traditional 
media.  A calcium phosphate mineral was mineralized into the pores of the cellulose hydrogel. 
This ligand was shown to have multimodal functionality with both cation exchange and metal 
affinity binding sites. Although not pure or highly crystalline HA, the mineral could still bind 
and elute various proteins. The anion exchange functionalities, Q and DEAE, were optimized 
for high protein static binding capacities and ligand densities comparable to current packed 
bed media. 
 
Chromatography-based purification of viruses from both clarified and unclarified feed 
streams was examined in chapter 5. Purification of adenovirus and lentivirus from clarified 
lysate was shown to have comparable recoveries to packed bed chromatography. However, 
load and elution flow rates needed to be minimal to maximize recovery. Both the HA and 
DEAE ligands had similar capacities before DEAE ligand optimization. AAV serotype 9 was 
purified using HA (bind and elute) and Q (flow-through) style chromatography. Although 
possible, recoveries and capacities were low compared to the state-of-the-art affinity ligands 
now used for AAV.  M13 bacteriophage was used as a model virus for comparison to an 
expanded bed purification process. Q functionalized 3D-printed chromatography columns 
were shown to be as effective as expanded bed chromatography with significant advantages 
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in processing time and simplicity in use. Varying flow rates at different steps during 
chromatography allowed for an optimized purification that was 300% faster than a similar 
expanded bed operation. 
 
The final experimental chapter investigated the potential for upscaling this technology from 
lab to preparative/pilot scale. Using current wax 3D printing templates as large as 5 cm in 
diameter by 20 cm long, 300 µm Schoen gyroid could be made. However, support wax 
removal from larger templates and smaller hydraulic diameters proved to be a limiting step 
for upscaling—issues including time required for complete removal and template cracking 
limited useable templates. A segmentation and stacking method were used to circumvent the 
need for single-piece columns with no performance drawback shown in small-scale testing.  
500 µm Schoen gyroid, 5 cm diameter by 6 cm long templates were printed, had their support 
wax removed, and were turned into cellulose structures using newly designed equipment. 
This method produced a single-piece of 3D-printed hydrogel column, which is a 1500% size 
increase. 
 
Overall, this work has shown 3D-printed chromatography columns to be a potential 
alternative to expanded bed chromatography to directly purify viruses from cell culture. High 
capacity anion exchange functionalities combined with solid tolerant 3D-printed 
chromatography columns can operate similarly to expanded bed chromatography without 
complications arising from fluidized beds. For this technology to be adopted by the industry, 
it will require upscaling, which has been shown in a limited capacity is currently possible. 
Advancements in printing and post-processing technology will allow 3D-printed columns to 





7.2 Recommendations for future work 
From the work completed in this thesis, the following recommendations are made for the 
future development of 3D-printed chromatography columns. 
 
1. HA optimization 
Although HA could be used for the purification of viruses, poor capacity limited its 
usefulness. Chapter 4 showed the mineral was not pure HA and suggested a possible reaction 
scheme for the conversion of OCP into HA which should be explored. Additionally, 
improvements to the mineral’s crystallinity by may also improve capacity and selectivity. 
 
2. Testing of purification from cell lysates 
Purification of M13 bacteriophage from cell culture was possible, however, cell cultures have 
significantly less contaminates in them than cell lysates. The majority of viruses used in gene 
therapies require cell lysis to release the viral particle into solution from inside the cell. 
Therefore, purification from these more contaminated feed streams (such as crude adenovirus 
lysate) needs to be shown if this technology is to replace expanded bed chromatography. 
Moreover, a variety of different cell lysates should be tested to show this is indeed a platform-
style technology.  
 
3. Affinity ligands 
Purification of viruses and other proteins by affinity ligands is extremely effective as 
selectivity binding them away from contaminates.  Incorporation of these affinity ligands into 
3D-printed columns should allow for direct purification from cell culture or lysates with high 
capacity, recovery and purity. A starting point for this would be an investigation into camelid 
anti-body fragments used for AAV purification. Development of chemistry to bind these 
ligands onto the cellulose or agarose stationary phase would be required.  
 
4. Upscale testing 
Chapter 6 produced a method to create a pilot-scale sized column with 500 µm hydraulic 
diameter channels. A full pilot-scale column using these column segments should be tested 
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with tracers to determine performance. A method will also need to be developed to 
functionalize larger columns before they can be used to purify viruses from a model 
feedstream. A cylindrical flow reactor similar to the setup used by the first support wax 
removal rig could help evenly mix reaction chemicals through long pieces of column. 
 
5. 3D printing process 
The post-processing of templates constrains the current templating process for the creation of 
these columns. A full study into the wax materials used for build and support wax and how 
the dissolution of support wax occurs may resolve this issue. Development of new post-
processing techniques or an alternative solvent may also be required. Identification of wax 
material composition followed by dissolution studies would help better understand the 
support wax removal process.  
 
6. Column structure  
Lastly, in this work, only one channel shape based on the TPMS structure, the Schoen gyroid, 
was used. An investigation into varying channel shape and column voidage may influence 
performance and increase available surface area for binding. Tracer peak analysis studies 
alongside protein DBC testing using a range of these structures could be used to determine 
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Ligand density – Calculations  
The below calculations show how the ligand density was calculated for each of the various 
anion exchangers tested: 
 
1 mL of Q functionalized 500 µm, Schoen gyroid column.  
 
Initial pH = 1.30 
Final pH = 7.00 
Initial level =20.30 mL 
Final level = 24.25 mL 
 
Blank column 500 µm 
 
Initial pH = 1.26 
Final pH = 7.00 
Initial level =27.90 mL 




24.25 − 20.30 = 3.95 𝑚𝐿 
No column 
31.50 − 27.90 = 4.5 𝑚𝐿 
Difference 
4.5 − 3.95 = 0.55 𝑚𝐿 
Conversion to Moles 
 






× 2 = 0.00011 𝑚𝑜𝑙𝑒𝑠 




0.00011 𝑚𝑜𝑙𝑒𝑠 ÷ 0.785 𝑚𝐿 × 1,000,000
𝜇𝑚
𝑚𝑜𝑙𝑒𝑠
= 140 𝜇𝑚/𝑚𝐿 
qPCR Calculations 
The below calculations show how the titer of AAV serotype 9 samples were calculated from 
qPCR: 
 
Ct = 20.11 
 
Equation for known standards to determine femto genomes (fg) is given by the Thermocycler 
as shown in Figure A-1. 
 
 
Figure A-1:  Standard curve computer generated from known qPCR reactions 
 
4861.8 × 𝑒−0.668𝐶𝑡 
 
4.86.8 × 𝑒−0.668×20.11 = 0.00712 𝑓𝑔 
 
 
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑝𝑖𝑒𝑠 𝑝𝑒𝑟 𝑓𝑔 =
𝑓𝑔 × 6.022 × 1023
660 × 5900 × 1015
 
 
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑔𝑒𝑛𝑜𝑚𝑒𝑠 =
0.00712 × 6.022 × 1023
660 × 5900 × 1015
= 2.20 × 103 𝑉𝐺/𝑓𝑔 
 
Dilution factor = 𝑆𝑡𝑎𝑟𝑡𝑖𝑛𝑔
𝑣𝑜𝑙𝑢𝑚𝑒






















= 1.24 × 106 𝑉𝐺/𝜇𝐿 
 
1.24 × 106𝑉𝐺/𝜇𝐿 × 1000 𝜇𝐿/𝑚𝐿 = 1.24 × 109 𝑉𝐺/𝑚𝐿 
 
A melt of the multiplied DNA was also completed to ensure only a single product was 








Peak analyses from RTD 
 
The peaks from RTD graphs were analyzed to determine both As and HETP values. Figure A-
3 shows an example normalized peak with guidelines showing how it was dissected to 
determine correct values to be used for determining HETP and 𝐴𝑠. Explanation of these values 

















































Figure A-3: Example image of a normalized peak dissected to determine 𝑤ℎ, 𝑉𝑅, a and b values.  
 
 
